Modified cytomegalovirus proteins and stabilized complexes
Stabilized HCMV complexes with variant polypeptides address the stability and immunogenicity issues of current vaccines by enhancing thermal stability and epitope accessibility, leading to improved production and immune response efficacy.
Patent Information
- Application Number
- JP2021521000
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-17
- Filing Date
- 2019-10-15
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2039-10-15
AI Technical Summary
Current HCMV vaccines lack stability and immunogenicity, particularly in pentamer complexes, which are crucial for targeting endothelial and epithelial cells, and there is a need for improved thermal stability to enhance production and accessibility of neutralizing epitopes.
Development of stabilized HCMV complexes, such as gH/gL, gH/gL/gO, and gH/gL/UL128/UL130/UL131A, with variant polypeptides containing stabilizing mutations like cavity-filling, hydrophobic, hydrophilic, disulfide bridge, and deglycosylation modifications, enhancing thermal stability and epitope accessibility.
The stabilized complexes exhibit increased stability and immunogenicity, facilitating higher yield production and improved immune responses, including neutralizing antibody production.
Smart Images

Figure 0007584405000043 
Figure 0007584405000044 
Figure 0007584405000045
Abstract
Description
[Technical field]
[0001] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII text file format (Name: VU66664_SeqLstg_ST25.txt, Size: 195,489 bytes, Created: October 15, 2018), which is incorporated by reference in its entirety herein.
[0002] Disclosure by inventor or co-inventor The inventors, the present inventors, or persons who obtained the subject matter from the inventor(s) have been directed to Chandramouli et al., 2017 Science Immunology 2(12): eaan1457, Protein Data Bank (PDB) ID 5VOB, and International Patent Application PCT / IB2018 / 000491, filed April 18, 2018.
[0003] FIELD OF THEINVENTION The present invention is in the field of vaccination against human cytomegalovirus (HCMV) and in particular provides mutant gH, gL, pUL128, pUL130 and pUL131A polypeptides, and stabilized HCMV complexes comprising two or more of the gH, gL, pUL128, pUL130 and pUL131A polypeptides, where at least one of the two polypeptides is a mutant, and their use in immunogenic or vaccine compositions. [Background technology]
[0004] Cytomegalovirus (CMV) is a genus of virus that belongs to the family of viruses known as Herpesviridae or herpesviruses. The species that infects humans is commonly known as HCMV or human herpesvirus-5 (HHV-5). Within the Herpesviridae family, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals.
[0005] Although HCMV can be found throughout the body, HCMV infection is more often associated with the salivary glands. HCMV infects 50%-80% of adults in the United States (40% worldwide), as indicated by the presence of antibodies in many of the general population. HCMV infection typically goes unnoticed in healthy individuals, but can be fatal to immunocompromised individuals, such as HIV-infected individuals, organ transplant recipients, or newborns (Mocarski et al., Cytomegalovirus in FIELDS VIROLOGY, David M Knipe and Peter M Howley, eds., Philadelphia, Pa., USA: Lippincott Williams and Wilkins, 2006). HCMV is the virus most frequently transmitted to the developing fetus. After infection, HCMV remains latent in the body for the life of the host and has the ability to occasionally reactivate from latency.
[0006] HCMV appears to have a profound effect on immune parameters later in life and may contribute to increased morbidity and ultimate mortality (Simanek et al., Seropositivity to Cytomegalovirus, Inflammation, All-Cause and Cardiovascular Disease-Related Mortality in the United States, 2011 PLoS ONE 6: e16103).
[0007] To date, the genomes of over 20 different HCMV strains have been sequenced, including genomes of both laboratory strains and clinical isolates. For example, the following strains of HCMV have been sequenced: Towne (NCBI GenInfo (GI) Identification Number 239909366), AD169 (GI:219879600), Toledo (GI:290564358), and Merlin (GI:155573956). The HCMV AD169, Towne, and Merlin strains are available from the American Type Culture Collection (ATCC VR538, ATCC VR977, and ATCC VR1590, respectively).
[0008] HCMV contains an unknown number of membrane protein complexes. Among the known glycoproteins in the viral envelope, gH and gL have emerged as of particular interest due to their presence in several different complexes, namely dimeric gH / gL, trimeric gH / gL / gO (also known as the gCIII complex) and pentameric gH / gL / pUL128 / pUL130 / pUL131A (the latter protein is also called pUL131). HCMV is thought to use the pentameric complex to enter epithelial and endothelial cells by endocytosis and low pH-dependent fusion, whereas it is thought to enter fibroblasts by direct fusion at the plasma membrane in a process involving gH / gL or possibly gH / gL / gO. While gH / gL and / or gH / gL / gO complexes are sufficient for infection of fibroblasts, the pentameric complex is required for infection of endothelial and epithelial cells (Ryckman, BJ, et al., Characterization of the Human Cytomegalovirus gH / gL / UL128-131 Complex That Mediates Entry into Epithelial and Endothelial Cells, 2008 J. Virol. 82: 60-70).
[0009] The pentamer complex is considered the primary target for CMV vaccination. The viral genes UL128, UL130, and UL131 are required for entry into endothelial cells (Hahn et al., Human Cytomegalovirus UL131-128 Genes are Indispensable for Virus Growth in Endothelial Cells and Virus Transfer of Leukocytes, 2004 Journal of Virology 78(18): 10023-10033). Non-endothelial cell tropic strains adapted to fibroblasts contain mutations in at least one of these three genes. For example, the Towne strain contains a two-base pair insertion that creates a frameshift in the UL130 gene, and AD169 contains a one-base pair insertion in the UL131 gene. Both Towne and AD169 can be adapted to grow in endothelial cells, and in both cases the frameshift mutation in the UL130 or UL131 gene has been repaired.
[0010] Genini et al. (Serum antibody response to the gH / gL / pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections, 2011 J. Clin. Vir. 52: 113-118.) disclose serum antibody responses to the pentameric complex of HCMV in primary and reactivated HCMV infections. Responses were determined by both indirect immunofluorescence (IFA) and ELISA using fixed or lysed epithelial (ARPE-19) cells infected with one or more adenoviral vectors each carrying one HCMV gene and in parallel with a control adenoviral vector. Specificity of the results was determined by the reactivity of human neutralizing monoclonal antibodies recognizing two, three, or four proteins of the complex. In 14 primary infections, IgG antibody seroconversion to the UL128-131 gene product was consistently detected within 2-4 weeks after onset of infection, and antibodies persisted for at least 12 months. IgG antibody responses to the UL128-131 gene product were generally superior to responses to gH and appeared to follow neutralizing antibody responses (as assessed in epithelial cells). In reactivation infections, antibody responses showed a tendency reminiscent of booster responses. IgG antibodies were detected in HCMV-seropositive healthy adult controls but not in HCMV-seronegative individuals.
[0011] Kinzler et al. (Expression and reconstitution of the gH / gL / gO complex of human cytomegalovirus, 2002 J. Clin. Vir. 25(Supp.2): 87-95) coexpressed gH, gL, and gO in insect cells using recombinant baculovirus but failed to produce the gH / gL / gO ternary complex. Instead, only gH / gL heterodimers, gH / gL heteromultimers, and gO homomultimers were detected. In contrast, coexpression of gH, gL, and gO in mammalian cells produced high molecular weight complexes that were highly similar to the gH / gL / gO complexes formed in HCMV-infected cells. Cell surface immunofluorescence demonstrated that these complexes were expressed and displayed on the surface of transfected cells.
[0012] U.S. Patent No. 7,704,510 discloses that pUL131A is required for epithelial cell tropism, that pUL128 and pUL130 form a complex with gH / gL that is incorporated into virions, and that this complex is required for infection of endothelial and epithelial cells, but not fibroblasts, and that anti-CD46 antibodies have been found to inhibit HCMV infection of epithelial cells.
[0013] WO2014 / 005959 (also published as U.S. Patent Publication No. 2016-0159864) discloses a purified HCMV pentamer complex comprising polypeptides gH, gL, pUL128, pUL130, and pUL131A and its use in immunogenic compositions or vaccines.
[0014] In general, there is an inverse correlation between the flexibility of a protein from a mesophilic organism and the thermostability of that protein, as recently shown for the lipase A enzyme from the mesophilic organism Bacillus subtilis (see Rathi et al., Structural rigidity and protein thermostability in variants of Lipase A from Bacillus subtilis, 2015 PLOS ONE 19(7): e0130289; DOI: 10.1371 / journal.pone.0130289; page 24). Increased antigen stability has already been associated with improved immunogenicity, for example for the pre-fusion conformation of the respiratory syncytial virus fusion protein (McLellan et al., Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus, 2013 Science 342(6158): 592-598.) and Neisseria meningitidis factor H binding protein (fHbp) (Rossi et al., Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H, 2016 Infect. Immun. 84(6): 1735-1742.).
[0015] Improved thermostability of HCMV complexes, such as pentamer complexes, is expected to have the following advantages: (i) facilitate their preparation and production; (ii) affect their use as antigens, providing better immunogenicity. Thus, there is a need for the development of HCMV complexes, particularly pentamer complexes, with improved thermostability for suitable use in immunogenic compositions or vaccines. Furthermore, glycans in close proximity to neutralizing epitopes on HCMV complexes are thought to limit the accessibility of the epitopes. Thus, there is a need for the development of deglycosylated HCMV complexes, particularly pentamer complexes, with more accessible epitopes (optionally with improved thermostability) suitable for use in immunogenic compositions or vaccines. Summary of the Invention [Means for solving the problem]
[0016] The invention is based on the recombinant expression of stabilized HCMV complexes comprising two or more of the gH, gL, pUL128, pUL130, and pUL131A polypeptides (e.g., gH / gL, gH / gL / gO, or gH / gL / UL128 / UL130 / pUL131A complexes), where at least one of the two polypeptides is mutant, and their use in immunogenic or vaccine compositions. Methods of making and using these are provided. Mutant polypeptides and nucleic acid molecules encoding them are also provided, as well as antibodies, expression vectors, and host cells.
[0017] In one aspect of the invention, there is provided an HCMV gH polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. In another aspect of the invention, there is provided an HCMV gL polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. In a further aspect of the invention, there is provided an HCMV pUL128 polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. In a further aspect of the invention, there is provided an HCMV pUL130 polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. In a further aspect of the invention, there is provided an HCMV pUL131A polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations.
[0018] In a further aspect of the invention, there is provided a pentameric complex of HCMV polypeptides comprising a gH polypeptide, a gL polypeptide, a pUL128 polypeptide, a pUL130 polypeptide, and a pUL131A polypeptide, wherein at least one polypeptide comprises one or more amino acid stabilizing mutations. In a further aspect of the invention, the pentameric complex has increased stability compared to a non-mutant pentameric complex. In a further aspect of the invention, there is provided an immunogenic composition comprising the pentameric complex of HCMV polypeptides.
[0019] In a further aspect of the invention, there is provided a gH / gL complex of HCMV polypeptides comprising a gH polypeptide and a gL polypeptide, at least one of the polypeptides comprising one or more stabilizing mutations. In a further aspect of the invention, the gH / gL complex has increased stability compared to a non-mutant gH / gL complex. In a further aspect of the invention, there is provided an immunogenic composition comprising the gH / gL complex of HCMV polypeptides.
[0020] In a further aspect of the invention, there is provided a gH / gL / gO complex of HCMV polypeptides comprising a gH polypeptide, a gL polypeptide, and a gO polypeptide, wherein at least one of the gH and gL polypeptides comprises one or more amino acid stabilizing mutations. In a further aspect of the invention, the gH / gL / gO complex has increased stability compared to a non-mutant gH / gL / gO complex. In a further aspect of the invention, there is provided an immunogenic composition comprising the gH / gL / gO complex of HCMV polypeptides.
[0021] In a further aspect of the present invention, the complex of the present invention is produced in high yield. For example, in a process comprising growing a host cell of the present invention in a growth medium, the protein complex of the present invention can accumulate to a level of more than 0.4 mg per liter of growth medium (e.g., 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4, 4.5, or 5 mg per liter of growth medium or more).
[0022] The present invention provides the following: Embodiment 1. An HCMV gH polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. Embodiment 2. The HCMV gH polypeptide or complex-forming fragment thereof of embodiment 1, wherein the stabilizing mutations comprise one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, one or more deglycosylation mutations, or one or more combinations thereof. Embodiment 3. The HCMV gH polypeptide or complex-forming fragment thereof of embodiment 1 or 2, wherein the stabilizing mutations comprise one or more cavity-filling mutations. Embodiment 4. An HCMV gH polypeptide or complex-forming fragment thereof according to embodiment 3, wherein one or more of amino acid residues A102, A372, A352, and L257 relative to the sequence set forth in SEQ ID NO:1, or at corresponding positions in other HCMV gH polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 5. The HCMV gH polypeptide of any one of embodiments 1 to 4, wherein the stabilizing mutations comprise one or more hydrophobic mutations. Embodiment 6. An HCMV gH polypeptide or complex-forming fragment thereof according to embodiment 5, wherein one or more of amino acid residues H252, K404, R255, E355, H480, S601, and R405 relative to the sequence set forth in SEQ ID NO:1, or at corresponding positions in other HCMV gH polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 7. An HCMV gH polypeptide or complex-forming fragment thereof according to any one of embodiments 1 to 6, wherein the stabilizing mutations comprise one or more hydrophilic mutations. Embodiment 8. The HCMV gH polypeptide or complex-forming fragment thereof of embodiment 7, wherein one or more of amino acid residues G358 and H275 are substituted with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), glutamic acid (E), lysine (K), histidine (H), and aspartic acid (D). Embodiment 9. An HCMV gH polypeptide or complex-forming fragment thereof according to any one of embodiments 1 to 8, wherein the stabilizing mutations comprise one or more disulfide bridge mutations. Embodiment 10. An HCMV gH polypeptide or a complex-forming fragment thereof according to embodiment 9, wherein amino acid residues V109 and / or L111 are substituted with cysteine (C). Embodiment 11. An HCMV gH polypeptide or complex-forming fragment thereof according to any one of embodiments 1 to 10, wherein the stabilizing mutations comprise one or more deglycosylation mutations. Embodiment 12. The HCMV gH polypeptide or complex-forming fragment thereof of embodiment 11, wherein one or more of amino acid residues N55, N62, N67, N192, N641, and N700 are substituted with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 13. An HCMV gH polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:1, and (b) one or more of amino acid residues A102, A372, A352, and L257 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 14. An HCMV gH polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:1, and (b) one or more of amino acid residues H252, K404, R255, E355, H480, S601, and R405 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 15. An HCMV gH polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:1, and (b) one or more of amino acid residues G358 and H327 are substituted with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), glutamic acid (E), lysine (K), histidine (H), and aspartic acid (D). Embodiment 16. An HCMV gH polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:1, and (b) amino acid residues V109 and / or L11 are substituted with cysteine (C). Embodiment 17. An HCMV gH polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:1, and (b) one or more of amino acid residues N55, N62, N67, N192, N641, and N700 are substituted with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 18. An HCMV gH polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:1, further comprising a substitution of one or more of amino acid residues A102, A372, A352, and L257 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 19. An HCMV gH polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:1, further comprising a substitution of one or more of amino acid residues H252, K404, R255, E355, H480, S601, and R405 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 20. An HCMV gH polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:1, further comprising a substitution of one or more of amino acid residues G358 and H327 with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (Y), glutamine (Q), arginine (R), glutamic acid (E), lysine (K), histidine (H), and aspartic acid (D). Embodiment 21. An HCMV gH polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:1, further comprising substitution of amino acid residues V109 and / or L11 with cysteine (C). Embodiment 22. An HCMV gH polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:1, further comprising a substitution of one or more of amino acid residues N55, N62, N67, N192, N641, and N700 with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 23. A nucleic acid molecule encoding an HCMV gH polypeptide or a complex-forming fragment thereof according to any one of embodiments 1 to 22. Embodiment 24. An HCMV gL polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. Embodiment 25. The HCMV gL polypeptide or complex-forming fragment thereof of embodiment 24, wherein the stabilizing mutations comprise one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, one or more deglycosylation mutations, or a combination thereof. Embodiment 26. The HCMV gL polypeptide or complex-forming fragment thereof of embodiment 25, wherein the stabilizing mutations comprise one or more cavity-filling mutations. Embodiment 27. An HCMV gL polypeptide or a complex-forming fragment thereof according to embodiment 26, in which one or more of the amino acid residues H177, G224, G140, G145, D146, G218, L119, C233, and P272 relative to the sequence set forth in SEQ ID NO:7, or at corresponding positions in other HCMV gL polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 28. The HCMV gL polypeptide of any of embodiments 24 to 27, wherein the stabilizing mutations comprise one or more hydrophobic mutations. Embodiment 29. An HCMV gL polypeptide or a complex-forming fragment thereof according to embodiment 28, wherein one or more of amino acid residues H267, H236, H245, G161, and C233 relative to the sequence set forth in SEQ ID NO:7, or at corresponding positions in other HCMV gL polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 30. An HCMV gL polypeptide or complex-forming fragment thereof according to any of embodiments 24 to 29, wherein the stabilizing mutations comprise one or more disulfide bridge mutations. Embodiment 31. An HCMV gL polypeptide or a complex-forming fragment thereof according to embodiment 30, wherein one or more of amino acid residues G161, D163, G224, G218, R166, G140, R160, and A150 are substituted with cysteine (C). Embodiment 32. An HCMV gL polypeptide or complex-forming fragment thereof according to any of embodiments 24 to 31, wherein the stabilizing mutations comprise one or more deglycosylation mutations. Embodiment 33. The HCMV gL polypeptide or complex-forming fragment thereof of embodiment 32, wherein N74 is substituted with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 34. An HCMV gL polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:5, and (b) one or more of amino acid residues H177, G224, G140, G145, D146, G218, L119, C233, and P272 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 35. An HCMV gL polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:7, and (b) one or more of amino acid residues H267, H236, H245, G161, and C233 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 36. An HCMV gL polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:7, and (b) one or more of amino acid residues G161, D163, G224, G218, R166, G140, R160, and A150 are substituted with cysteine (C). Embodiment 37. An HCMV gL polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:7, and (b) amino acid residue N74 is substituted with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 38. An HCMV gL polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:7, further comprising a substitution of one or more of amino acid residues H177, G224, G140, G145, D146, G218, L119, C233, and P272 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 39. An HCMV gL polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:7, further comprising a substitution of one or more of amino acid residues H267, H236, H245, G161, and C233 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 40. An HCMV gL polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:7, further comprising a substitution of one or more of amino acid residues G161, D163, G224, G218, R166, G140, R160, and A150 with a cysteine (C). Embodiment 41. An HCMV gL polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:7, further comprising a substitution of residue N74 with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 42. A nucleic acid molecule encoding an HCMV gL polypeptide or a complex-forming fragment thereof according to any one of embodiments 24 to 41. Embodiment 43. An HCMV pUL128 polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. Embodiment 44. The HCMV pUL128 polypeptide or complex-forming fragment thereof of embodiment 43, wherein the stabilizing mutations include one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or one or more combinations thereof. Embodiment 45. The HCMV pUL128 polypeptide or complex-forming fragment thereof of embodiment 40, wherein the stabilizing mutations comprise one or more cavity-filling mutations. Embodiment 46. An HCMV pUL128 polypeptide or a complex-forming fragment thereof described in embodiment 45, in which one or more of the amino acid residues G123, V77, L103, and Q119 relative to the sequence set forth in SEQ ID NO:13, or at corresponding positions in other HCMV pUL128 polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 47. The HCMV pUL128 polypeptide of any of embodiments 43 to 46, wherein the stabilizing mutations comprise one or more hydrophobic mutations. Embodiment 48. An HCMV pUL128 polypeptide or a complex-forming fragment thereof according to embodiment 47, wherein one or more of the amino acid residues G145, H90, and G112 relative to the sequence set forth in SEQ ID NO: 13, or at corresponding positions in other HCMV pUL128 polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 49. An HCMV pUL128 polypeptide or complex-forming fragment thereof according to any of embodiments 43 to 48, wherein the stabilizing mutations comprise one or more disulfide bridge mutations. Embodiment 50. An HCMV pUL128 polypeptide or a complex-forming fragment thereof according to embodiment 49, wherein one or more of amino acid residues R142, N99, Y98, A124, G126, L159, D45, V88, M48, G107, R51, D106, and S83 are substituted with cysteine (C). Embodiment 51. An HCMV pUL128 polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:13, and (b) one or more of amino acid residues G123, V77, L103, and Q119 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 52. An HCMV pUL128 polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO: 13, and (b) one or more of amino acid residues G145, H90, and G112 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 53. An HCMV pUL128 polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:13, and (b) one or more of amino acid residues R142, N99, Y98, A124, G126, L159, D45, V88, M48, G107, R51, D106, and S83 are substituted with cysteine (C). Embodiment 54. An HCMV pUL128 polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO: 13, further comprising a substitution of one or more of amino acid residues G123, V77, L103, and Q119 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 55. An HCMV pUL128 polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO: 13, further comprising a substitution of one or more of amino acid residues G145, H90, and G112 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 56. An HCMV pUL128 polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO: 13, further comprising replacement of one or more of amino acid residues R142, N99, Y98, A124, G126, L159, D45, V88, M48, G107, R51, D106, and S83 with cysteine (C). Embodiment 57. A nucleic acid molecule encoding an HCMV pUL128 polypeptide or a complex-forming fragment thereof according to any one of embodiments 43 to 56. Embodiment 58. An HCMV pUL130 polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. Embodiment 59. The HCMV pUL130 polypeptide or complex-forming fragment thereof of embodiment 58, wherein the stabilizing mutations include one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, one or more deglycosylation mutations, or one or more combinations thereof. Embodiment 60. The HCMV pUL130 polypeptide of embodiment 59, wherein the stabilizing mutations comprise one or more cavity-filling mutations. Embodiment 61. An HCMV pUL130 polypeptide or a complex-forming fragment thereof described in embodiment 60, in which one or more of amino acid residues D165 and H209 relative to the sequence set forth in SEQ ID NO:17, or at corresponding positions in other HCMV pUL130 polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 62. The HCMV pUL130 polypeptide of any of embodiments 58 to 61, wherein the stabilizing mutations comprise one or more hydrophobic mutations. Embodiment 63. An HCMV pUL130 polypeptide or a complex-forming fragment thereof according to embodiment 62, wherein one or more of the amino acid residues G116, G135, H150, and H209 relative to the sequence set forth in SEQ ID NO: 17, or at corresponding positions in other HCMV pUL130 polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 64. An HCMV pUL130 polypeptide of any of embodiments 54 to 63, wherein the stabilizing mutations comprise one or more disulfide bridge mutations. Embodiment 65. An HCMV pUL130 polypeptide or a complex-forming fragment thereof described in embodiment 64, in which one or more of the amino acid residues G116, H150, P64, S178, P62, E95, Y204, N211, I213, Y56, and T167 relative to the sequence set forth in SEQ ID NO:17, or at corresponding positions in other HCMV pUL130 polypeptides, are substituted with cysteine (C). Embodiment 66. The HCMV pUL130 polypeptide of any of embodiments 54 to 65, wherein the stabilizing mutations comprise one or more deglycosylation mutations. Embodiment 67. An HCMV pUL130 polypeptide or a complex-forming fragment thereof described in embodiment 66, in which one or more of the amino acid residues N85, N118, and N201 relative to the sequence set forth in SEQ ID NO:17, or at corresponding positions in other HCMV pUL130 polypeptides, are substituted with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 68. An HCMV pUL130 polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO: 17, and (b) one or more of amino acid residues D165 and H209 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 69. An HCMV pUL130 polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO: 17, and (b) one or more of amino acid residues G116, G135, H150, and H209 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 70. An HCMV pUL130 polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO: 17, and (b) one or more of amino acid residues G116, H150, P64, S178, P62, E95, Y204, N211, I213, Y56, and T167 are substituted with cysteine (C). Embodiment 71. An HCMV pUL130 polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO: 17, and (b) one or more of amino acid residues N85, N118, and N201 are substituted with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 72. An HCMV pUL130 polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO: 17, further comprising a substitution of one or more of amino acid residues D165 and H209 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 73. An HCMV pUL130 polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO: 17, further comprising a substitution of one or more of amino acid residues G116, G135, H150, and H209 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 74. An HCMV pUL130 polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO: 17, further comprising substitution of one or more of amino acid residues G116, H150, P64, S178, P62, E95, Y204, N211, I213, Y56, and T167 with cysteine (C). Embodiment 75. An HCMV pUL130 polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO: 17, further comprising a substitution of one or more of amino acid residues N85, N118, and N201 with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 76. A nucleic acid molecule encoding an HCMV pUL130 polypeptide or a complex-forming fragment thereof according to any one of embodiments 58 to 75. Embodiment 77. An HCMV pUL131A polypeptide or a complex-forming fragment thereof comprising one or more stabilizing mutations. Embodiment 78. The HCMV pUL131A polypeptide or complex-forming fragment thereof described in embodiment 77, wherein the stabilizing mutations include one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, one or more deglycosylation mutations, or one or more combinations thereof. Embodiment 79. The HCMV pUL131A polypeptide or complex-forming fragment thereof of embodiment 78, wherein the stabilizing mutations comprise one or more cavity-filling mutations. Embodiment 80. An HCMV pUL131A polypeptide or a complex-forming fragment thereof described in embodiment 79, in which one or more of the amino acid residues G99, S86, and S90 relative to the sequence set forth in SEQ ID NO:21, or at corresponding positions in other HCMV pUL131A polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 81. The HCMV pUL131A polypeptide of any of embodiments 77 to 80, wherein the stabilizing mutations comprise one or more hydrophobic mutations. Embodiment 82. An HCMV pUL131A polypeptide or a complex-forming fragment thereof according to embodiment 81, wherein one or more of amino acid residues H69, H35, H64, D38, V85, Y52, and A67 relative to the sequence set forth in SEQ ID NO:21, or at corresponding positions in other HCMV pUL131A polypeptides, are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 83. An HCMV pUL131A polypeptide or a complex-forming fragment thereof according to any of embodiments 77 to 82, wherein the stabilizing mutations comprise one or more hydrophilic mutations. Embodiment 84. An HCMV pUL131A polypeptide or a complex-forming fragment thereof according to embodiment 83, wherein amino acid residue R118 is substituted with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), glutamic acid (E), lysine (K), histidine (H), and aspartic acid (D). Embodiment 85. An HCMV pUL131A polypeptide or a complex-forming fragment thereof according to any of embodiments 77 to 84, wherein the stabilizing mutations comprise one or more disulfide bridge mutations. Embodiment 86. An HCMV pUL131A polypeptide or a complex-forming fragment thereof described in embodiment 85, in which one or more of amino acid residues H64 and W37 relative to the sequence set forth in SEQ ID NO:21, or at corresponding positions in other HCMV pUL131A polypeptides, are substituted with cysteine (C). Embodiment 87. An HCMV pUL131A polypeptide or a complex-forming fragment thereof according to any of embodiments 77 to 86, wherein the stabilizing mutations comprise one or more deglycosylation mutations. Embodiment 88. An HCMV pUL131A polypeptide or a complex-forming fragment thereof described in embodiment 87, wherein amino acid residue N81 relative to the sequence set forth in SEQ ID NO:21, or at the corresponding position in another HCMV pUL131A polypeptide, is substituted with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 89. An HCMV pUL131A polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:21, and (b) one or more of amino acid residues G99, S86, and S90 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 90. An HCMV pUL131A polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:21, and (b) one or more of amino acid residues H69, H35, H64, D38, V85, Y52, and A67 are substituted with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 91. An HCMV pUL131A polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:21, and (b) amino acid residue R118 is substituted with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), glutamic acid (E), lysine (K), histidine (H), and aspartic acid (D). Embodiment 92. An HCMV pUL131A polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:21, and (b) one or more of amino acid residues H64 and W37 are replaced with cysteine (C). Embodiment 93. An HCMV pUL131A polypeptide comprising an amino acid sequence, wherein (a) the sequence is at least 90% identical to SEQ ID NO:21, and (b) amino acid residue N81 is substituted with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 94. An HCMV pUL131A polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:21, further comprising a substitution of one or more of amino acid residues G99, S86, and S90 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), and leucine (L). Embodiment 95. An HCMV pUL131A polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:21, further comprising a substitution of one or more of amino acid residues H69, H35, H64, D38, V85, Y52, and A67 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Embodiment 96. An HCMV pUL131A polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:21, further comprising a substitution of amino acid residue R118 with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), glutamic acid (E), lysine (K), histidine (H), and aspartic acid (D). Embodiment 97. An HCMV pUL131A polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:21, further comprising a substitution of one or more of amino acid residues H64 and W37 with cysteine (C). Embodiment 98. An HCMV pUL131A polypeptide or a complex-forming fragment thereof comprising the amino acid sequence of SEQ ID NO:21, further comprising a substitution of amino acid residue N81 with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Embodiment 99. A nucleic acid molecule encoding an HCMV pUL131A polypeptide or a complex-forming fragment thereof according to any of embodiments 77 to 98. Embodiment 100. An isolated antibody or antigen-binding fragment thereof specific for an HCMV gH polypeptide of any of embodiments 1 to 22. Embodiment 101. An isolated antibody or antigen-binding fragment thereof specific for an HCMV gL polypeptide of any of embodiments 24 to 41. Embodiment 102. An isolated antibody or antigen-binding fragment thereof specific for an HCMV pUL128 polypeptide of any of embodiments 43 to 56. Embodiment 103. An isolated antibody or antigen-binding fragment thereof specific for an HCMV pUL130 polypeptide of any of embodiments 58 to 75. Embodiment 104. An isolated antibody or antigen-binding fragment thereof specific for an HCMV pUL131A polypeptide of any of embodiments 77 to 98. Embodiment 105. A complex comprising an HCMV gH polypeptide according to any one of embodiments 1 to 22, and at least one of an HCMV gL polypeptide, an HCMV pUL128 polypeptide, an HCMV pUL130 polypeptide, and an HCMV pUL131A polypeptide. Embodiment 106. A complex according to embodiment 105, comprising an HCMV gH polypeptide, an HCMV gL polypeptide, an HCMV pUL128 polypeptide, an HCMV pUL130 polypeptide, and an HCMV pUL131A polypeptide according to any one of embodiments 1 to 22. Embodiment 107. A complex comprising an HCMV gL polypeptide according to any of embodiments 24 to 41 and at least one of an HCMV gH polypeptide, an HCMV pUL128 polypeptide, an HCMV pUL130 polypeptide, and an HCMV pUL131A polypeptide. Embodiment 108. A complex according to embodiment 107, comprising an HCMV gL polypeptide according to any of embodiments 24 to 41, and an HCMV gH polypeptide, an HCMV pUL128 polypeptide, an HCMV pUL130 polypeptide, and an HCMV pUL131A polypeptide. Embodiment 109. A complex comprising an HCMV pUL128 polypeptide according to any of embodiments 43 to 56, and at least one of an HCMV gH polypeptide, an HCMV gL polypeptide, an HCMV pUL130 polypeptide, and an HCMV pUL131A polypeptide. Embodiment 110. A complex described in embodiment 109, comprising an HCMV pUL128 polypeptide described in any of embodiments 43 to 56, and an HCMV gH polypeptide, an HCMV gL polypeptide, an HCMV pUL130 polypeptide, and an HCMV pUL131A polypeptide. Embodiment 111. A complex comprising an HCMV pUL130 polypeptide according to any of embodiments 58 to 75, and at least one of an HCMV gH polypeptide, an HCMV gL polypeptide, an HCMV pUL128 polypeptide, and an HCMV pUL131A polypeptide. Embodiment 112. A complex according to embodiment 111, comprising an HCMV pUL130 polypeptide according to any of embodiments 58 to 75, and an HCMV gH polypeptide, an HCMV gL polypeptide, an HCMV pUL128 polypeptide, and an HCMV pUL131A polypeptide. Embodiment 113. A complex comprising an HCMV pUL131A polypeptide according to any of embodiments 77 to 98, and at least one of an HCMV gH polypeptide, an HCMV gL polypeptide, an HCMV pUL128 polypeptide, and an HCMV pUL130 polypeptide. Embodiment 114. A complex described in embodiment 113, comprising an HCMV pUL131A polypeptide described in any of embodiments 77 to 98, and an HCMV gH polypeptide, an HCMV gL polypeptide, an HCMV pUL128 polypeptide, and an HCMV pUL130 polypeptide. Embodiment 115. A complex comprising an HCMV gH polypeptide described in any one of embodiments 1 to 22, an HCMV gL polypeptide described in any one of embodiments 24 to 41, an HCMV pUL128 polypeptide described in any one of embodiments 43 to 56, an HCMV pUL130 polypeptide described in any one of embodiments 58 to 75, and an HCMV pUL131A polypeptide described in any one of embodiments 77 to 98. Embodiment 116. The conjugate of any one of embodiments 105 to 115, which is a modified HCMV pentamer conjugate, ((i)) (a) a pUL128 polypeptide having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, and a pUL130 polypeptide having a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17; (b) a gL polypeptide having a glutamine (Q) at residue 74, numbered relative to SEQ ID NO:7; (c) a gL polypeptide having a phenylalanine (F) at residue 140, numbered relative to SEQ ID NO:7; (d) a gL polypeptide having a leucine (L) at residue 145, numbered relative to SEQ ID NO:7; (e) a pUL131 polypeptide having a phenylalanine (F) at residue 52 and a valine (V) at residue 67, numbered relative to SEQ ID NO:21; (f) a gL polypeptide having a valine (V) at residue 233, numbered relative to SEQ ID NO:7; (g) a gH polypeptide having an arginine (R) at residue 358, numbered relative to SEQ ID NO:3; (h) a gL polypeptide having a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7, and a pUL130 polypeptide having a cysteine (C) at residue 64, numbered relative to SEQ ID NO:17; (i) a pUL128 polypeptide having a cysteine (C) at residue 83, numbered relative to SEQ ID NO:13, and a pUL130 polypeptide having a cysteine (C) at residue 167, numbered relative to SEQ ID NO:17; (j) a gL polypeptide having a cysteine (C) at residue 160, numbered relative to SEQ ID NO:7, and a pUL130 polypeptide having a cysteine (C) at residue 56, numbered relative to SEQ ID NO:17; (k) a gL polypeptide having a cysteine (C) at residue 166, numbered relative to SEQ ID NO:7, and a pUL130 polypeptide having a cysteine (C) at residue 62, numbered relative to SEQ ID NO:17; (l) a pUL128 polypeptide having a cysteine (C) at residue 98, numbered relative to SEQ ID NO:13, and a pUL130 polypeptide having a cysteine (C) at residue 204, numbered relative to SEQ ID NO:17; (m) a pUL131 polypeptide having a phenylalanine (F) at residue 86, numbered relative to SEQ ID NO:21; (n) a pUL128 polypeptide having a cysteine (C) at residue 48 and a cysteine (C) at residue 107, numbered relative to SEQ ID NO:13; (o) a pUL128 polypeptide having an isoleucine (I) at residue 77, numbered relative to SEQ ID NO:13; (p) a pUL128 polypeptide having a leucine (L) at residue 145, numbered relative to SEQ ID NO:13; or (q) Combinations thereof Including, (ii) the modified HCMV pentamer complex has increased thermal stability compared to a control HCMV pentamer complex; Complex. Embodiment 117. A modified HCMV pentamer complex according to embodiment 116, comprising ((i)), (q) and ((ii)), wherein combination (q) is (1) (a) and one of (b), (c), (d), (f), and (g). (2) (c) and (e), or (3) (d) and (e) A modified HCMV pentamer complex comprising: Embodiment 118. An immunogenic composition comprising a conjugate of any one of embodiments 105 to 117. Embodiment 119. The immunogenic composition of embodiment 118, further comprising an HCMV gB polypeptide. Embodiment 120. The immunogenic composition of embodiment 118 or 119, further comprising a non-antigenic component. Embodiment 121. The immunogenic composition of embodiment 120, wherein the non-antigenic component is an immunologically effective amount of an adjuvant. Embodiment 122. The immunogenic composition of embodiment 121, wherein the adjuvant is AS01, an oil-in-water emulsion, an aluminum salt, a TLR7 agonist (TLR7a), TLR7a conjugated to an aluminum salt (alum-TLR7a), or a combination thereof. Embodiment 123. Non-antigenic components and (i) an HCMV gH polypeptide according to any one of embodiments 1 to 22; (ii) an HCMV gL polypeptide according to any one of embodiments 24 to 41; (iii) an HCMV pUL128 polypeptide according to any of embodiments 43 to 56; (iv) an HCMV pUL130 polypeptide according to any of embodiments 58 to 75, and (v) an HCMV pUL131A polypeptide according to any one of embodiments 77 to 98; A composition comprising at least one of the following: Embodiment 124. A nucleic acid molecule comprising one or more operably linked polynucleotide sequences which together encode a complex of any of embodiments 105 to 117. Embodiment 125. An expression vector comprising the nucleic acid molecule of embodiment 124. Embodiment 126. An expression vector comprising a nucleic acid molecule according to any one of embodiments 23, 42, 57, 76, 99, and 124. Embodiment 127. A plurality of expression vectors, each of which comprises one or more of the nucleic acid molecules described in embodiments 23, 42, 57, 76, and 99, and wherein the plurality of expression vectors together encode a complex described in any of embodiments 105 to 117. Embodiment 128. The multiple expression vectors of embodiment 127, wherein a first expression vector encodes an HCMV gH polypeptide and an HCMV gL polypeptide, and a second expression vector encodes an HCMV pUL128 polypeptide, an HCMV pUL130 polypeptide, and an HCMV pUL131A polypeptide. Embodiment 129. A host cell comprising a nucleic acid molecule according to any one of embodiments 23, 42, 57, 76, 99, and 124. Embodiment 130. The host cell of embodiment 129, wherein the nucleic acid molecule is integrated into the genome of the host cell. Embodiment 131. A host cell comprising an expression vector according to embodiment 125 or 126. Embodiment 132. A host cell comprising a plurality of expression vectors according to embodiment 127. Embodiment 133. A cell culture comprising a host cell of any of embodiments 129 to 132. Embodiment 134. A method of producing a modified HCMV polypeptide or a modified HCMV complex, comprising culturing a host cell according to any one of embodiments 129 to 133. Embodiment 135 The method of embodiment 134, further comprising contacting the culture medium with an antibody of any of embodiments 100 to 104. Embodiment 136 The method of embodiment 134 or 135, further comprising isolating the modified HCMV polypeptide or modified HCMV complex from the culture medium. Embodiment 137 The method of any one of embodiments 134 to 136, wherein the HCMV complex is a modified HCMV pentamer complex. Embodiment 138. A method for producing an HCMV complex, comprising introducing the nucleic acid molecule of embodiment 124 into a host cell genome. Embodiment 139. A modified HCMV polypeptide comprising any one or more of the mutations listed in Tables 1B, 2B, 3B, 4B, 5B, 22, and 23. Embodiment 140. A method of eliciting an immune response against cytomegalovirus (CMV), comprising administering to a subject an immunologically effective amount of the immunogenic composition of any of embodiments 118 to 122. Embodiment 141. The method of embodiment 140, wherein the immune response comprises the production of neutralizing antibodies against CMV. Embodiment 142. A method according to embodiment 140 or 141, (A) specific for an HCMV gH polypeptide according to any one of embodiments 1 to 22; (B) specific for an HCMV gL polypeptide according to any one of embodiments 24 to 41; (C) specific for an HCMV pUL128 polypeptide according to any one of embodiments 43 to 56; (D) specific for an HCMV pUL130 polypeptide according to any one of embodiments 58 to 75; or (E) specific for an HCMV pUL131A polypeptide according to any one of embodiments 77 to 98; An antibody or an antigen-binding fragment thereof. Embodiment 143. A pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof described in any of embodiments 100 to 104 and 142. Embodiment 144. The pharmaceutical composition of embodiment 143, further comprising a non-antigenic component. Embodiment 145. A method for inhibiting CMV entry into a cell, comprising contacting the cell with a complex of any of embodiments 105 to 117, an immunogenic composition of any of embodiments 118 to 122, or an antibody or antigen-binding fragment thereof of any of embodiments 100 to 104 and 142. Embodiment 146 The immunogenic composition of any of embodiments 118 to 122 for use in eliciting an immune response against cytomegalovirus (CMV). Embodiment 147. An immunogenic composition according to any of embodiments 118 to 122 for use in inhibiting CMV entry into cells. Embodiment 147. A pharmaceutical composition according to embodiment 143 or 144 for use in inhibiting CMV entry into cells. Embodiment 148. Use of an immunogenic composition according to any of embodiments 118 to 122 to elicit an immune response against cytomegalovirus (CMV). Embodiment 149. Use of an immunogenic composition according to any of embodiments 118 to 122 to inhibit CMV entry into a cell. Embodiment 133. Use of an antibody or antigen-binding fragment thereof according to any of embodiments 100 to 104 and 142 to inhibit CMV entry into a cell. Embodiment 150. Use of the pharmaceutical composition of embodiment 143 or 144 for inhibiting CMV entry into a cell. Embodiment 151 Use of an immunogenic composition according to any of embodiments 118 to 122 for the manufacture of a medicament for eliciting an immune response against cytomegalovirus (CMV). Embodiment 152. Use of an immunogenic composition according to any one of embodiments 118 to 122 for the manufacture of a medicament for inducing an immune response against cytomegalovirus (CMV), wherein the medicament is prepared for administration. Embodiment 153 Use of an immunogenic composition according to any of embodiments 118 to 122 for the manufacture of a medicament for inhibiting CMV entry into a cell. Embodiment 154. Use of an antibody or antigen-binding fragment thereof according to any one of embodiments 100 to 104 and 142 for the manufacture of a medicament for inhibiting CMV entry into a cell. Embodiment 155. Use of the pharmaceutical composition of embodiment 143 or 144 for the manufacture of a medicament for inhibiting CMV entry into a cell. Embodiment 156. A complex comprising one or more mutant human cytomegalovirus (HCMV) polypeptides, wherein the one or more mutant HCMV polypeptides are (a) a pUL128 polypeptide having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, or a complex-forming fragment thereof; a gL polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 140 and a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7; and a pUL130 polypeptide having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, or a complexing fragment thereof; (b) a pUL128 polypeptide or a complex-forming fragment thereof having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13; a gL polypeptide or a complex-forming fragment thereof having a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7; and a pUL130 polypeptide having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, or a complexing fragment thereof; (c) a pUL128 polypeptide having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, or a complex-forming fragment thereof; a gL polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 145 and a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7; and a pUL130 polypeptide having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, or a complexing fragment thereof; (d) a pUL128 polypeptide having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, or a complex-forming fragment thereof; a gL polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 224 and a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7; and a pUL130 polypeptide having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, or a complexing fragment thereof; (e) a pUL128 polypeptide having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, or a complex-forming fragment thereof; A gL polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 224 numbered relative to SEQ ID NO:7; and pUL130 polypeptide or a complex-forming fragment thereof having a cysteine (C) at residue 95 numbered relative to SEQ ID NO:17; (f) a pUL128 polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 77 and a cavity-filling mutation at residue 103, numbered relative to SEQ ID NO:13; and a gL polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 140 and a cavity-filling mutation at residue 145, numbered relative to SEQ ID NO:7; (g) a pUL128 polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 77 and a cavity-filling mutation at residue 103, numbered relative to SEQ ID NO:13; and a gL polypeptide or a complex-forming fragment thereof having a cavity-filling mutant at residue 140, a cavity-filling mutant at residue 145, and a cavity-filling mutant at residue 224, numbered relative to SEQ ID NO:7; (h) a gL polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 140 numbered relative to SEQ ID NO:7; and pUL131 polypeptide or a complex-forming fragment thereof having a repacking hydrophobic mutation at residue 52 and a repacking hydrophobic mutation at residue 67, numbered relative to SEQ ID NO:21; (i) a pUL131 polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 86 numbered relative to SEQ ID NO: 21; or (j) a pUL128 polypeptide or a complex-forming fragment thereof having a cysteine (C) at residue 83 numbered relative to SEQ ID NO:13; and pUL130 polypeptide or a complex-forming fragment thereof having a cysteine (C) at residue 167, numbered relative to SEQ ID NO:17. A complex. Embodiment 157. The conjugate of embodiment 156, wherein the cavity-filling mutant at residue 140, numbered relative to SEQ ID NO:7, is tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), or leucine (L). Embodiment 158. The conjugate of embodiment 157, wherein the cavity-filling mutant is phenylalanine (F). Embodiment 159. The conjugate of embodiment 156, wherein the cavity-filling mutant at residue 145, numbered relative to SEQ ID NO:7, is tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), or leucine (L). Embodiment 160. The conjugate of embodiment 159, wherein residue 145, numbered relative to SEQ ID NO:7, is leucine (L). Embodiment 161. The conjugate of embodiment 156, wherein the cavity-filling mutant at residue 224, numbered relative to SEQ ID NO:7, is tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), or leucine (L). Embodiment 162. The conjugate of embodiment 161, wherein residue 224, numbered relative to SEQ ID NO:7, is a valine (V). Embodiment 163. The conjugate of embodiment 156, wherein the cavity-filling mutant at residue 77, numbered relative to SEQ ID NO:13, is tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), or leucine (L). Embodiment 164. The conjugate of embodiment 163, wherein residue 77, numbered relative to SEQ ID NO: 13, is isoleucine (I). Embodiment 165. The conjugate of embodiment 156, wherein said cavity-filling mutant at residue 103, numbered relative to SEQ ID NO: 13, is tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), or leucine (L). Embodiment 166 The conjugate of embodiment 165, wherein residue 103, numbered relative to SEQ ID NO: 13, is isoleucine (I). Embodiment 167. The complex of embodiment 156, wherein the repacking hydrophobic variant at residue 52, numbered relative to SEQ ID NO:21, is tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), or proline (P). Embodiment 168. The conjugate of embodiment 167, wherein residue 52, numbered relative to SEQ ID NO:21, is phenylalanine (F). Embodiment 169. The complex of embodiment 156, wherein the repacking hydrophobic variant at residue 67, numbered relative to SEQ ID NO:21, is tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), or proline (P). Embodiment 170. The conjugate of embodiment 169, wherein residue 67, numbered relative to SEQ ID NO:21, is a valine (V). Embodiment 171. The conjugate of embodiment 156, wherein the cavity-filling mutant at residue 86, numbered relative to SEQ ID NO:21, is tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), or leucine (L). Embodiment 172. The conjugate of embodiment 171, wherein residue 86, numbered relative to SEQ ID NO:21, is phenylalanine (F). Embodiment 173. A conjugate according to any of embodiments 156 to 172, having increased thermal stability compared to a control conjugate under the same conditions. Embodiment 174. A complex according to any of embodiments 156 to 173 which is an HCMV pentamer complex comprising one or more mutant HCMV polypeptides. Embodiment 175. An immunogenic composition comprising a conjugate according to any one of embodiments 156 to 174 and optionally a non-antigenic component. Embodiment 176. An isolated nucleic acid molecule comprising one or more operably linked polynucleotide sequences encoding a complex of any of embodiments 156 to 174. Embodiment 177. An expression vector comprising the isolated nucleic acid molecule of embodiment 176. Embodiment 178. A host cell comprising the isolated nucleic acid molecule of embodiment 176 or the expression vector of embodiment 177. Embodiment 179. A method for producing a complex, comprising culturing the host cell of embodiment 178. Embodiment 180. A method of eliciting an immune response against human cytomegalovirus (HCMV), comprising administering to a subject an immunologically effective amount of the immunogenic composition of embodiment 175. Embodiment 181. A method of inhibiting entry of human cytomegalovirus (HCMV) into a cell, comprising contacting the cell with a complex of embodiment 174. Embodiment 182. Use of the immunogenic composition of embodiment 175 to induce an immune response against cytomegalovirus (CMV). Embodiment 183. Use of the immunogenic composition of embodiment 175 to inhibit CMV entry into cells (e.g. epithelial cells). Embodiment 184. Use of the immunogenic composition of embodiment 175 for the manufacture of a medicament for eliciting an immune response against cytomegalovirus (CMV). Embodiment 185. Use of the immunogenic composition of embodiment 175 for the manufacture of a medicament for eliciting an immune response against cytomegalovirus (CMV), wherein the medicament is prepared for administration. Embodiment 186. Use of the immunogenic composition of embodiment 175 for the manufacture of a medicament for inhibiting CMV entry into a cell (e.g., an epithelial cell). [Brief description of the drawings]
[0023] [Figure 1] Figure 1 is a diagram depicting the crystal structure of the HCMV pentamer complex (pentamer) containing gH, gL, pUL128, pUL130, and pUL131A (the positions of each are indicated by labels). In particular, Figure 1 provides two 180° rotated views of a cartoon representation of the pentamer. Disulfide bonds and modeled Asn-linked oligomannose are represented as black sticks. [Figure 2A]Figure 2A is a diagram depicting the HCMV pentamer complex containing gH, gL, pUL128, pUL130, and pUL131A. Five interfaces are boxed and enlarged subpanels are provided to show details of key residue interactions. Disulfides are shown as black sticks and polar contacts are shown as black dashed lines. The UL130-UL131A, UL128-UL130-UL131A, gL-UL130, gL-UL128, and gH-gL interfaces are depicted in Figure 2A and enlarged depictions of each of those interfaces are shown in Figures 2B-2F, respectively. [Figure 2B] Figure 2B provides an expanded view of a subpanel of the UL130-UL131A interface from Figure 2A. Figure 2B shows the α2 and α3 helices of pUL130 and pUL130 residues L69, Y113, and N118. The position of the pUL130 α3 helix is indicated by an arrow. Figure 2B also shows the α3 helix of pUL131A and pUL131A residues D66, H69, and L71. Disulfides are shown as black sticks and polar contacts are shown as black dashed lines. [Figure 2C] FIG. 2C provides an expanded view of a subpanel of the UL128-UL130-UL131A interface from FIG. 2A. FIG. 2C shows the α1 and α2 helices, β1, β4, β5, and β6 sheets of pUL128, and pUL128 residues D45, K92, and L103. FIG. 2C shows the β5, β4, and β6 sheets of pUL130 (the position of each is indicated by an arrow). FIG. 2C also shows pUL130 residue H209. FIG. 2C shows the α1, α2, and α3 helices of pUL131A, and pUL131A residue H35. The positions of the pUL131A α1 and α2 helices are indicated by arrows. Disulfides are shown as black sticks, and polar contacts are shown as black dashed lines. [Figure 2D]Figure 2D provides an expanded view of a subpanel of the gL-UL130 interface from Figure 2A. Figure 2D shows the β1 and β2 sheets of gL and gL residues L82, Y152, R160, Y162, and R166. Figure 2D also shows the α1 helix and β3 sheet of pUL130 and pUL130 residues Y56, P58, F59, L60, Y61, P62, P64, P65, R66, and L99. Disulfides are shown as black sticks and polar contacts are shown as black dashed lines. [Figure 2E] Figure 2E provides an expanded view of a subpanel of the gL-UL128 interface from Figure 2A. Figure 2E shows the α4, α3, and α2 helices and β2 and β1 sheets of gL, as well as gL residues L101, L106, L122, V137, and D157. Figure 2E also shows the α3 helix of pUL128, as well as pUL128 residues R142, L146, L150, L159, V161, and C162. Figure 2E also shows pUL130 residue Q97. Disulfides are shown as black sticks and polar contacts are shown as black dashed lines. [Figure 2F] Figure 2F provides an expanded view of a subpanel of the gH-gL interface from Figure 2A. Figure 2F shows the β1, β3, β4, and β5 sheets of gH and the α1 helix of gH (the position of each is indicated by an arrow). Figure 2F also shows gH residue C95. Figure 2F shows the β5, β4, and β3 sheets of gL (the position of each is indicated by an arrow) and the α1 and α6 helices of gL. Figure 2F also shows gL residues C47 and C54. Disulfides are shown as black sticks and polar contacts are shown as black dashed lines. [Figure 3A] Figure 3 depicts the conformational flexibility of the HCMV pentamer complex (pentamer): Figure 3A shows side and top views of gH-based superpositions of the pentamer-8I21 Fab at 4.0 Å and 3.0 Å resolution. [Figure 3B]Figure 3 depicts the conformational flexibility of the HCMV pentamer complex (pentamer). Figure 3B shows a side view of the superposition between the pentamer-9I6 Fab and the 3.0 Å resolution pentamer-8I21 Fab complex. The boxed region after a 45° rotation is shown in the subpanel, highlighting the position of the gH helix linker that likely serves as a hinge for the rigid arm movement of the UL. [Figure 3C] Figure 3 is a diagram depicting the conformational flexibility of the HCMV pentamer complex (pentamer). Figure 3C shows a pUL130 / pUL131A-based superposition of the pentamer-9I6 complex and the pentamer-8I21 Fab complex at 3.0 Å resolution. [Figure 4A] Figure 4A is a diagram depicting cavities within the pentameric complex and locations where stabilizing mutations of the invention may be made. Cavities are indicated by line-filled irregular shapes and stabilizing mutation locations are indicated by dots (the dots in Figure 4A represent locations only, i.e., there is no 1:1 relationship between the number of dots in Figure 4A and the number of stabilizing mutations of the invention). Figure 4A also identifies with boxes the UL interface and the gH-gL-UL interface. [Figure 4B] Figure 4B provides a close-up view of the gH-gL-UL interface from Figure 4A. Figure 4B depicts cavities within the gH-gL-UL interface, indicated by irregular shapes filled with lines. [Figure 4C] Figure 4C provides a close-up view of the UL interface from Figure 4A. Figure 4C depicts a cavity within the UL interface, indicated by an irregular shape filled with lines. [Figure 5A] Figure 5A depicts cavity filling within the HCMV pentamer complex due to the presence of stabilizing mutations. Five cavity filling mutations are shown, each in one of the pUL128, pUL130, pUL131A, gL, and gH pentamer complex subproteins. Subpanels are provided for each of the five cavity filling mutations. The cavities are indicated by line-filled irregular shapes. [Figure 5B]Figure 5B provides a close-up of the UL128 G123W cavity-filling mutation subpanel from Figure 5A. The location of the G123W side chain and its presence within the cavity are indicated by an arrow. The cavity is indicated by a line-filled irregular shape. [Figure 5C] Figure 5C provides a close-up of the UL130 D165W cavity-filling mutation subpanel from Figure 5A. The location of the D165W side chain and its presence within the cavity are indicated by an arrow. The cavity is indicated by a line-filled irregular shape. [Figure 5D] Figure 5D provides a close-up of the UL131 G99W cavity-filling mutation subpanel from Figure 5A. The location of the G99W side chain and its presence within the cavity are indicated by an arrow. The cavity is indicated by a line-filled irregular shape. [Figure 5E] Figure 5E provides a close-up of the gL H177W cavity-filling mutation subpanel from Figure 5A. The location of the H177W side chain and its presence within the cavity are indicated by an arrow. The cavity is indicated by a line-filled irregular shape. [Figure 5F] Figure 5F provides a close-up of the gH A102W cavity-filling mutation subpanel from Figure 5A. The location of the A102W side chain and its presence within the cavity are indicated by an arrow. The cavity is indicated by a line-filled irregular shape. [Figure 6A] Figure 6A depicts disulfide bridge mutations within the HCMV pentamer complex. The 16 disulfide bridge mutations and the resulting 8 disulfide bonds / bridges (bridging cysteine residues) are shown and numbered (1) through (8). Disulfide bonds are represented by sticks. The top subpanel of Figure 6A shows disulfide bonds (1), (2), (3), (4), (7), and (8). The bottom subpanel of Figure 6B shows disulfide bonds (5) and (6). [Figure 6B]Figure 6B provides an expanded view of the top subpanel from Figure 6A. Disulfide bonds are represented by sticks. (1) shows the intra-disulfide bond resulting from disulfide bridge mutations pUL130 G116C and pUL130 H150C. (2) shows the inter-disulfide bond resulting from disulfide bridge mutations gL G161C and pUL130 P64C. (3) shows the inter-disulfide bond resulting from disulfide bridge mutations pUL130 S178C and pUL131A H64C. (4) shows the inter-disulfide bond resulting from disulfide bridge mutations gL D163C and pUL130 P62C. (7) shows the inter-disulfide bond resulting from disulfide bridge mutations pUL128 R142C and pUL130 E95C. (8) shows the inter-disulfide bond resulting from the disulfide bridge mutations gL R166C and pUL130 P62C. [Figure 6C] Figure 6C provides an expanded view of the lower subpanel from Figure 6A. Disulfide bonds are represented by sticks. (5) shows the inter-disulfide bond resulting from disulfide bridge mutations gH V109C and gL G224C. (6) shows the inter-disulfide bond resulting from disulfide bridge mutations gH L111C and gL G218C. [Figure 7]FIG. 7 is a diagram depicting the location of five non-overlapping neutralizing epitopes on the pentamer in ovals (sites 1, 2, 3, 4, and 5). The label for site 4 is shown as "4 / 6" meaning that site 4 overlaps site 6, and the label for site 3 is shown as "3 / 7" meaning that site 3 overlaps site 7. FIG. 7 further depicts eleven glycans on the pentamer surface. The general location of each glycan is shown as a rectangle. In particular, ten glycans are found on the face of the pentamer molecule depicted on the left side of FIG. 7 (six glycans on gH, one on gL, and four on UL). On the other face of the pentamer molecule depicted on the right side of FIG. 7, one (the eleventh) glycan is found on pUL130, located adjacent to site 2. The other glycans depicted on the right side of FIG. 7 are also depicted on the left side of FIG. 7. Within the rectangles are spheres representing carbon atoms, nitrogen atoms, oxygen atoms, and hydrogen atoms. [Figure 8] FIG. 8 provides the results of a neutralizing antibody assay using epithelial cells. FIG. 8 represents the geometric mean antibody titers (GMTs) of serum samples taken from mice 3 weeks after the second dose of a composition comprising one of the seven pentamer conjugates (further described in Example 5.2 and Table 25) and AS01E adjuvant was administered intramuscularly, with immunogenic amounts listed along the x-axis. The y-axis provides the neutralizing antibody (nAb) titers (GMT, 95% confidence interval (CI)) on a scale of 101 to 106. The lower limit of detection (LLOD) is indicated by a dashed line. Set 2_20 had the highest nAb titers, with titers higher than Set 2_36, Set 2_21, and the control ("Penta (LSG)") (p-value < 0.05 represented by a star (*)). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] Described herein is the crystal structure of an HCMV pentamer complex made of polypeptides gH, gL, pUL128, pUL130, and pUL131A in combination with an antigen-binding fragment (Fab) of a monoclonal antibody (mAb). The inventors analyzed the crystal structure and characterized (i) the presence of small interfaces between some of the domains of the complex, (ii) the presence of several cavities at the domain interfaces, and (iii) the inherent flexibility or mobility of the complex. The inventors also characterized and described herein modifications of the polypeptides (i.e., modifications of polypeptides gH, gL, pUL128, pUL130, and / or pUL131A) that improve the thermostability of the pentamer complex. In particular, the inventors provide specific amino acids in each of the polypeptides of the HCMV pentamer complex that, when modified as described herein, improve the thermostability of a complex containing it. Without wishing to be bound by theory, it is believed that the amino acid modifications of the present invention improve the thermostability of the complex by reducing the conformational flexibility of the complex. This is believed to occur, for example, because (A) the mutant amino acids of the invention (those resulting from the stabilizing mutations described herein) have longer side chains than the original amino acids (those naturally present in the referenced non-mutated protein sequence), and the atoms of the side chains of the modified amino acids fill the buried cavities between domain interfaces and / or the protein core cavities. In this way, the structural features of the mutant amino acids with longer side chains affect the filling of the buried cavities between domain interfaces and / or the protein core cavities, resulting in improved stability of the complex. Such mutations may be referred to herein as "cavity-filling mutations" and the resulting mutant amino acids may be referred to as "cavity-filling mutants". The amino acid modifications of the invention are further believed to (B) improve the thermal stability of the complex by "repacking" the complex through increasing contacts with neighboring residues and / or replacing undesirable clusters of charged residues in or between proteins. Such mutations may be referred to herein as "repacking mutations" and the resulting amino acids may be referred to as "repacking mutants".Certain repacking mutations are referred to herein as "hydrophobic mutations" or "hydrophilic mutations," and the resulting mutant amino acids may be referred to as "hydrophobic mutants" or "hydrophilic mutants," respectively. Thus, the structural features of the mentioned mutant amino acids that are hydrophobic or hydrophilic result in increased contacts with their neighboring residues and / or reduced undesirable clusters of charged residues, leading to improved stability of the complex. Furthermore, the amino acid modifications of the present invention are believed to (C) improve the thermal stability of the complex by introducing disulfide bridges throughout the complex. This is believed to occur because the newly introduced disulfide bridges anchor (constrain) the polypeptide, thereby reducing the mobility of the polypeptide. Thus, the structural features of the mutant amino acids that are cysteines or other residues that are structurally capable of forming disulfide bonds result in the introduction of disulfide bridges, leading to improved stability of the complex. Such mutations are referred to herein as "disulfide bridge mutations," and the resulting amino acids may be referred to as "disulfide bridge mutants." Thus, the present invention provides modified HCMV pentamer complex proteins (gH, gL, pUL128, pUL130, and pUL131A), optionally in HCMV complexes (e.g., pentamer, gH / gL, or gH / gL / gO complexes), in which one or more variant amino acids confer at least one of A-C and thereby improved thermostability of the complex. Analysis of the crystal structure of the HCMV pentamer complex and its neutralizing epitopes led the inventors to select additional glycans that are in close proximity to the neutralizing epitopes and are expected to similarly limit the accessibility of the respective HCMV pentamer epitope(s). Thus, the inventors expect that by introducing one or more of the deglycosylation mutations into the HCMV complex, the corresponding epitope(s) will become more accessible compared to the non-mutated epitope. In particular, it is believed that removal of one or more of the identified glycans will "unmask" the corresponding epitope, increasing antigenicity.The inventors specifically propose to replace the identified asparagine residues with any non-asparagine amino acid (e.g., glutamine) using known techniques, thereby preventing N-linked glycosylation at that position, thereby unmasking the corresponding epitope. Thus, the present invention provides modified HCMV pentamer complex proteins (gH, gL, pUL128, pUL130, and pUL131A), optionally in an HCMV complex (e.g., pentamer, gH / gL, or gH / gL / gO complex), in which one or more variant amino acids result in deglycosylation. Such deglycosylation can unmask the epitope, making it more accessible to, for example, a neutralizing antibody or antibody fragment.
[0025] The polypeptides of the present invention are mutants and therefore have a different structure compared to non-mutant (e.g., wild-type or control) polypeptides.Similarly, since the complexes of the present invention comprise at least one mutant HCMV gH, gL, UL128, UL130, and pUL131A polypeptides, the complexes comprising the polypeptides of the present invention have a different structure compared to non-mutant complexes (e.g., wild-type or control complexes).Furthermore, the complexes of the present invention may have a different function compared to non-mutant complexes in that the complexes of the present invention may have increased thermal stability compared to non-mutant (e.g., wild-type or control) complexes.
[0026] It is therefore an object of the present invention to provide HCMV gH, gL, pUL128, pUL130, and pUL131A polypeptides as defined herein which offer the advantage of forming complexes (e.g. pentamer, gH / gL, or gH / gL / gO complexes) with improved thermostability and / or more accessible epitopes. Although the present invention is applicable to polypeptides derived from any HCMV strain, for ease of understanding, when referring to amino acid positions herein, numbering is given with reference to the amino acid sequence of polypeptides derived from the Merlin strain, unless otherwise stated. In particular, unless otherwise stated, gH amino acid positions are given relative to the sequence of Merlin gH in SEQ ID NO: 1, gL amino acid positions are given relative to the sequence of Merlin gL in SEQ ID NO: 7, pUL128 amino acid positions are given relative to the sequence of Merlin pUL128 in SEQ ID NO: 13, pUL130 amino acid positions are given relative to the sequence of Merlin pUL130 in SEQ ID NO: 17, pUL131A amino acid positions are given relative to the sequence of Merlin pUL131A in SEQ ID NO: 21, and gO amino acid positions are given relative to the sequence of Merlin gO in SEQ ID NO: 25. However, the invention is not limited to Merlin strains. Using the teachings of the present invention, the equivalent amino acid positions in the polypeptides of any other HCMV strains can be readily determined by one of skill in the art by aligning the amino acid sequences using readily available alignment algorithms (e.g., BLAST with default settings, ClustalW2 with default settings, or the algorithm described by Corpet (Multiple Sequence Alignment with Hierarchical Clustering, 1998 Nucleic Acids Research 16(22): 10881-10890) with default parameters). Thus, reference to an "HCMV polypeptide" should be understood as an HCMV polypeptide from any strain (in addition to the Merlin strain). The actual numbering of amino acid residue positions will need to be adjusted for polypeptides from other strains depending on the actual sequence alignment.
[0027] "Corresponding to residue ## of SEQ ID NO:##" or "corresponding to residue ## of SEQ ID NO:##" or "related to residue ## of SEQ ID NO:##" or "at a position corresponding to 'X' of SEQ ID NO:##" or "at a position corresponding to the location of residue ## of SEQ ID NO:##" or "numbered relative to residue ## of SEQ ID NO:##" are exemplary phrases used in the context of the present invention for clarity, particularly within the claims, to provide a means of identifying a particular position within an amino acid sequence. Furthermore, these phrases are used to encompass amino acid sequences that encode a polypeptide having the same or similar function as, for example, a protein having a referenced amino acid sequence of SEQ ID NO:##, but have a substantially different structure (i.e., the encompassed polypeptide has the same or similar function as the referenced protein, but the encompassed polypeptide and the referenced protein have different amino acid sequences). By way of example, a polypeptide comprising a mutation at "an amino acid residue corresponding to P45 in the pUL131A sequence of SEQ ID NO:21" would encompass at least a polypeptide having a mutation at P45 in the pUL131A sequence of SEQ ID NO:21 (Merlin strain), a polypeptide having a mutation at P45 in the pUL131A sequence of SEQ ID NO:23 (Towne strain), and a polypeptide having a mutation at P49 in the pUL131A sequence of SEQ ID NO:24 (AD169 strain) (all of which are underlined in the multiple sequence alignment of SEQ ID NOs:21, 23, and 24 below; the signal sequence residues are also underlined). TIFF0007584405000001.tif44140
[0028] By "HCMV complex" or simply "complex" in the sense of the present invention is meant a group of two or more associated proteins comprising at least one of the HCMV polypeptides gH, gL, pUL128, pUL130, pUL131A or a complex-forming fragment thereof. HCMV complexes or "complexes" in the sense of the present invention include, for example, gH / UL115, gH / gL (e.g. gH / gL heterodimers or gH / gL dimers of heterodimers), gH / gL / gO, and pentameric complexes. A "mutant HCMV complex" or simply "mutant complex" in the sense of the present invention is meant a group of two or more associated proteins comprising at least one of the HCMV polypeptides gH, gL, pUL128, pUL130, pUL131A or a complex-forming fragment thereof, wherein at least one HCMV polypeptide or complex-forming fragment thereof comprises one or more stabilizing mutant amino acid residues.
[0029] By "pentameric complex" in the sense of the present invention is meant an HCMV complex comprising five different HCMV polypeptides gH, gL, pUL128, pUL130, and pUL131A. Although generally referred to herein as a gH / gL / pUL128 / pUL130 / pUL131A pentamer (or a pentameric complex comprising gH, gL, pUL128, pUL130, and pUL131A), it is not necessary that each of the five polypeptides is a full-length polypeptide. The term "pentameric complex" also encompasses pentamers formed by complex-forming fragments of the gH, gL, pUL128, pUL130, and pUL131A polypeptides.
[0030] The term "complex subprotein" or simply "subprotein" may be used in the sense of the present invention to mean an HCMV polypeptide present in the mentioned HCMV complex. For example, a "subprotein" of the HCMV pentamer complex means any one of gH, gL, pUL128, pUL130, and pUL131A, which in this example is synonymous with "HCMV pentamer complex protein". In a further example, a "gH / gL complex subprotein" means a gH or gL polypeptide.
[0031] A "complex-forming fragment" of an HCMV polypeptide, in the sense of the present invention, refers to any part or portion of the polypeptide that retains the ability to form a complex (e.g., pentameric complex, gH / gL dimer, and gH / gL / gO trimer) with other HCMV polypeptides of the complex. As used herein, a "complex-forming fragment" of a mutant polypeptide comprises one or more mutant amino acid residues (i.e., a fragment of a mutant protein comprises mutation(s)). The ability to form a complex (e.g., pentameric complex) of the present invention can be tested by performing a purification of the protein and analyzing the protein by non-reducing PAGE, Western blot, and / or size exclusion chromatography. If the protein forms part of a complex, the protein may all be present as a single band on a native PAGE gel and / or as a single peak in a size exclusion chromatogram.
[0032] "Improved thermo-stability" or "improved thermostability" or "higher thermostability" or "enhanced thermostability" or simply "improved stability" or "higher stability" or "enhanced stability" in the sense of the present invention means that a complex (e.g., a pentameric complex) has at least a lower unfolding rate under the same conditions than the same complex not containing any stabilizing mutation (in other words, the complex unfolds slower than a non-mutant complex under the same conditions). "Conditions" as used herein include, for example, experimental conditions and physiological conditions. A composition comprising a stabilized complex of the present invention may be specified to have an extended shelf life compared to a composition comprising a non-mutant complex. See, e.g., U.S. Patent Publication No. 2011 / 0229507A1, which is incorporated herein by reference in its entirety; Clapp et al., Vaccines with Aluminum-Containing Adjuvants: Optimizing Vaccine Efficacy and Thermal Stability, 2011 J. Pharm. Sci. 100(2): 388-401, which discusses adjuvant-mediated stability enhancement and evaluates antigen stability under varying conditions of pH, hydration, and temperature; and Rossi et al., 2016 Infect. Immun. 84(6): 1735-1742. Stability herein may be provided by a delta stability (dStability or dS) scoring method, which is a calculated determined difference between the relative thermal stability of an in silico mutant protein and the thermal stability of the corresponding wild-type or non-mutant protein. Methods for determining dS stability are provided in Example 3 and include, for example, known tools, such as Molecular Operating Environment (MOE) software (REF: Molecular Operating Environment (MOE) software; Chemical Computing Group Inc., available at WorldWideWeb (www).chemcomp.com). dS is measured in kcal / mol. A low dS value indicates high protein stability and conversely, a high dS value indicates low protein stability.The mutant polypeptides of the invention may be identified as having a higher relative thermal stability (in kcal / mol) than the non-mutant polypeptide under the same experimental conditions. The mutant polypeptides of the invention may further be identified as having a lower dS value than the non-mutant polypeptide under the same experimental conditions. It is understood from the present invention that a mutant polypeptide having a lower dS value than the non-mutant polypeptide under the same experimental conditions is more stable than the non-mutant polypeptide. The improved stability can be assessed using differential scanning calorimetry (DSC), for example, as discussed in Bruylants et al. (Differential Scanning Calorimetry in Life Sciences: Thermodynamics, Stability, Molecular Recognition and Application in Drug Design, 2005 Curr. Med. Chem. 12: 2011-2020) and Calorimetry Sciences Corporation's "Characterizing Protein stability by DSC" (Life Sciences Application Note, Doc. No. 20211021306 February 2006), or by differential scanning fluorimetry (DSF). The increase in stability was assessed by DSC or DSF as the thermal transition midpoint (T m A "significant" increase or improvement in thermostability may be characterized as an increase of at least about 5°C in the calculated Tm of the complex (e.g., calculated by the protocol provided in Example 4.7). See, e.g., Thomas et al., Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen, 2013 Hum. Vaccin. Immunother. 9(4): 744-752. A "significant" increase or improvement in thermostability is defined as an increase of at least about 5°C in the calculated Tm of the complex (e.g., calculated by the protocol provided in Example 4.7).
[0033] A "mutation" in the sense of the present invention means the substitution of an amino acid residue with another amino acid residue. In the context of a nucleic acid sequence, this substitution occurs via a missense mutation in the corresponding codon of the coding region (a mutant polypeptide encoded by such a mutant nucleic acid sequence may be referred to as a "mutein"). The term "mutation" as used herein also includes modifications that introduce non-naturally occurring amino acids or amino acid analogs into a polypeptide. A "mutation" as used herein does not include an "identical mutation", which is a substitution of an amino acid residue with a naturally occurring or synthetically produced amino acid having the same chemical structure. As an example, the substitution of an alanine with an alanine at position 102 of the sequence of SEQ ID NO: 1 (A102A) is an "identical mutation" as used herein and does not fall within the meaning of "mutation" in the sense of the present invention. Thus, the mutations of the present invention may be defined on the premise that identical mutations are excluded.
[0034] "Stabilizing mutation" or "stabilizing variant" in the sense of the present invention means any mutation in an HCMV polypeptide which, upon formation of a pentameric complex, results in a complex with improved thermo-stability compared to a pentameric complex formed with an HCMV polypeptide not containing such a mutation. Stabilizing mutations in the sense of the present invention include in particular cavity-filling mutations, repacking mutations (which include hydrophobic and hydrophilic mutations) and disulfide bridge mutations. The stabilizing mutations of the present invention are not detrimental to the use of the mutated protein as an antigen. In particular, the stabilizing mutations do not block all epitopes capable of inducing the production of antibodies capable of binding to at least the HCMV complexes described herein and / or capable of neutralizing the biological effect of said HCMV complexes. Moreover, the stabilizing mutations of the present invention do not prevent the mutant polypeptide from forming a complex. "Stabilized complex" in the sense of the present invention means a complex (e.g. a pentameric complex) comprising at least one polypeptide comprising at least one stabilizing mutation.
[0035] As used herein, the terms "amino acid," "residue," and "amino acid residue" all refer to an organic compound that contains at least one amino group (-NH2) and at least one carboxyl group (-COOH). However, for clarity, particularly in the claims, an amino acid that occurs at a particular position in a wild-type or non-mutant sequence (e.g., a wild-type amino acid) may be referred to as an "amino acid," and the compound that occurs at the corresponding position in a mutant sequence (a mutant amino acid) may be referred to as a "residue" (i.e., an amino acid that results from a missense mutation may be referred to as a "residue").
[0036] "Non-mutant" in the sense of the present invention means that the referred molecule (e.g., sequence, polypeptide, or complex) does not comprise a stabilizing mutation or a deglycosylation mutation of the present invention. Thus, the term "non-mutant" encompasses the "wild-type" structure, but also encompasses, for example, truncated wild-type polypeptides. For example, an HCMV gH polypeptide having the amino acid sequence of SEQ ID NO: 3 is a "non-mutant" polypeptide, since at least it is truncated and therefore does not have the "wild-type" HCMV gH structure. Furthermore, an HCMV gL polypeptide having, for example, the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 29 is a "non-mutant" polypeptide in the sense of the present invention. For clarity, "non-mutant" is used herein as a reference to structure and not to function. A non-mutant polypeptide may, for example, be described as having a wild-type function (e.g., an HCMV gH polypeptide comprising SEQ ID NO: 3).
[0037] A "cavity-filling mutation" in the sense of the present invention refers to the substitution of a first amino acid (e.g., a wild-type amino acid) with a second amino acid having a longer side chain than the first amino acid. Such a second amino acid may be referred to as a "cavity-filling mutant." In other words, a cavity-filling mutation herein is a substitution of an amino acid with a residue, where the residue has a longer side chain than the amino acid. Such amino acid residues with long side chains include tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L).
[0038] A "repacking mutation" in the sense of the present invention refers to the substitution of a first amino acid residue (e.g., a wild-type amino acid) with a second amino acid residue that increases the interaction with neighboring residues in a polypeptide. Such a second amino acid may be referred to as a "repacking mutant." Repacking mutations include, for example, amino acid substitutions that (1) enhance hydrophobic interactions (e.g., with hydrophobic amino acids) or hydrogen bond formation (with polar or charged (i.e., hydrophilic) amino acids) or (2) reduce undesirable or repulsive interactions of neighboring residues (e.g., by removing clusters of similarly charged residues). Repacking mutations in the sense of the present invention include, in particular, hydrophobic and hydrophilic mutations.
[0039] "Hydrophobic mutation" in the sense of the present invention refers to the replacement of a first amino acid residue (e.g., a wild-type amino acid) with a second amino acid residue having a hydrophobic side chain. Such a second amino acid may be referred to as a "hydrophobic mutant" or a "hydrophobic repacking mutant". Such amino acid residues having a hydrophobic side chain include tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Tyrosine (Y) may also be classified as hydrophobic.
[0040] A "hydrophilic mutation" in the sense of the present invention refers to the substitution of a first residue (e.g., a wild-type amino acid residue) with a second amino acid that has a hydrophilic side chain. Such a second amino acid may be referred to as a "hydrophilic mutant" or a "hydrophilic repacking mutant". A "hydrophilic side chain" encompasses both substitutions with amino acids that have polar side chains and substitutions with amino acids that have charged side chains. It is generally understood in the art that polar amino acid side chains are hydrophilic but uncharged, and charged amino acid side chains are both hydrophilic and charged. A "polar mutation" in the sense of the present invention refers to the substitution of a first amino acid residue (e.g., a wild-type amino acid) with a second amino acid residue that has a polar side chain. Amino acid residues that have polar side chains include serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), and glutamine (Q). A "charged mutation" in the sense of the present invention refers to the replacement of a first amino acid residue (e.g., a wild-type amino acid) with a second amino acid residue that has a charged side chain. Amino acid residues that have a charged side chain include arginine (R), glutamic acid (E), lysine (K), histidine (H), and aspartic acid (D).
[0041] "Disulfide bridge mutation" in the sense of the present invention means a substitution of an amino acid residue by a cysteine (C) residue, which results in the formation of a disulfide bridge in or between polypeptides. The present invention includes individual proteins (e.g. gH, gL, pUL128, pUL130, and pUL131A) that consist of one disulfide bridge mutation (i.e., substitution of one amino acid by cysteine). The disulfide bridge is formed between two residues, either an "intra-disulfide bridge" (formed between two residues in the same polypeptide) or an "inter-disulfide bridge" (formed between two residues, the first residue in the first polypeptide and the second residue in the second polypeptide). Therefore, in order to increase the stability of a protein complex using only disulfide bridge mutations, disulfide bridge mutations must be introduced into the complex in pairs (multiples of two), with at least one pair of disulfide bridge mutations each in one or more of the complex subproteins. The complex may be specified to contain 2n disulfide bridge mutations, where "n" is any positive integer including 0. The complex may be further specified to contain 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, or more disulfide bridge mutations, in multiples of two. For example, the invention encompasses a stabilized pentameric complex comprised of a pair of disulfide bridge mutations, a first disulfide bridge mutation at a residue corresponding to G116C of pUL130 having the sequence of SEQ ID NO: 17, and a second disulfide bridge mutation at a residue corresponding to H150C of pUL130 having the sequence of SEQ ID NO: 17 (see Table 21 below). Further by way of example, the present invention encompasses a stabilized pentamer complex consisting of a pair of disulfide bridge mutations, the first at a residue corresponding to D163C in gL having the sequence of SEQ ID NO:7, and the second at a residue corresponding to P62C in pUL130 having the sequence of SEQ ID NO:17 (see Table 21 below).Further, for example, the present invention includes a stabilized pentamer complex consisting of two pairs of disulfide bridge mutations, a first pair of disulfide bridge mutations consisting of a first disulfide bridge mutation at a residue corresponding to D163C of gL having the sequence of SEQ ID NO: 7 and a second disulfide bridge mutation at a residue corresponding to P62C of pUL130 having the sequence of SEQ ID NO: 17, and a second pair of disulfide bridge mutations consisting of a third disulfide bridge mutation at a residue corresponding to V109C of gH having the sequence of SEQ ID NO: 1 and a fourth disulfide bridge mutation at a residue corresponding to G224C of gL having the sequence of SEQ ID NO: 7 (see Table 21 below). For stabilized complexes of the present invention comprising, for example, one repacking mutation and one disulfide bridge mutation, it is not necessary to specify the pair of disulfide bridge mutations, since only one repacking mutation may be sufficient to generate increased stability.
[0042] "Deglycosylation mutation(s)" in the sense of the present invention refers to the substitution of an asparagine amino acid (e.g., a wild-type asparagine amino acid) with a second amino acid, thereby preventing the addition of a glycan to the asparagine nitrogen atom at that residue (i.e., preventing N-linked glycosylation at that residue). Such a second amino acid may be referred to as a "deglycosylation mutant." The second amino acid may be any non-asparagine residue. Thus, a polypeptide or complex comprising a deglycosylation mutation may be specified to comprise a glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), or aspartic acid (D) residue, and a non-mutant (e.g., wild-type or control) polypeptide or complex, respectively, to comprise an asparagine (N) residue. The HCMV polypeptides, or complex-forming fragments thereof, or HCMV complexes of the present invention may comprise one or more deglycosylation mutations, or may comprise a combination of one or more stabilizing mutations (i.e., cavity-filling mutations, repacking mutations, and / or disulfide bridge mutations) and one or more deglycosylation mutations.
[0043] "Antigenicity" is used herein to mean the ability of an antigen to combine with an antibody, e.g., bind to a neutralizing antibody. Thus, "increased antigenicity" or "enhanced antigenicity" encompasses, for example, an increase in the binding affinity of a neutralizing antibody to a mutant antigen compared to the binding affinity to a non-mutant antigen. The increase in binding affinity can be provided as a decrease in the dissociation constant (Kd) value (in nM). See generally, e.g., Ma et al., Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies, 2011 PLoS Path. 7(9), e1002200.
[0044] "Immunogenicity" is used herein to mean the ability of an antigen to elicit an immune response. See generally, e.g., Ma et al., 2011 PLoS Path. 7(9), e1002200.
[0045] As used in this disclosure and the claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise. That is, "a" means "one or more" unless otherwise indicated.
[0046] The term "about" or "approximately" means approximately, around, or in the region. The term "about" or "approximately" further means within an acceptable contextual error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the degree of accuracy required for a particular purpose (e.g., the amount of complex in a medium) or the limitations of the measurement system. When the term "about" or "approximately" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values described. For example, "about 5.5-6.5 mg / ml" means that the boundaries of the numerical range are extended below 5.5 and above 6.5, thereby achieving the same functional results as the particular value in question falls within the range. For example, "about" and "approximately" can mean within or above 1 standard deviation according to the practice of the art. Alternatively, "about" and "approximately" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably up to 1% of a given value.
[0047] The term "and / or," when used in a phrase, e.g., "A and / or B," is intended to include "A and B," "A or B," "A," and "B." Similarly, the term "and / or," when used in a phrase, e.g., "A, B, and / or C," is intended to encompass each of the following embodiments: "A, B, and C," "A, B, or C," "A or C," "A or B," "B or C," "A and C," "A and B," "B and C," "A (single)," "B (single)," and "C (single)."
[0048] Unless otherwise specified, the designations "A% to B%, "A to B%, "A% to B%, "A to B%, "A% to B%, "A% to B%, "A% to B%, "A% to B", "A% to B", "A% to B" are all given their ordinary and accustomed meaning. In some embodiments, these designations are synonymous.
[0049] The term "comprising" encompasses "including" as well as "consisting," e.g., a composition "comprising" X may consist exclusively of X or may include something additional (e.g., X+Y). The terms "including" and "having," when used herein as transitional phrases, are open-ended, while the term "consisting of," when used herein as a transitional phrase, is closed (i.e., limited to what is recited and nothing more).
[0050] The word "substantially" does not exclude "completely". For example, a composition that is "substantially" free of Y may be completely free of Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.
[0051] An "effective amount" means an amount sufficient to elicit a stated effect or result, e.g., in a "therapeutically effective amount of an antigen and / or adjuvant." An "effective amount" can be determined empirically and in a routine manner using known techniques relevant to the stated purpose.
[0052] Unless specifically stated, a process that includes a step of mixing two or more components does not require any particular order of mixing. Thus, the components can be mixed in any order. If there are three components, two components may be combined with each other and the combination may be combined with a third component, etc. Similarly, when method steps are numbered (e.g., (1), (2), (3), etc., or (i), (ii), (iii)), the numbering of the steps does not imply that the steps must be performed in numerical order (i.e., step 1, then step 2, then step 3, etc.). The word "then" may be used to specify the order of method steps.
[0053] "Recombinant" as used herein to describe a polynucleotide means a polynucleotide of semisynthetic or synthetic origin, genomic, cDNA, RNA (including mRNA), that, by its origin or manipulation, (1) is not associated with all or a portion of the polynucleotide with which it is naturally associated, and / or (2) is linked to a polynucleotide other than the polynucleotide to which it is naturally linked. The term "recombinant" as used in reference to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide. A nucleic acid molecule may be referred to as "heterologous" (i.e., the nucleic acid molecule is heterologous to at least that polynucleotide) when it is operably linked to another polynucleotide with which it is not naturally associated. Similarly, a polypeptide may be referred to as "heterologous" (i.e., the polypeptide is heterologous to at least that protein) when it is in contact with or in a complex with another protein with which it is not naturally associated. Furthermore, if a host cell contains a nucleic acid molecule or polypeptide that it does not naturally contain, the nucleic acid molecule and polypeptide can be referred to as "heterologous" (i.e., the nucleic acid molecule is heterologous to the host cell and the polypeptide is heterologous to the host cell).
[0054] The sequence identity between polypeptide sequences is preferably determined by a pairwise alignment algorithm using the Needleman-Wunsch global alignment algorithm (Needleman and Wunsch, A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins, 1970 J. Mol. Biol. 48(3): 443-453), using default parameters (e.g., with the EBLOSUM62 scoring matrix, gap opening penalty=10.0, gap extension penalty=0.5). This algorithm is conveniently implemented in the needle tool in the EMBOSS package (Rice et al., EMBOSS: The European Molecular Biology Open Software Suite, 2000 Trends Genetics 16: 276-277). The sequence identity should be calculated over the entire length of the polypeptide sequence of the invention.
[0055] gH Polypeptide HCMV glycoprotein H (gH), encoded by the UL75 gene, is a virion glycoprotein that is important for infectivity and is conserved among members of the alpha-, beta-, and gamma-herpesviruses.
[0056] gH from the HCMV Merlin strain has been reported to consist of 742 amino acids (NCBI GI:52139248, which is also NCBI GenBank accession number YP_081523.1, SEQ ID NO:1). gH from the HCMV Towne strain (NCBI GI:138314, which is also NCBI UniProtKB accession number P17176.1, SEQ ID NO:5) also consists of 742 amino acids (SEQ ID NO:5). gH from the HCMV AD169 strain has been published under NCBI UniProtKB accession number P12824.1 (SEQ ID NO:6 herein). HCMV gH has been reported to have six N-glycosylation sites (at residues 55, 62, 67, 192, 641, and 700) and consists of a hydrophobic signal sequence at its N-terminus (amino acid residues 1-23 of SEQ ID NO:1), an ectodomain that protrudes from the cell into the extracellular space (residues 24-717 of SEQ ID NO:1), a hydrophobic TM domain (residues 718-736 of SEQ ID NO:1), and a C-terminal cytoplasmic domain (residues 737-742 of SEQ ID NO:1).
[0057] The ectodomain of gH corresponds to the portion of gH that lacks the hydrophobic TM. The location and length of the ectodomain can be predicted based on a pairwise alignment of a given sequence with SEQ ID NO:1, for example by aligning the amino acid sequence of a gH polypeptide of interest with SEQ ID NO:1 and identifying sequences that align to residues 24-717 of SEQ ID NO:1. Similarly, the location of the TM domain and the C-terminal domain can be predicted by aligning the amino acid sequence of a gH polypeptide of interest with SEQ ID NO:1 and identifying sequences that align to residues 718-736 and residues 737-742 of SEQ ID NO:1, respectively. Alternatively, the location and length of the ectodomain, signal sequence, and TM domain can be predicted based on a computational analysis of the hydrophobicity along the length of a given gH protein sequence. The signal sequence and TM domain have the highest levels of hydrophobicity, and these two regions are adjacent to the ectodomain, which is less hydrophobic. The absence of a TM domain means that the modified polypeptide cannot reside in a lipid bilayer. In some embodiments, the gH polypeptide lacks the entire native TM domain, while in other embodiments, the gH polypeptide can retain a portion of the native TM domain, but not enough to allow the protein to reside in a lipid bilayer. Thus, the polypeptide can include up to 10 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) of the native gH TM domain.
[0058] Typically, the N-terminal signal sequence of the gH polypeptide is cleaved by a host cell signal peptidase to produce a mature gH protein. In a preferred embodiment, the HCMV gH polypeptide mutated according to the invention lacks an N-terminal signal sequence. An example of an HCMV gH polypeptide lacking an N-terminal sequence is SEQ ID NO: 2. In a further preferred embodiment, the HCMV gH polypeptide mutated according to the invention lacks an N-terminal signal sequence, a transmembrane (TM) domain, and a C-terminal domain. Expression of the full-length UL75 gene sequence precludes purification of soluble complexes containing gH. Rather, complexes containing gH can be purified in high yield and purity by omitting at least a portion of the TM domain of gH. For example, a construct encoding only the N-terminal signal sequence and ectodomain (or a majority of the gH ectodomain) of gH, but not the TM domain, can be used to express a form of gH that can be easily purified (see, for example, WO2014 / 005959, also published as U.S. Patent Publication No. 2016-0159864). The construct may encode most of the gH ectodomain (e.g., 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) but none or only a small portion of the TM domain. The gH polypeptides of the invention may comprise the entire gH ectodomain or a truncated form of the gH ectodomain (e.g., a gH polypeptide consisting of SEQ ID NO: 3 or 4 that does not include residues 716 or 717 of the ectodomain of SEQ ID NO: 1, and that does not include the TM domain or the C-terminal domain). The truncated form of the ectodomain may lack 1 to 20 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues) at its N-terminus and / or C-terminus relative to the full-length HCMV gH protein. In an alternative embodiment, the HCMV gH polypeptide mutated according to the invention lacks the N-terminal signal sequence, the TM domain, and the C-terminal domain.An example of a preferred HCMV gH polypeptide for use in the present invention is SEQ ID NO:3, which has a truncated ectodomain of the gH sequence of SEQ ID NO:1, lacks the transmembrane (TM) domain, and lacks the C-terminal cytoplasmic domain. SEQ ID NO:3 consists of amino acid residues 1 to 715 of SEQ ID NO:1. An example of a preferred gH protein of the present invention is SEQ ID NO:4, which lacks the N-terminal signal sequence of the gH sequence of SEQ ID NO:1, has a truncated ectodomain, lacks the TM domain, and lacks the C-terminal domain. SEQ ID NO:4 consists of amino acid residues 24 to 715 of SEQ ID NO:1.
[0059] As shown in the Examples, the gH polypeptide is glycosylated (contains glycans via N-linked glycosylation) at six asparagine residues, N55, N62, N67, N192, N641, and N700, numbered relative to the amino acid sequence of gH in SEQ ID NO: 1. HCMV gH polypeptides or complex-forming fragments thereof for use in the present invention may include deglycosylation mutations at one or more of the asparagines located at residues 55, 62, 67, 192, 641, and 700, numbered relative to the sequence of gH in SEQ ID NO: 1. The deglycosylation mutations may be glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), or aspartic acid (D). In particular, the deglycosylation mutations may be glutamine (Q), serine (S), threonine (T), or alanine (A). More particularly, the deglycosylation mutation may be a glutamine (Q).
[0060] The gH proteins of the invention can include additional amino acid residues, such as an N-terminal or C-terminal extension. Such extensions can include one or more tags that can facilitate detection (e.g., an epitope tag for detection by monoclonal antibodies) and / or purification (e.g., a polyhistidine tag allowing purification on a nickel-chelating resin) of the gH protein. For example, a gH protein of the invention can include a truncated gH ectodomain fused to a C-terminal extension (see, e.g., WO2014 / 005959, also published as U.S. Patent Publication No. 2016-0159864).
[0061] The gH proteins of the invention may have various degrees of identity to SEQ ID NO: 1, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 1. The gH proteins of the invention may have various degrees of identity to SEQ ID NO: 2, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 2. The gH proteins of the invention may have various degrees of identity to SEQ ID NO:3, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:3. The gH proteins of the invention may have various degrees of identity to SEQ ID NO:4, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:4. The gH proteins of the invention may have various degrees of identity to SEQ ID NO:5, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:5. The gH proteins of the invention may have various degrees of identity to SEQ ID NO:6, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:6.A preferred gH protein or fragment thereof is capable of (i) dimerizing with HCMV gL, (ii) forming part of a trimeric gH / gL / gO complex, (iii) forming part of a pentameric gH / gL / pUL128 / pUL130 / pUL131A complex, (iv) comprising at least one epitope from SEQ ID NO:1, 2, 3, 4, 5, or 6, and / or (v) eliciting antibodies in vivo that are immunologically cross-reactive with HCMV virions. An exemplary complex-forming fragment of gH comprises residues Arg1-Leu125 of SEQ ID NO:2, which, when in complex with full-length gL (possibly using the flexible C-terminus of gL as a linker), full-length pUL128, full-length pUL130, and full-length pUL131A, can form a truncated HCMV pentameric complex that nevertheless maintains the five conformational epitope sites set forth in FIG. 7.
[0062] The HCMV gH polypeptide or complex-forming fragment thereof of the present invention comprises one or more stabilizing mutations, preferably one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. Any gH polypeptide having a sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4, or any gH polypeptide having a sequence at least 90% identical to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4, may preferably comprise any one or more stabilizing mutations identified and defined herein. Thus, in some embodiments, the HCMV gH polypeptide or complex-forming fragment thereof having a sequence set forth in SEQ ID NO:1 comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, the HCMV gH polypeptide or complex-forming fragment thereof having a sequence set forth in SEQ ID NO:2 comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In further alternative embodiments, an HCMV gH polypeptide having the sequence set forth in SEQ ID NO:3, or a complex-forming fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In further alternative embodiments, an HCMV gH polypeptide having the sequence set forth in SEQ ID NO:4, or a complex-forming fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof.
[0063] As described in more detail in Example 3 and illustrated in Figures 2A-2F, the inventors have identified several cavities at the gH / gL / UL interface in the crystal structure of the pentamer complex. Thus, any cavity-filling mutation whose purpose is to fill the cavities observed at such interfaces in the HCMV gH polypeptide is expected to contribute favorably to the stability of the complex (e.g., the pentamer, gH / gL, or gH / gL / gO complex) when associated with other components of the complex. Similarly, any repacking mutation, e.g., any hydrophobic mutation or any hydrophilic mutation whose purpose is to increase contacts between neighboring residues in the HCMV gH polypeptide is expected to contribute favorably to the stability of the complex (e.g., the pentamer, gH / gL, or gH / gL / gO complex) when associated with other components of the complex. Similarly, any disulfide bridge mutations whose purpose is to introduce intra-disulfide bridges in the HCMV gH polypeptide and / or inter-disulfide bridges between the HCMV gH polypeptide and any of the other components of the complex (e.g., the HCMV gL, HCMV pUL128, HCMV pUL130, or HCMV pUL131A polypeptides of the HCMV pentameric complex) are expected to favorably contribute to a complex with improved thermal stability.
[0064] Identification of relevant amino acid residues in the HCMV gH polypeptide to be mutated for cavity filling and / or repacking and / or disulfide bridging can be performed both by visual inspection of the three-dimensional structure, for example with the aid of molecular graphics software, or by using any suitable in silico mutagenesis method. For example, software such as the Molecular Operating Environment (MOE) (compiled by Chemical Computing Group Inc.) allows for systematic analysis of the amino acid sequence to identify specific regions or specific amino acids in the polypeptide whose mutations are predicted to improve thermostability.
[0065] Suitable non-limiting exemplary amino acid residues to be mutated in HCMV gH polypeptides are provided in Table 1 with the sequence set forth as SEQ ID NO:1 for reference only. Mutations at similar positions in other HCMV gH polypeptides, such as polypeptides having the sequence set forth in SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4, or gH polypeptides derived from HCMV strains different from the Merlin strain, are also contemplated in the present invention. It is within the ability of one of ordinary skill in the art to determine such similar positions in other HCMV gH polypeptides. Equivalent amino acid positions in a given HCMV polypeptide can be determined by aligning amino acid sequences using readily available and known alignment and algorithms (e.g., BLAST or ClustalW2). The actual numbering of the amino acid positions will have to be adjusted for other HCMV gH polypeptides depending on the actual sequence alignment.
[0066] [Table 1-1]
[0067] Thus, in some embodiments, the amino acids mutated in the HCMV gH polypeptide to fill the cavity are A102, A372, A352, or L257 of the sequence set forth in SEQ ID NO: 1, or at the corresponding positions in HCMV gH polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of replacing any of them, and / or more than one of them, and possibly all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L). Thus, in some embodiments, the HCMV gH polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to 102, 372, 352, and 257 of SEQ ID NO: 1 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L).
[0068] Suitable non-limiting exemplary amino acids to be mutated in an HCMV gH polypeptide for hydrophobic mutations are H252, K404, R255, E355, H480, S601, or R405 of the sequence set forth in SEQ ID NO: 1, or at the corresponding positions in HCMV gH polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of substituting any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Thus, in some embodiments, the HCMV gH polypeptides of the invention comprise at least one amino acid substitution at positions 252, 404, 255, 355, 480, 601, and 405 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P).
[0069] Suitable non-limiting exemplary amino acids to be mutated in an HCMV gH polypeptide for hydrophilicity mutations are G358 or H275 of the sequence set forth in SEQ ID NO: 1, or at the corresponding positions in HCMV gH polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of substituting any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), and glutamic acid (E). Thus, in some embodiments, the HCMV gH polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to G358 and H275 of SEQ ID NO: 1 with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), and glutamic acid (E). Suitable non-limiting exemplary amino acids to be mutated in an HCMV gH polypeptide for a polar mutation are G358 or H275 of the sequence set forth in SEQ ID NO: 1, or at the corresponding positions in an HCMV gH polypeptide from a different HCMV strain. Suitably, mutation of these amino acid residues may consist of replacing any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), and glutamine (Q). Thus, in some embodiments, the HCMV gH polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to G358 and H275 of SEQ ID NO: 1 with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), and glutamine (Q). Suitable non-limiting exemplary amino acids to mutate in an HCMV gH polypeptide for a charge mutation are G358 or H275 of the sequence set forth in SEQ ID NO: 1, or at the corresponding positions in HCMV gH polypeptides from different HCMV strains. Suitably, these amino acid residues are Mutation of the group may consist of substituting any of them, and / or more than one of them, and possibly all of them, with the amino acid residues arginine (R) or glutamic acid (E).Thus, in some embodiments, the HCMV gH polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to G358 and H275 of SEQ ID NO:1 with arginine (R) or glutamic acid (E).
[0070] Suitable non-limiting exemplary amino acids to mutate in an HCMV gH polypeptide for disulfide bridge mutations are V109 or L111 of the sequence set forth in SEQ ID NO: 1, or at the corresponding positions in HCMV gH polypeptides from different HCMV strains. Thus, in some embodiments, an HCMV polypeptide of the invention comprises at least one substitution, preferably both, of the residue corresponding to V109 of SEQ ID NO: 1 with a cysteine (C) or the residue corresponding to L111 of SEQ ID NO: 1 with a cysteine (C).
[0071] Thus, in some embodiments, the amino acids mutated in the HCMV gH polypeptide for deglycosylation are N55, N62, N67, N192, N641, and N700 of the sequence set forth in SEQ ID NO: 1, or at the corresponding positions in an HCMV gH polypeptide from a different HCMV strain. Suitably, mutation of these amino acid residues may consist of substituting any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Thus, in some embodiments, the HCMV gH polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to 55, 62, 67, 192, 641, and 700 of SEQ ID NO:1 with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D).
[0072] [Table 1-2]
[0073] gL polypeptide HCMV glycoprotein L (gL), encoded by the UL115 gene, is believed to be essential for viral replication. All known functional properties of gL are directly associated with its dimerization with gH. The gL / gH complex is required for fusion of the viral membrane with the plasma membrane, leading to viral entry into the host cell. gL from HCMV Merlin strain (NCBI GI:39842115, also NCBI GenBank Accession No. AAR31659.1, SEQ ID NO:7) and HCMV Towne strain (NCBI GI:239909463, also NCBI GenBank Accession No. ACS32410.1, SEQ ID NO:11 herein) has been reported to be 278 amino acids in length. gL from HCMV strain AD169 (NCBI GI:2506510, which is also NCBI UniProtKB accession number P16832.2, SEQ ID NO:12 herein) has been reported to be 278 amino acids in length, contains a signal sequence at its N-terminus (amino acid residues 1-35), has two N-glycosylation sites (at residues 74 and 114), and lacks a TM domain (Rigoutsos et al., In silico pattern-based analysis of the human cytomegalovirus genome, 2003 J. of Virology 77: 4326-44). By sequencing the full-length gL gene from 22-39 clinical isolates as well as a laboratory strain of AD169, Towne and Toledo revealed less than 2% amino acid sequence variation among isolates (Rasmussen et al., The Genes Encoding the gCIII Complex of Human Cytomegalovirus Exist in Highly Diverse Combinations in Clinical Isolates, 2002 J. of Virology 76: 10841-10888). Typically, the N-terminal signal sequence of the gL protein is cleaved by a host cell signal peptidase to produce a mature gL polypeptide. The gL polypeptide for use in the present invention may lack the N-terminal signal sequence.An example of an HCMV gL polypeptide lacking the N-terminal sequence is SEQ ID NO: 8, which consists of amino acid residues 31-278 of SEQ ID NO: 7. Examples of preferred gL polypeptides for use in the invention are SEQ ID NO: 9 or 10, which contain an LSG mutation at a putative protease recognition site, which reduces protease cleavage. Examples of preferred gL polypeptides for use in the invention are SEQ ID NO: 29 or 30, which contain an IDG mutation at a putative protease recognition site, which reduces protease cleavage.
[0074] As shown in the Examples, the gL polypeptide is glycosylated (contains glycans via N-linked glycosylation) at one asparagine residue, i.e., N74, numbered relative to the amino acid sequence of gL in SEQ ID NO: 7. HCMV gL polypeptides or complex-forming fragments thereof for use in the present invention may comprise a deglycosylation mutation at residue 74, numbered relative to the sequence of gL in SEQ ID NO: 7. The deglycosylation mutation may be glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), or aspartic acid (D). In particular, the deglycosylation mutation may be glutamine (Q), serine (S), threonine (T), or alanine (A). More particularly, the deglycosylation mutation may be glutamine (Q).
[0075] The gL proteins of the invention may have various degrees of identity to SEQ ID NO:7, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:7. The gL proteins of the invention may have various degrees of identity to SEQ ID NO:8, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:8. The gL proteins of the invention may have various degrees of identity to SEQ ID NO:9, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:9. The gL proteins of the invention may have various degrees of identity to SEQ ID NO:10, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:10. The gL protein of the invention may have various degrees of identity to SEQ ID NO: 11, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 11. The gL protein of the invention may have various degrees of identity to SEQ ID NO: 12, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 12.The gL proteins of the invention may have various degrees of identity to SEQ ID NO: 29, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 29. The gL proteins of the invention may have various degrees of identity to SEQ ID NO: 30, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 30. A preferred gL protein or fragment thereof is capable of (i) dimerizing with HCMV gH, (ii) forming part of a trimeric gH / gL / gO complex, (iii) forming part of a pentameric gH / gL / pUL128 / pUL130 / pUL131A complex, (iv) comprising at least one epitope from SEQ ID NO:7, 8, 9, 10, 11, 12, 29, or 30, and / or (v) eliciting antibodies in vivo that are immunologically cross-reactive with HCMV virions. An exemplary complex-forming fragment of gL comprises residues Thr76-Tyr169 of SEQ ID NO:7, which when in complex with full-length pUL128, full-length pUL130, and full-length pUL131A (i.e., in the absence of gH), can form a truncated HCMV pentameric complex that nevertheless maintains the five conformational epitope sites set forth in FIG. 7.
[0076] The HCMV gL polypeptides or complexing fragments thereof of the present invention comprise one or more stabilizing mutations, preferably one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. Any gL polypeptide having a sequence set forth in SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:29, or SEQ ID NO:30, or any gL polypeptide having a sequence at least 90% identical to SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:29, or SEQ ID NO:30, or a complexing fragment thereof, may preferably comprise any one or more stabilizing mutations identified and defined herein. Thus, in some embodiments, the HCMV gL polypeptide having a sequence set forth in SEQ ID NO:7, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, an HCMV gL polypeptide having the sequence set forth in SEQ ID NO:8 or a complex-forming fragment thereof comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In a further alternative embodiment, an HCMV gL polypeptide having the sequence set forth in SEQ ID NO:9 or a complex-forming fragment thereof comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In a further alternative embodiment, an HCMV gL polypeptide having the sequence set forth in SEQ ID NO:10 or a complex-forming fragment thereof comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In a further alternative embodiment, an HCMV gL polypeptide having the sequence set forth in SEQ ID NO:29 or a complex-forming fragment thereof comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof.In further alternative embodiments, the HCMV gL polypeptide having the sequence set forth in SEQ ID NO:30, or a complex-forming fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof.
[0077] As described in more detail in Example 3 and illustrated in Figures 2A-2F, the inventors have identified several cavities at the gH / gL / UL interface in the crystal structure of the pentamer complex. Thus, any cavity-filling mutation whose purpose is to fill the cavities observed at such interfaces in the HCMV gL polypeptide is expected to contribute favorably to the stability of the complex (e.g., the pentamer, gH / gL, or gH / gL / gO complex) when associated with other components of the complex. Similarly, any repacking mutation, e.g., any hydrophobic mutation or any hydrophilic mutation whose purpose is to increase contacts between neighboring residues in the HCMV gL polypeptide, is expected to contribute favorably to the stability of the complex (e.g., the pentamer, gH / gL, or gH / gL / gO complex) when associated with other components of the complex. Similarly, any disulfide bridge mutation whose purpose is to introduce intra-disulfide bridges in the HCMV gL polypeptide and / or inter-disulfide bridges between the HCMV gL polypeptide and any other component of the complex (e.g., the HCMV gH, HCMV pUL128, HCMV pUL130, or HCMV pUL131A polypeptides of the HCMV pentamer complex) is expected to favorably contribute to a complex with improved thermal stability.
[0078] Identification of relevant amino acid residues in the HCMV gL polypeptide to be mutated for cavity filling and / or repacking and / or disulfide bridging can be performed both by visual inspection of the three-dimensional structure, for example with the aid of molecular graphics software, or by using any suitable in silico mutagenesis method. For example, software such as the Molecular Operating Environment (MOE) (compiled by Chemical Computing Group Inc.) allows for systematic analysis of the amino acid sequence to identify specific regions or specific amino acids in the polypeptide whose mutations are predicted to improve thermostability.
[0079] Suitable non-limiting exemplary amino acid residues to be mutated in the HCMV gL polypeptide are provided in Table 2 with the sequence set forth as SEQ ID NO:7 for reference only. Mutations at similar positions in other HCMV gL polypeptides, such as polypeptides having the sequences set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:29, or SEQ ID NO:30, or gL polypeptides derived from HCMV strains different from the Merlin strain, are also contemplated in the present invention. It is within the ability of one of ordinary skill in the art to determine such similar positions in other HCMV gL polypeptides. Equivalent amino acid positions in a given HCMV gL polypeptide can be determined by aligning amino acid sequences using readily available and known alignment and algorithms (e.g., BLAST or ClustalW2). The actual numbering of the amino acid positions will have to be adjusted for other HCMV gL polypeptides depending on the actual sequence alignment.
[0080] Thus, in some embodiments, the amino acid mutated in the HCMV gL polypeptide for deglycosylation is N74 of the sequence set forth in SEQ ID NO: 7, or at the corresponding position in an HCMV gL polypeptide from a different HCMV strain. Suitably, the mutation of this amino acid residue may consist of substituting this amino acid with an amino acid residue selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Thus, in some embodiments, the HCMV gL polypeptide of the invention comprises at least one amino acid substitution at the position corresponding to 74 of SEQ ID NO: 7 with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D).
[0081] [Table 2-1]
[0082] Thus, in some embodiments, the amino acids mutated in the HCMV gL polypeptide to fill the cavity are H177, G224, G140, G145, D146, G218, L119, C233, or P272 of the sequence set forth in SEQ ID NO: 7, or at the corresponding positions in an HCMV gL polypeptide from a different HCMV strain. Suitably, mutation of these amino acid residues may consist of substituting any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L). Thus, in some embodiments, the HCMV gL polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to 177, 224, 140, 145, 146, 218, 119, 233, and 272 of SEQ ID NO:7 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L).
[0083] Suitable non-limiting exemplary amino acids to be mutated in an HCMV gL polypeptide for hydrophobic mutations are H267, H236, H245, G161, or C233 of the sequence set forth in SEQ ID NO: 7, or at the corresponding positions in HCMV gL polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of substituting any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), proline (P), and tyrosine (Y). Thus, in some embodiments, an HCMV gL polypeptide of the invention comprises at least one amino acid substitution at positions corresponding to 267, 236, 245, 161, and 233 of SEQ ID NO:7 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P).
[0084] Suitable non-limiting exemplary amino acids to mutate in an HCMV gL polypeptide for disulfide bridge mutations are G161, D163, G224, G218, R166, G140, R160, or A150 of the sequence set forth in SEQ ID NO: 7, or at the corresponding positions in HCMV gL polypeptides from different HCMV strains. Thus, in some embodiments, the HCMV gL polypeptides of the invention comprise at least one substitution selected from the group consisting of G161C, D163C, G224C, G218C, R166C, G140C, R160C, A150C, and combinations thereof.
[0085] [Table 2-2]
[0086] pUL128 Polypeptide pUL128 (or simply "UL128") from HCMV Merlin strain is reported to consist of 130 amino acids and contain one nucleotide substitution causing a premature termination (NCBI GI:39842124 (also NCBI GenBank Accession No. AAR31668.1), SEQ ID NO:13). pUL128 from HCMV Towne strain (NCBI GI:39841882 (also NCBI GenBank Accession No. AAR31451.1), SEQ ID NO:15) and AD169 strain (NCBI GI:59803078 (also NCBI UniProtKB Accession No. P16837.2), SEQ ID NO:16) is reported to consist of 171 amino acids. Due to the premature termination of SEQ ID NO:13, SEQ ID NOs:15 and 17 share only 75% identity over the entire length of SEQ ID NO:13. pUL128 is predicted to have an N-terminal signal sequence located at residues 1-27 of SEQ ID NO:13, but is predicted to lack a TM domain. Typically, the N-terminal signal sequence of the pUL128 polypeptide is cleaved by a host cell signal peptidase to produce the mature pUL128 polypeptide. A pUL128 polypeptide for use in the present invention may lack an N-terminal signal sequence. An example of an HCMV pUL128 polypeptide lacking an N-terminal sequence is SEQ ID NO:14, which consists of amino acid residues 28-130 of SEQ ID NO:13.
[0087] The pUL128 proteins of the present invention may have various degrees of identity to SEQ ID NO: 13, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 13. The pUL128 proteins of the present invention may have various degrees of identity to SEQ ID NO: 14, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 14. The pUL128 proteins of the present invention may have various degrees of identity to SEQ ID NO: 15, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 15. The pUL128 proteins of the present invention may have various degrees of identity to SEQ ID NO: 16, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 16. Preferred pUL128 proteins or fragments thereof (i) form part of a pentameric gH / gL / pUL128 / pUL130 / pUL131A complex, (ii) contain at least one epitope of SEQ ID NO: 13, 14, 15, or 16, and / or (iii) are capable of eliciting antibodies in vivo that immunologically cross-react with HCMV virions.
[0088] The HCMV pUL128 polypeptides or complexing fragments thereof of the present invention comprise one or more stabilizing mutations, preferably one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. Any pUL128 polypeptide having a sequence set forth in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16, or any pUL128 polypeptide having a sequence at least 90% identical to SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16, or a complexing fragment thereof, may preferably comprise any one or more stabilizing mutations identified and defined herein. Thus, in some embodiments, the HCMV pUL128 polypeptide having a sequence set forth in SEQ ID NO: 13, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, an HCMV pUL128 polypeptide having the sequence set forth in SEQ ID NO: 14, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In a further alternative embodiment, an HCMV pUL128 polypeptide having the sequence set forth in SEQ ID NO: 15, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In a further alternative embodiment, an HCMV pUL128 polypeptide having the sequence set forth in SEQ ID NO: 16, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof.
[0089] As described in more detail in Example 3 and illustrated in Figures 2A-2F, the inventors have identified several cavities at the gH / gL / UL interface in the crystal structure of the pentamer complex. Thus, any cavity-filling mutation whose purpose is to fill the cavities observed at such interfaces in the HCMV pUL128 polypeptide is expected to contribute favorably to the stability of the complex (e.g., the pentamer complex) when associated with other components of the complex. Similarly, any repacking mutation, e.g., any hydrophobic mutation or any hydrophilic mutation whose purpose is to increase contacts between neighboring residues in the HCMV pUL128 polypeptide, is expected to contribute favorably to the stability of a complex (e.g., the pentamer complex) with improved thermal stability when associated with other components of the complex. Similarly, any disulfide bridge mutations whose purpose is to introduce intra-disulfide bridges in the HCMV pUL128 polypeptide and / or inter-disulfide bridges between the HCMV pUL128 polypeptide and any of the other components of the complex (e.g., the HCMV gH, HCMV gL, HCMV pUL130, or HCMV pUL131A polypeptides of the HCMV pentamer complex) are expected to favorably contribute to a complex with improved thermal stability.
[0090] Identification of relevant amino acid residues in the HCMV pUL128 polypeptide to be mutated for cavity filling and / or repacking and / or disulfide bridging can be performed both by visual inspection of the three-dimensional structure, for example with the aid of molecular graphics software, or by using any suitable in silico mutagenesis method. Such methods are known to those skilled in the art. For example, software such as the Molecular Operating Environment (MOE) (compiled by Chemical Computing Group Inc.) allows the systematic analysis of the amino acid sequence to identify specific regions or specific amino acids in the polypeptide whose mutations are predicted to improve thermostability.
[0091] Suitable non-limiting exemplary amino acid residues to be mutated in HCMV pUL128 polypeptides are provided in Table 3 with the sequence set forth as SEQ ID NO: 13 as a reference only. Mutations at similar positions in other HCMV pUL128 polypeptides, such as polypeptides having the sequence set forth in SEQ ID NO: 14, or gL polypeptides from HCMV strains different from the Merlin strain, such as SEQ ID NO: 15 or SEQ ID NO: 16, are also contemplated in the present invention. It is within the ability of one of ordinary skill in the art to determine such similar positions in other HCMV pUL128 polypeptides. Equivalent amino acid positions in a given HCMV pUL128 polypeptide can be determined by aligning amino acid sequences using readily available and known alignment and algorithms (e.g., BLAST or ClustalW2). The actual numbering of the amino acid positions will have to be adjusted for other HCMV pUL128 polypeptides depending on the actual sequence alignment.
[0092] [Table 3-1]
[0093] Thus, in some embodiments, the amino acids mutated in the HCMV pUL128 polypeptide to fill the cavity are G123, V77, L103, or Q119 of the sequence set forth in SEQ ID NO: 13, or at the corresponding positions in HCMV pUL128 polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of replacing any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L). Thus, in some embodiments, the HCMV pUL128 polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to 123, 77, 103, and 119 of SEQ ID NO: 13 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L).
[0094] Suitable non-limiting exemplary amino acids to be mutated in an HCMV pUL128 polypeptide for hydrophobicity mutations are G145, H90, or G112 of the sequence set forth in SEQ ID NO: 13, or at the corresponding positions in HCMV pUL128 polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of substituting any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Thus, in some embodiments, the HCMV pUL128 polypeptide of the invention comprises at least one amino acid substitution at positions corresponding to 145, 90, and 112 of SEQ ID NO: 13 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P).
[0095] Suitable non-limiting exemplary amino acids to mutate in an HCMV pUL128 polypeptide for disulfide bridge mutations are R142, N99, Y98, A124, G126, L159, D45, V88, M48, G107, R51, D106, or S83 of the sequence set forth in SEQ ID NO: 13, or at the corresponding positions in an HCMV pUL128 polypeptide from a different HCMV strain. Thus, in some embodiments, an HCMV pUL128 polypeptide of the invention comprises at least one substitution selected from the group consisting of R142C, N99C, Y98C, A124C, G126C, L159C, D45C, V88C, M48C, G107C, R51C, D106C, S83C, and combinations thereof.
[0096] [Table 3-2]
[0097] pUL130 Polypeptide pUL130 (or simply "UL130") is the central and largest (214 codon) gene of the HCMV UL131A-128 locus. The sequence of pUL130 from the HCMV Merlin strain is publicly available (NCBI GI: 39842125 (also NCBI GenBank Accession No. AAR31669.1), SEQ ID NO: 17 herein). The sequence of pUL130 from the HCMV Towne strain is publicly available (NCBI GI: 239909473 (also NCBI ACS32420.1), SEQ ID NO: 19 herein). Similarly, the sequence of pUL130 from the HCMV AD169 strain is publicly available (NCBI UniprotKB Accession No. P16772, SEQ ID NO: 20 herein). The Merlin and Towne pUL130 sequences consist of 214 and 229 amino acids, respectively. The sequence of Merlin pUL130, SEQ ID NO:17, contains a 25 amino acid long N-terminal signal sequence at residues 1-25 preceding a hydrophilic protein containing two potential N-linked glycosylation sites (Asn85 and Asn118) within the putative chemokine domain (amino acids 46-120), as well as an additional N-glycosylation site (Asn201) near the end of a unique C-terminal region. pUL130 is predicted to lack a TM domain.
[0098] Typically, the N-terminal signal sequence of the pUL130 polypeptide is cleaved by a host cell signal peptidase to produce the mature pUL130 protein. A pUL130 polypeptide for use in the present invention may lack an N-terminal signal sequence. An example of an HCMV pUL130 polypeptide lacking an N-terminal sequence is SEQ ID NO:18, which consists of amino acid residues 26-214 of SEQ ID NO:17.
[0099] As shown in the Examples, the pUL130 polypeptide is glycosylated (containing glycans via N-linked glycosylation) at three asparagine residues, namely N85, N118, and N201, numbered relative to the amino acid sequence of pUL130 in SEQ ID NO: 17. The HCMV pUL130 polypeptide or complex-forming fragment thereof for use in the present invention may include a deglycosylation mutation at one or more of the asparagines located at residues 85, 118, and 201, numbered relative to the sequence of pUL130 in SEQ ID NO: 17. The deglycosylation mutation may be glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), or aspartic acid (D). In particular, the deglycosylation mutation may be glutamine (Q), serine (S), threonine (T), or alanine (A). More particularly, the deglycosylation mutation may be glutamine (Q).
[0100] The pUL130 proteins of the present invention may have various degrees of identity to SEQ ID NO: 17, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 17. The pUL130 proteins of the present invention may have various degrees of identity to SEQ ID NO: 18, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 18. The pUL130 proteins of the present invention may have various degrees of identity to SEQ ID NO: 19, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 19. The pUL130 proteins of the present invention may have various degrees of identity to SEQ ID NO: 20, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 20. A preferred pUL130 protein or fragment thereof is capable of (i) forming a pentameric gH / gL / pUL128 / pUL130 / pUL131A complex, (ii) comprising at least one epitope of SEQ ID NO: 17, 18, 19, or 20, and / or (iii) eliciting antibodies in vivo that are immunologically cross-reactive with HCMV virions. An exemplary complex-forming fragment of pUL130 comprises residues Thr45 to Val214 of SEQ ID NO: 17, which, when in a complex with full-length pUL131A (i.e., no gH, gL, or pUL128 is present), can form a truncated HCMV pentameric complex that nevertheless maintains the five conformational epitope sites set forth in FIG. 7.Alternatively, the complexing fragment of pUL130 includes residues Thr45 to Val214 of SEQ ID NO:17, which, when in complex with the complexing fragment of pUL131A including residues Gln19 to Asn129 of SEQ ID NO:21 (i.e., no gH, gL, or pUL128 are present), can form a truncated HCMV pentamer complex that nevertheless maintains the five conformational epitope sites described in Figure 7.
[0101] The HCMV pUL130 polypeptides or complexing fragments thereof of the present invention comprise one or more stabilizing mutations, preferably one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. Any pUL130 polypeptide having a sequence set forth in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20, or any pUL130 polypeptide having a sequence at least 90% identical to SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20, or a complexing fragment thereof, may preferably comprise any one or more stabilizing mutations identified and defined herein. Thus, in some embodiments, the HCMV pUL130 polypeptide having a sequence set forth in SEQ ID NO: 17, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, an HCMV pUL130 polypeptide having the sequence set forth in SEQ ID NO: 18, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, an HCMV pUL130 polypeptide having the sequence set forth in SEQ ID NO: 19, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, an HCMV pUL130 polypeptide having the sequence set forth in SEQ ID NO: 20, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof.
[0102] As described in more detail in Example 3 and illustrated in Figures 2A-2F, the inventors have identified several cavities at the gH / gL / UL interface in the crystal structure of the pentamer complex. Thus, any cavity-filling mutation whose purpose is to fill the cavities observed at such interfaces in the HCMV pUL130 polypeptide is expected to contribute favorably to the stability of the complex (e.g., the pentamer complex) when associated with other components of the complex. Similarly, any repacking mutation, e.g., any hydrophobic mutation or any hydrophilic mutation whose purpose is to increase contacts between neighboring residues in the HCMV pUL130 polypeptide, is expected to contribute favorably to the stability of the complex (e.g., the pentamer complex) when associated with other components of the complex. Similarly, any disulfide bridge mutations whose purpose is to introduce intra-disulfide bridges in the HCMV pUL130 polypeptide and / or inter-disulfide bridges between the HCMV gH polypeptide and any of the other components of the complex (e.g., the HCMV gH, HCMV gL, HCMV pUL128, or HCMV pUL131A polypeptides of the HCMV pentamer complex) are expected to favorably contribute to a complex with improved thermal stability.
[0103] Identification of relevant amino acid residues in the HCMV pUL130 polypeptide to be mutated for cavity filling and / or repacking and / or disulfide bridging can be performed both by visual inspection of the three-dimensional structure, for example with the aid of molecular graphics software, or by using any suitable in silico mutagenesis method. Such methods are known to those skilled in the art. For example, software such as the Molecular Operating Environment (MOE) (compiled by Chemical Computing Group Inc.) allows the systematic analysis of the amino acid sequence to identify specific regions or specific amino acids in the polypeptide whose mutations are predicted to improve thermostability.
[0104] Suitable non-limiting exemplary amino acid residues to be mutated in HCMV pUL130 polypeptides are provided in Table 4 with the sequence set forth as SEQ ID NO: 17 as a reference only. Mutations at similar positions in other HCMV pUL130 polypeptides, such as polypeptides having the sequences set forth in SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or pUL130 polypeptides derived from HCMV strains different from the Merlin strain, are also contemplated in the present invention. It is within the ability of one of ordinary skill in the art to determine such similar positions in other HCMV pUL130 polypeptides. Equivalent amino acid positions in a given HCMV pUL130 polypeptide can be determined by aligning amino acid sequences using readily available and known alignment and algorithms (e.g., BLAST or ClustalW2). The actual numbering of the amino acid positions will have to be adjusted for other HCMV pUL130 polypeptides depending on the actual sequence alignment.
[0105] [Table 4-1]
[0106] Thus, in some embodiments, the amino acids mutated in the HCMV pUL130 polypeptide to fill the cavity are D165 or H209 of the sequence set forth in SEQ ID NO: 17, or at the corresponding positions in HCMV pUL130 polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of replacing any of them, and / or more than one of them, and possibly all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L). Thus, in some embodiments, the HCMV pUL130 polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to 165 and 209 of SEQ ID NO: 17 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L).
[0107] Suitable non-limiting exemplary amino acids to be mutated in an HCMV pUL130 polypeptide for hydrophobicity mutations are G116, G135, H150, or H209 of the sequence set forth in SEQ ID NO: 17, or at the corresponding positions in HCMV pUL130 polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of substituting any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Thus, in some embodiments, the HCMV pUL130 polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to G116, G135, H150, and H209 of SEQ ID NO: 17 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P).
[0108] Suitable non-limiting exemplary amino acids to mutate in an HCMV pUL130 polypeptide for disulfide bridge mutations are G116, H150, P64, S178, P62, E95, Y204, N211, I213, Y56, or T167 of the sequence set forth in SEQ ID NO: 17, or at the corresponding positions in HCMV pUL130 polypeptides from different HCMV strains. Thus, in some embodiments, an HCMV pUL130 polypeptide of the invention comprises at least one substitution selected from the group consisting of G116C, H150C, P64C, S178C, P62C, E95C, Y204C, N211C, I213C, Y56C, T167C, and combinations thereof.
[0109] Thus, in some embodiments, the amino acids mutated in an HCMV pUL130 polypeptide for deglycosylation are N85, N118, and N201 of the sequence set forth in SEQ ID NO: 17, or at the corresponding positions in an HCMV pUL130 polypeptide from a different HCMV strain. Suitably, mutation of these amino acid residues may consist of replacing any of them, and / or more than one of them, and possibly all of them, with an amino acid residue selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Thus, in some embodiments, an HCMV pUL130 polypeptide of the invention comprises at least one amino acid substitution at positions corresponding to 85, 118, and 201 of SEQ ID NO: 17 with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D).
[0110] [Table 4-2]
[0111] pUL131A Polypeptide The function of pUL131A is required for the replication of HCMV in epithelial cells as well as in endothelial cells. pUL131A from HCMV Merlin strain (NCBI GI:39842126 (also NCBI GenBank Accession No. AAR31670.1), SEQ ID NO:21) and Towne strain (NCBI GI:239909474 (also NCBI GenBank Accession No. ACS32421.1), SEQ ID NO:23) and AD169 strain (NCBI GI:219879712 (also NCBI GenBank Accession No. DAA06452.1), SEQ ID NO:24) is reported to consist of 129, 129, and 76 amino acids, respectively. pUL131A contains an N-terminal signal sequence, which is located at residues 1-18 of SEQ ID NO:21, and lacks a TM domain. UL131A from the AD169 strain has been reported to contain a one base pair insertion that causes a frameshift (Wang and Shenk, Human Cytomegalovirus UL131 Open Reading Frame Is Required for Epithelial Cell Tropism, 2005 J. Virol. 79: 10330-10338). SEQ ID NO:21 is 96% identical to SEQ ID NO:24 over the N-terminal 28 amino acids, but is only 36% identical to SEQ ID NO:24 over the entire length of SEQ ID NO:21 due to a frameshift in the AD169 UL131A gene.
[0112] Typically, the N-terminal signal sequence of the pUL131A polypeptide is cleaved by a host cell signal peptidase to produce the mature pUL131A protein. A pUL131A polypeptide for use in the present invention may lack an N-terminal signal sequence. An example of an HCMV pUL131A polypeptide lacking an N-terminal sequence is SEQ ID NO:22, which consists of amino acid residues 19 to 129 of SEQ ID NO:21.
[0113] As shown in the Examples, the pUL131A polypeptide is glycosylated (contains glycans via N-linked glycosylation) at asparagine residue N81, numbered relative to the amino acid sequence of gH in SEQ ID NO: 21. HCMV pUL131A polypeptides or complex-forming fragments thereof for use in the present invention may comprise a deglycosylation mutation at the asparagine located at residue 81, numbered relative to the sequence of pUL131A in SEQ ID NO: 21. The deglycosylation mutation may be glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), or aspartic acid (D). In particular, the deglycosylation mutation may be glutamine (Q), serine (S), threonine (T), or alanine (A). More particularly, the deglycosylation mutation may be glutamine (Q).
[0114] The pUL131A proteins of the present invention may have various degrees of identity to SEQ ID NO:21, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:21. The pUL131A proteins of the present invention may have various degrees of identity to SEQ ID NO:22, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO:22. The pUL131A proteins of the present invention may have various degrees of identity to SEQ ID NO: 23, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 23. The pUL131A proteins of the present invention may have various degrees of identity to SEQ ID NO: 24, for example at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence recited in SEQ ID NO: 24. A preferred pUL131A protein is capable of (i) forming a pentameric gH / gL / pUL128 / pUL130 / pUL131A complex, (ii) comprising at least one epitope of SEQ ID NO:21, 22, 23, or 24, and / or (iii) eliciting antibodies in vivo that are immunologically cross-reactive with HCMV virions. An exemplary complex-forming fragment of pUL131A comprises residues Gln19 to Asn129 of SEQ ID NO:21, which, when in complex with full-length pUL130 (i.e., no gH, gL, or pUL128 is present), can form a truncated HCMV pentameric complex that nevertheless maintains the five conformational epitope sites set forth in FIG. 7.Alternatively, the complexing fragment of pUL131A contains residues Gln19 to Asn129 of SEQ ID NO:21, which, when in complex with the complexing fragment of pUL130 containing residues Thr45 to Val214 of SEQ ID NO:17 (i.e., no gH, gL, or pUL128 are present), can form a truncated HCMV pentamer complex that nevertheless maintains the five conformational epitope sites described in Figure 7.
[0115] The HCMV pUL131A polypeptide or a complexing fragment thereof of the present invention comprises one or more stabilizing mutations, preferably one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. Any pUL131A polypeptide having a sequence set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24, or any pUL131A polypeptide having a sequence at least 90% identical to SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24, or a complexing fragment thereof, may preferably comprise any one or more stabilizing mutations identified and defined herein. Thus, in some embodiments, the HCMV pUL131A polypeptide having a sequence set forth in SEQ ID NO:21, or a complexing fragment thereof comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, an HCMV pUL131A polypeptide having the sequence set forth in SEQ ID NO:22, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, an HCMV pUL131A polypeptide having the sequence set forth in SEQ ID NO:23, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof. In an alternative embodiment, an HCMV pUL131A polypeptide having the sequence set forth in SEQ ID NO:24, or a complexing fragment thereof, comprises one or more cavity-filling mutations, one or more hydrophobic mutations, one or more hydrophilic mutations, one or more disulfide bridge mutations, or any combination of one or more thereof.
[0116] As described in more detail in Example 3 and illustrated in Figures 2A-2F, the inventors have identified several cavities at the gH / gL / UL interface in the crystal structure of the pentamer complex. Thus, any cavity-filling mutation whose purpose is to fill the cavities observed at such interfaces in the HCMV pUL131A polypeptide is expected to contribute favorably to the stability of the complex (e.g., the pentamer complex) when associated with other components of the complex. Similarly, any repacking mutation, e.g., any hydrophobic mutation or any hydrophilic mutation whose purpose is to increase contacts between neighboring residues in the HCMV pUL131A polypeptide is expected to contribute favorably to the stability of the complex (e.g., the pentamer complex) when associated with other components of the complex. Similarly, any disulfide bridge mutations whose purpose is to introduce intra-disulfide bridges in the HCMV pUL131A polypeptide and / or inter-disulfide bridges between the HCMV gH polypeptide and any of the other components of the complex (e.g., the HCMV gH, HCMV gL, HCMV pUL128, or HCMV pUL130 polypeptides of the HCMV pentamer complex) are expected to favorably contribute to a complex with improved thermal stability.
[0117] Identification of relevant amino acid residues in the HCMV pUL131A polypeptide to be mutated for cavity filling and / or repacking and / or disulfide bridging can be performed both by visual inspection of the three-dimensional structure, for example with the aid of molecular graphics software, or by using any suitable in silico mutagenesis method. Such methods are known to those skilled in the art. For example, software such as the Molecular Operating Environment (MOE) (compiled by Chemical Computing Group Inc.) allows systematic analysis of the amino acid sequence to identify specific regions or specific amino acids in the polypeptide whose mutations are predicted to improve thermostability.
[0118] Suitable non-limiting exemplary amino acid residues to be mutated in HCMV pUL131A polypeptides are provided in Table 5 with the sequence set forth as SEQ ID NO:21 as a reference only. Mutations at similar positions in other HCMV pUL131A polypeptides, such as polypeptides having the sequences set forth in SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, or pUL131A polypeptides derived from HCMV strains other than the Merlin strain, are also contemplated in the present invention. It is within the ability of one of ordinary skill in the art to determine such similar positions in other HCMV pUL131A polypeptides. Equivalent amino acid positions in a given HCMV pUL131A polypeptide can be determined by aligning amino acid sequences using readily available and known alignment and algorithms (e.g., BLAST or ClustalW2). The actual numbering of the amino acid positions will have to be adjusted for other HCMV pUL130 polypeptides depending on the actual sequence alignment.
[0119] [Table 5-1]
[0120] Thus, in some embodiments, the amino acids mutated in the HCMV pUL131A polypeptide to fill the cavity are G99, S86, or S90 of the sequence set forth in SEQ ID NO:21, or at the corresponding positions in HCMV pUL131A polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of replacing any of them, and / or more than one of them, and possibly all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L). Thus, in some embodiments, the HCMV pUL131A polypeptides of the invention comprise at least one amino acid substitution at positions corresponding to 99, 86, or 90 of SEQ ID NO:21 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), tyrosine (Y), valine (V), isoleucine (I), and leucine (L).
[0121] Suitable non-limiting exemplary amino acids to be mutated in an HCMV pUL131A polypeptide for hydrophobic mutations are H69, H35, H64, D38, V85, Y52, or A67 of the sequence set forth in SEQ ID NO: 21, or at the corresponding positions in HCMV pUL131A polypeptides from different HCMV strains. Suitably, mutation of these amino acid residues may consist of replacing any of them, and / or more than one of them, and optionally all of them, with an amino acid residue selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P). Thus, in some embodiments, the HCMV pUL131A polypeptide of the invention comprises at least one amino acid substitution at positions corresponding to 69, 35, 64, 38, 85, 52, and 67 of SEQ ID NO:21 with an amino acid selected from the group consisting of tryptophan (W), phenylalanine (F), methionine (M), cysteine (C), alanine (A), leucine (L), isoleucine (I), valine (V), and proline (P).
[0122] A suitable non-limiting exemplary amino acid to mutate in an HCMV pUL131A polypeptide for hydrophilicity mutation is R118 of the sequence set forth in SEQ ID NO:21 or at the corresponding position in an HCMV gH polypeptide from a different HCMV strain. Suitably, mutation of this amino acid residue may consist of replacing it with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), and glutamic acid (E). Thus, in some embodiments, the HCMV pUL131A polypeptide of the invention comprises at least one amino acid substitution at a position corresponding to R118 of SEQ ID NO:21 with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), glutamine (Q), arginine (R), and glutamic acid (E). A suitable non-limiting exemplary amino acid to be mutated in an HCMV pUL131A polypeptide for a polar mutation is R118 of the sequence set forth in SEQ ID NO:21, or at the corresponding position in an HCMV gH polypeptide from a different HCMV strain. Suitably, the mutation of this amino acid residue may consist of replacing it with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), and glutamine (Q). Thus, in some embodiments, the HCMV pUL131A polypeptide of the invention comprises at least one amino acid substitution at position R118 with an amino acid selected from the group consisting of serine (S), threonine (T), cysteine (C), tyrosine (Y), asparagine (N), and glutamine (Q). A suitable non-limiting exemplary amino acid to mutate in the HCMV pUL131A polypeptide for a charge mutation is R118 of the sequence set forth in SEQ ID NO: 21, or at the corresponding position in an HCMV gH polypeptide from a different HCMV strain. Suitably, mutation of this amino acid residue may consist of replacing it with arginine (R) or glutamic acid (E).Thus, in some embodiments, HCMV gH polypeptides of the invention comprise at least one amino acid substitution at the position corresponding to R118 of SEQ ID NO:21 with the amino acids arginine (R) or glutamic acid (E).
[0123] Suitable non-limiting exemplary amino acids to mutate in an HCMV pUL131A polypeptide for disulfide bridge mutations are H64 or W37 of the sequence set forth in SEQ ID NO:21, or at the corresponding positions in HCMV gH polypeptides from different HCMV strains. Thus, in some embodiments, an HCMV polypeptide of the invention comprises at least one substitution, preferably both, of the residue corresponding to H64 in SEQ ID NO:21 with a cysteine (C) or the residue corresponding to W37 in SEQ ID NO:21 with a cysteine (C).
[0124] Thus, in some embodiments, the amino acid mutated in the HCMV pUL131A polypeptide for deglycosylation is N81 of the sequence set forth in SEQ ID NO:21, or at the corresponding position in an HCMV gH polypeptide from a different HCMV strain. Suitably, the mutation of this amino acid residue may consist of replacing it with an amino acid residue selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D). Thus, in some embodiments, the HCMV pUL131A polypeptide of the invention comprises at least one amino acid substitution at position 81 of SEQ ID NO:21 with an amino acid selected from the group consisting of glutamine (Q), serine (S), threonine (T), alanine (A), glutamic acid (E), and aspartic acid (D).
[0125] [Table 5-2]
[0126] gO Polypeptide HCMV glycoprotein O (gO), encoded by the UL74 gene, has been reported to act as a molecular chaperone and increase ER transport and incorporation of gH / gL into virions. It has been proposed that gH / gL (lacking pUL128-131A) is incorporated into virions because gO competes with pUL128-131A for binding to gH / gL but is released from gH / gL (Ryckman et al., Human Cytomegalovirus TR Strain Glycoprotein O Acts as a Chaperone Promoting gH / gL Incorporation into Virions but Is Not Present in Virions, 2010 Journal of Virology 84: 2597-2609). Compared to other viral genes, HCMV gO is highly variable among different HCMV strains, with variability in the gO amino acid sequence reaching 45% among 22-39 clinical isolates and the laboratory strains AD169, Towne, and Toledo (i.e., gO amino acid sequence identity among different isolates was only 55%) (Rasmussen et al., The Genes Encoding the gCIII Complex of Human Cytomegalovirus Exist in Highly Diverse Combinations in Clinical Isolates, 2002 J. Virol. 76: 10841-10888). gO from HCMV strains Merlin (NCBI GI:39842082 (also NCBI GenBank Accession No. AAR31626.1), SEQ ID NO:25 herein), AD169 (NCBI GI:136968 (also NCBI UniProtKB Accession No. P16750.1), SEQ ID NO:28 herein), and Towne (NCBI GI:239909431 (also NCBI GenBank Accession No. ACS32378.1), SEQ ID NO:27 herein) have been reported to consist of 472, 466, and 457 amino acids, respectively.gO of HCMV strain AD169, which shares 73% amino acid similarity with SEQ ID NO:25, has 18 N-glycosylation sites (at residues 75, 83, 87, 103, 130, 157, 162, 171, 219, 242, 288, 292, 350, 385, 392, 399, 433, and 454) and may contain a cleavable signal sequence (predicted to consist of amino acid residues 1-30) at its N-terminus that is not present in the mature polypeptide. Rigoutsos et al. (In silico pattern-based analysis of the human cytomegalovirus genome, 2003 J. Virol. 77: 4326-4344) predicted the presence of a TM domain (in regions 10-28 and 190-212) and a coiled-coil region (residues 240-272).
[0127] Typically, the N-terminal signal sequence of the gO protein is cleaved by a host cell signal peptidase to produce the mature gO protein. The gO protein in the HCMV membrane complex of the present invention may lack an N-terminal signal sequence. An example of a desirable gO protein of the present invention is SEQ ID NO: 26, which lacks the N-terminal signal sequence and consists of amino acid residues 31 to 472 of SEQ ID NO: 25.
[0128] The gO proteins of the invention can have varying degrees of identity to SEQ ID NO:25, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO:25. The gO proteins of the invention can have varying degrees of identity to SEQ ID NO:26, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO:26. The gO proteins of the invention can have varying degrees of identity to SEQ ID NO:27, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO:27. The gO proteins of the invention can have varying degrees of identity to SEQ ID NO:28, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO:28. The gO nucleotide sequences of the invention can have various degrees of identity to SEQ ID NO: 39, e.g., at least 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO: 39. Desirable gO proteins or fragments thereof (i) are capable of forming part of a trimeric gH / gL / gO complex, (ii) are incapable of forming part of a pentameric gH / gL / pUL128 / pUL130 / pUL131A complex, (iii) comprise at least one epitope of SEQ ID NO: 25, 26, 27, or 28, and / or (iv) are capable of eliciting antibodies in vivo that immunologically cross-react with HCMV virions.
[0129] Complex In another aspect, the invention provides pentameric complexes comprising a mutated HCMV polypeptide as described herein or a complex-forming fragment thereof. Such complexes may, for example, comprise (i) any of the HCMV gH polypeptides described above comprising one or more stabilizing mutations, (ii) any of the HCMV gL polypeptides described above comprising one or more stabilizing mutations, (iii) any of the HCMV pUL128 polypeptides described above comprising one or more stabilizing mutations, (iv) any of the HCMV pUL130 polypeptides described above comprising one or more stabilizing mutations, and (v) any of the HCMV pUL131A polypeptides described above comprising one or more stabilizing mutations. Such complexes may further comprise, for example, (vi) any of the HCMV gH, gL, pUL130, and pUL131A deglycosylation mutations described above.
[0130] In another aspect, the invention provides gH / gL complexes comprising a mutated HCMV polypeptide as described herein or a complex-forming fragment thereof. Such complexes may, for example, comprise (i) any of the HCMV gH polypeptides described above comprising one or more stabilizing mutations, and / or (ii) any of the HCMV gL polypeptides described above comprising one or more stabilizing mutations. Such complexes may, for example, further comprise (iii) any of the HCMV gH and gL deglycosylation mutations described above.
[0131] In another aspect, the invention provides gH / gL / gO complexes comprising a mutated HCMV polypeptide as described herein or a complex-forming fragment thereof. Such complexes may, for example, comprise (i) any of the HCMV gH polypeptides described above comprising one or more stabilizing mutations, and / or (ii) any of the HCMV gL polypeptides described above comprising one or more stabilizing mutations. Such complexes may, for example, further comprise (iii) any of the HCMV gH and gL deglycosylation mutations described above.
[0132] In another aspect, the invention provides pentameric complexes comprising a mutated HCMV polypeptide as described herein or a complex-forming fragment thereof. Such complexes may, for example, comprise (i) any of the HCMV gH polypeptides described above comprising one or more deglycosylation mutations, (ii) any of the HCMV gL polypeptides described above comprising a deglycosylation mutation, (iii) any of the HCMV pUL130 polypeptides described above comprising one or more deglycosylation mutations, and (iv) any of the HCMV pUL131A polypeptides described above comprising a deglycosylation mutation. Such complexes may further comprise, for example, (vi) any of the HCMV gH, gL, pUL130, and pUL131A stability mutations described above.
[0133] In another aspect, the invention provides gH / gL complexes comprising a mutated HCMV polypeptide as described herein or a complex-forming fragment thereof. Such complexes may, for example, comprise (i) any of the HCMV gH polypeptides described above comprising one or more deglycosylation mutations, and / or (ii) any of the HCMV gL polypeptides described above comprising a deglycosylation mutation. Such complexes may, for example, further comprise (iii) any of the HCMV gH and gL stability mutations described above.
[0134] In another aspect, the invention provides gH / gL / gO complexes comprising a mutated HCMV polypeptide as described herein or a complex-forming fragment thereof. Such complexes may, for example, comprise (i) any of the HCMV gH polypeptides described above comprising one or more deglycosylation mutations, and / or (ii) any of the HCMV gL polypeptides described above comprising a deglycosylation mutation. Such complexes may, for example, further comprise (iii) any of the HCMV gH and gL stability mutations described above.
[0135] composition In another aspect, the invention provides a composition comprising a mutant polypeptide or a mutant complex-forming fragment thereof, wherein the mutant polypeptide or mutant fragment is at least one of HCMV gH, gL, pUL128, pUL130, and pUL131A, and wherein the mutant polypeptide or mutant fragment comprises at least one stabilizing mutation. In another aspect, the invention provides a composition comprising a mutant polypeptide or a mutant complex-forming fragment thereof, wherein the mutant polypeptide or mutant fragment is at least one of HCMV gH, gL, pUL130, and pUL131A, and wherein the mutant polypeptide or mutant fragment comprises at least one deglycosylation mutation. In another aspect, the invention provides a composition comprising a complex having at least one mutant polypeptide or a mutant complex-forming fragment thereof, wherein the mutant polypeptide or mutant fragment is at least one of HCMV gH, gL, pUL128, pUL130, and pUL131A, and wherein the mutant polypeptide or mutant fragment comprises at least one stabilizing mutation. In another aspect, the present invention provides a composition comprising a complex having at least one mutant polypeptide or mutant complex-forming fragment thereof, wherein the mutant polypeptide or mutant fragment is at least one of HCMV gH, gL, pUL130, and pUL131A, and the mutant polypeptide or mutant fragment comprises at least one deglycosylation mutation. Complexes of the present invention include gH / gL, gH / gL / gO, and pentameric complexes. The composition of the present invention may be an immunogenic composition. The composition of the present invention may be a vaccine composition. Such a composition can be used to raise antibodies in a mammal (e.g., a human, a rodent, a guinea pig, or a macaque).
[0136] The invention provides pharmaceutical compositions comprising a stabilized HCMV conjugate (e.g., pentamer conjugate) described herein. The invention also provides methods of making a pharmaceutical composition comprising combining a stabilized HCMV conjugate (e.g., pentamer conjugate) of the invention with a pharma- ceutical acceptable carrier.
[0137] In addition to the antigen, the immunogenic and pharmaceutical compositions of the present invention typically include "non-antigenic components" which may be adjuvants or pharma- ceutically acceptable carriers when used in the context of the present invention. A thorough discussion of such carriers is available in Remington: The Science and Practice of Pharmacy. Pharmaceutically acceptable carriers include any carrier that does not itself induce the production of neutralizing antibodies. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose, trehalose, lactose, and lipid aggregates (e.g., oil droplets or liposomes). Sterile pyrogen-free phosphate-buffered saline is an exemplary carrier. Such carriers are well known to those skilled in the art. Non-antigenic components may be diluents, such as water, saline, glycerol, and the like. In addition, non-antigenic components may be auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like. Non-antigenic components of the present invention include antimicrobial agents, especially when packaged in multi-dose form. Non-antigenic components of the present invention include detergents, such as TWEEN® (polysorbates), e.g., TWEEN 80®. Detergents are generally present at low levels, e.g., less than 0.01%. Non-antigenic components of the present invention include sodium salts (e.g., sodium chloride) to provide tonicity. A concentration of 1.0±2 mg / ml NaCl is typical. Non-antigenic components of the present invention include buffers, e.g., phosphate buffers. Non-antigenic components of the present invention include, for example, sugar alcohols (e.g., mannitol) or disaccharides (e.g., sucrose or trehalose) at approximately 15-30 mg / ml (e.g., 25 mg / ml).
[0138] The pH of the composition is typically between 6 and 8, more preferably between 6.5 and 7.5 (e.g., about 7). A stable pH may be maintained by the use of a buffer, such as a Tris buffer, a citrate buffer, a phosphate buffer, or a histidine buffer. Thus, the composition will generally include a buffer. The composition may be sterile and / or pyrogen-free. The composition may be isotonic with respect to humans. The composition comprises an immunologically effective amount of the reference antigen(s). An "immunologically effective amount" is an amount that, when administered to a subject, is effective to elicit an antibody response against the antigen. This amount may vary depending on the health and physical condition of the individual being treated, the age, the ability of the individual's immune system to synthesize antibodies, the degree of protection desired, the vaccine formulation, the treating physician's evaluation of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined by routine testing. The antigen content of the composition of the invention is generally expressed in terms of mass of protein per dose. Doses of 10 to 500 μg (e.g., 50 μg) per antigen may be useful. The immunogenic composition may include an immunological adjuvant.
[0139] The composition may also include an antimicrobial, especially if packaged in a multi-dose form. Antimicrobials such as thiomersal and 2-phenoxyethanol are commonly found in vaccines, although it is desirable to either use mercury-free preservatives or to use no preservatives at all. The composition may also include a detergent, such as a polysorbate, e.g. polysorbate 80. Detergents are generally present at low levels, e.g. less than 0.01%. The composition may also include a sodium salt (e.g. sodium chloride) to provide tonicity. A concentration of 10+2 mg / ml, e.g. about 9 mg / ml NaCl, is typical.
[0140] The composition of the present invention is to be administered directly to the subject as a whole. Direct delivery can be accomplished by parenteral injection (e.g. subcutaneous, intraperitoneal, intravenous, intramuscular, or into the interstitial space of tissue), or any other suitable route. Intramuscular administration, for example, into the thigh or upper arm, is preferred. Injection can be via a needle (e.g. a hypodermic needle), although needle-free injection can alternatively be used.
[0141] Vaccines of the invention may be prophylactic (ie, to prevent disease) or therapeutic (ie, to reduce or eliminate symptoms of disease).
[0142] Expression system In one aspect, the present invention provides a method for expressing the mutant HCMV polypeptide(s) of the present invention. Expression systems suitable for use in the present invention are described in detail, for example, in Doyle (High Throughput Protein Expression and Purification: Methods and Protocols in METHODS IN MOLECULAR BIOLOGY, Humana Press, edited by Doyle, 2008). Any system or vector suitable for maintaining, amplifying and expressing nucleic acid molecules to produce polypeptides in the required host may be used. The appropriate nucleotide sequence may be inserted into the expression system by techniques described, for example, in Sambrook (J. Molecular Cloning: A Laboratory Manual. 3rd. Cold Spring Harbor Laboratory Press, 2000). In general, the coding gene may be placed under the control of control elements, such as a promoter and, optionally, an operator, so that the DNA sequence encoding the desired peptide is transcribed into RNA in the transformed host cell.
[0143] Examples of suitable expression systems include, for example, chromosomal, episomal, and viral-derived systems, including vectors derived from bacterial plasmids, bacteriophages, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses, such as baculoviruses, papovaviruses, such as SV40, vaccinia viruses, adenoviruses, fowlpox viruses, pseudorabies viruses, and retroviruses, or combinations thereof, such as vectors derived from plasmids and bacteriophage genetic elements, including cosmids and phagemids.Human artificial chromosomes (HACs) can also be used to deliver fragments of DNA larger than can be contained and expressed in a plasmid. Suitable expression systems include microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected or transfected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, or CaMV, tobacco mosaic virus, or TMV) or bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be used to produce the proteins of the invention. Preferably, the proteins of the invention are produced in eukaryotic cells, such as mammalian cells.
[0144] Recombinant polypeptides may be expressed transiently or stably. Preferably, recombinant proteins are stably expressed. For example, cell lines stably expressing a peptide of interest may be transfected using an expression vector, which may contain a viral origin of replication and / or endogenous expression elements, and a selectable marker gene on the same or a separate vector. After introduction of the vector, cells may be grown in rich medium for 1-2 days and then switched to selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows the growth and recovery of cells that successfully express the introduced sequence. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.
[0145] Mammalian cell lines available as hosts (or host cells) for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO), HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, human embryonic kidney (HEK) 293, Bowes melanoma, and human hepatocellular carcinoma (e.g., Hep G2) cells, as well as several other cell lines. Expression in mammalian cells is preferred because the proteins produced will have native mammalian glycosylation patterns and thus carry epitopes present on infectious HCMV particles. Thus, production of the membrane protein complex of the present invention in mammalian cells can result in the production of antibodies capable of binding to naturally occurring HCMV particles during infection.
[0146] In the baculovirus system, materials for baculovirus / insect cell expression systems are commercially available in kit format, inter alia, from Invitrogen, San Diego CA ("MaxBac" kit). These techniques are fully described in Summers et al. (Summers and Smith, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555, 1987). Particularly suitable host cells for use in this system include insect cells, such as Drosophila S2 (i.e., by recombinant baculovirus infection of stably transfected Drosophila S2 cells) and Spodoptera Sf9 cells. In some embodiments, the proteins of the invention are not produced in insect cells. There are many plant cell culture and whole plant gene expression systems known in the art. Examples of suitable plant cell gene expression systems include those described in U.S. Patent No. 5,693,506, U.S. Patent No. 5,659,122, and U.S. Patent No. 5,608,143. In particular, any plant from which protoplasts can be isolated and cultured to obtain a whole regenerated plant can be utilized, thus recovering the whole plant containing the transferred gene. Virtually any plant can be regenerated from cultured cells or tissues, including, but not limited to, sugarcane, sugar beet, cotton, fruit trees and other trees, legumes, and all major species of vegetables.
[0147] Examples of prokaryotic expression systems include those that use streptococci, staphylococci, E. coli, Streptomyces, and Bacillus subtilis as host cells.
[0148] Examples of fungal expression systems include those that use yeast (eg, S. cerevisiae) and Aspergillus as host cells.
[0149] HEK293 cells are suitable for transient expression of the HCMV proteins of the present invention due to their high transfection capacity by various techniques, including calcium phosphate and polyethyleneimine (PEI) methods. A useful cell line of HEK293 is a cell line expressing the EBNA1 protein of EBV, such as 293-6E (Loignon et al., Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells, 2008 BMC Biotechnology 8:65). It has been shown that transformed HEK293 cells secrete high levels of the protein complexes of the present invention into the growth medium, thus allowing for the purification of such protein complexes directly from the growth medium.
[0150] CHO cells are particularly suitable mammalian hosts for industrial production of the HCMV proteins of the invention for use as immunogens or antigens because they allow long-term stable gene expression and high yields of protein.
[0151] In some embodiments, the mutant HCMV polypeptide(s) or mutant complexes of the invention are secreted from the cells in which they are expressed. In other embodiments of the invention, the mutant polypeptides or mutant complexes of the invention are not secreted. For example, in E. coli, non-secreted proteins may accumulate in inclusion bodies. Methods for purifying recombinant proteins from inclusion bodies are well known in the art.
[0152] Transfection can be carried out by a variety of methods including using calcium phosphate, electroporation, or by mixing cationic lipids with materials that produce liposomes that fuse with the cell membrane and deliver the cargo inside.
[0153] nucleic acid moleculeThe invention provides recombinant nucleic acid molecules having a nucleotide sequence encoding a mutated HCMV gH polypeptide, a mutated HCMV gL polypeptide, a mutated HCMV pUL128 polypeptide, a mutated HCMV pUL130 polypeptide, and / or a mutated HCMV pUL131A polypeptide as described herein. The recombinant nucleic acid molecules of the invention may be present in a vector (e.g., an expression vector) and may be operably linked to one or more control elements (e.g., a promoter and / or an enhancer). An example of the recombinant nucleic acid may be a single molecule encoding a gL polypeptide of the invention, a gH polypeptide of the invention, a pUL128 polypeptide of the invention, a pUL130 polypeptide of the invention, and a pUL131A polypeptide of the invention. A further example of the recombinant nucleic acid may be a single molecule encoding a gL polypeptide of the invention and a gH polypeptide of the invention, and optionally further encoding a gO polypeptide of the invention. The invention also provides a plurality of recombinant nucleic acid molecules encoding one or more mutated polypeptides of the invention. For example, in one embodiment, the invention provides two nucleic acid molecules: a first molecule encoding a gH polypeptide of the invention and a gL polypeptide of the invention, and a second molecule encoding a pUL128 protein of the invention, a pUL130 protein of the invention, and a pUL131A polypeptide of the invention. For example, in one embodiment, the invention provides three nucleic acid molecules: a first recombinant nucleic acid molecule encoding a gL protein of the invention, a second recombinant nucleic acid molecule encoding a gH protein of the invention, and a third recombinant nucleic acid molecule encoding one or more additional HCMV proteins, such as gO, pUL128, pUL130, or pUL131A. For example, in one embodiment, the invention provides five nucleic acid molecules: a first recombinant nucleic acid molecule encoding a gL protein of the invention, a second recombinant nucleic acid molecule encoding a gH protein of the invention, a third recombinant nucleic acid molecule encoding a pUL128 protein of the invention, a fourth recombinant nucleic acid molecule encoding a pUL130 protein of the invention, and a fifth recombinant nucleic acid molecule encoding a pUL131A protein of the invention.Preferably, the recombinant nucleic acid molecule(s) of the invention (a) is not a self-replicating RNA molecule, (b) is not an alphavirus replicon, (c) does not encode any alphavirus nonstructural proteins, such as NSP1, NSP2, NSP3, and NSP4, (d) does not contain an internal ribosome entry site (IRES), such as EMCV or EV71, and / or (e) does not contain a viral 2A site, such as FMDV. Thus, the sequences encoding each of the individual polypeptides in the complex can be present on a single nucleic acid molecule or distributed across two or more nucleic acid molecules.
[0154] In one embodiment, the invention provides a plurality of recombinant nucleic acids comprising: (i) a first recombinant nucleic acid molecule encoding a gL protein of the invention, (ii) a second recombinant nucleic acid molecule encoding a gH protein of the invention, (iii) a third recombinant nucleic acid molecule encoding a pUL128 protein of the invention, (iv) a fourth recombinant nucleic acid molecule encoding a pUL130 protein of the invention, and (v) a fifth recombinant nucleic acid molecule encoding a pUL131A protein of the invention. See, e.g., WO 2014 / 005959 (also published as U.S. Patent Publication No. 2016-0159864). Preferably, the first, second, third, fourth, and / or fifth recombinant nucleic acid molecule(s) (a) is not a self-replicating RNA molecule, (b) is not an alphavirus replicon, (b) does not encode any alphavirus nonstructural proteins, such as NSP1, NSP2, NSP3, and NSP4, (c) does not contain an internal ribosome entry site (IRES), such as EMCV or EV71, and / or (d) does not contain a viral 2A site, such as FMDV.
[0155] Nucleic acid molecules encoding gH proteins of the invention can have different degrees of identity with SEQ ID NO: 1, for example at least 89% 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 1. Nucleic acid molecules encoding gH proteins of the invention can have different degrees of identity with SEQ ID NO: 3, for example at least 89% 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 3. Nucleic acid molecules encoding gL proteins of the invention can have different degrees of identity with SEQ ID NO: 7, for example at least 89% 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 7. Nucleic acid molecules encoding the gL protein of the invention can have different degrees of identity with SEQ ID NO: 9, for example at least 89% 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 9. Nucleic acid molecules encoding the gL protein of the invention can have different degrees of identity with SEQ ID NO: 29, for example at least 89% 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 29. Nucleic acid molecules encoding the pUL128 protein of the invention can have different degrees of identity with SEQ ID NO: 13, for example at least 89% 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 13. Nucleic acid molecules encoding the pUL130 protein of the invention can have various degrees of identity with SEQ ID NO: 17, such as at least 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 17. Nucleic acid molecules encoding the pUL131A protein of the invention can have various degrees of identity with SEQ ID NO: 21, such as at least 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 21.
[0156] The recombinant nucleic acid molecules of the present invention may comprise DNA, optionally including introns, and / or cDNA. Some genes are more efficiently expressed when introns are present. The genomic UL128 and UL131A genes each consist of two exons, while UL130 does not contain any introns. The recombinant nucleic acid molecules of the present invention may comprise ribonucleic acid (RNA), e.g., mRNA, with the proviso that the RNA molecule(s) of the present invention (a) are not self-replicating RNA molecules, (b) are not alphavirus replicons, (c) do not encode any alphavirus nonstructural proteins, e.g., NSP1, NSP2, NSP3, and NSP4, (d) do not contain an internal ribosome entry site (IRES), e.g., EMCV or EV71, and / or (e) do not contain a viral 2A site, e.g., FMDV. The nucleic acid molecules of the present invention may comprise polynucleotide sequences (DNA or RNA) that are codon-optimized for expression in a host cell, e.g., codon-optimized for expression in a bacterial or mammalian host cell.
[0157] The present invention provides a vector comprising the nucleic acid molecule of the present invention. The vector of the present invention can be an expression vector comprising a promoter and a terminator suitable for expression in a host cell. Such promoters and terminators are described, for example, by US Patent Publication Nos. 2015 / 0322115 and 2015 / 0359879. The recombinant nucleic acid molecule can be a plasmid or can be integrated into the genome of a cell. The promoter in these vectors can be an HCMV promoter or a non-HCMV promoter (see, for example, US Patent Publication Nos. 2015 / 0322115 and 2015 / 0359879).
[0158] Exemplary procedures sufficient to illustrate to one of skill in the art the production of the recombinant HCMV nucleic acids of the invention can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, 1989; Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Press, 2001; Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates, 1992 (and 2003 supplement); and Ausubel et al., Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, 4th ed., Wiley & Sons, 1999.
[0159] The invention also provides methods of expressing an HCMV complex (e.g., an HCMV pentamer complex) comprising one or more mutated HCMV gH, gL, pUL128, pUL13, and / or pUL131A polypeptides of the invention by introducing one or more recombinant nucleic acid molecules encoding the one or more mutated polypeptides into an expression system, expressing the one or more nucleic acid molecules in the expression system, and purifying the HCMV complex. In some embodiments, the method includes transfecting a cell with a first nucleic acid construct encoding a mutated HCMV gH, gL, pUL128, pUL130, and pUL131A polypeptide of the invention. In some embodiments, the method may include transfecting a cell with a first nucleic acid construct encoding an HCMV gH polypeptide of the invention, a second nucleic acid construct encoding an HCMV gL polypeptide of the invention, and one or more third nucleic acid constructs encoding one or more additional HCMV glycoproteins of the invention. In some embodiments, the method may include transfecting a cell with a first nucleic acid construct encoding a gH polypeptide of the invention and a gL polypeptide of the invention, and a second nucleic acid construct encoding an HCMV pUL128, HCMV pUL130, and HCMV pUL131A polypeptide of the invention. The HCMV complex may be expressed in a mammalian cell. The isolated HCMV membrane protein complex may optionally be purified.
[0160] cell The invention also provides a cell expressing one or more nucleic acid molecules of the invention, the cell not containing the complete HCMV genome. The cell may be stably transformed with the one or more nucleic acid molecules of the invention. Preferably, the cell is a mammalian cell, such as a 293-6E cell (see WO2014 / 005959, also published as U.S. Patent Publication No. 2016 / 0159864) or a CHO cell (see WO2016 / 116904).
[0161] The invention also provides a cell producing a complex of the invention, which does not: (i) contain an HCMV genome, and / or (ii) produce HCMV virions, and / or (iii) express any non-enveloped HCMV protein. Ideally, the cell lacks one of (i), (ii), or (iii), preferably lacks two, and more preferably lacks all three of (i), (ii), and (iii). Thus, it may be defined that the cell of the invention does not contain an HCMV genome, and / or does not produce HCMV virions, and / or does not express any non-enveloped HCMV protein.
[0162] antibody Because the modified polypeptides of the present invention (and mutant construct-forming fragments thereof) differ in structure from the non-mutant polypeptides but retain their immunogenic properties or epitope(s), it is a further object of the present invention to utilize the mutant polypeptides and mutant fragments thereof in polypeptide / antibody interactions. Polypeptide / antibody interactions for non-mutant polypeptides have been described, for example, by WO 2014 / 005959 (also published as U.S. Patent Publication No. 2016 / 0159864); Macagno et al., Isolation of Human Monoclonal Antibodies that Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH / gL / UL128-131A complex, 2010 J. Virol. 84(2): 1005-1013; and Gerna et al., Monoclonal antibodies to different components of the human cytomegalovirus (HCMV) pentamer gH / gL / pUL128L and Trimer gH / gL / gO as well as antibodies elicited during primary HCMV infection prevent epithelial cell syncytium formation, 2016 J. Virol. 90(14): 6216-6223. See also U.S. Patent No. 9,527,902. Prior to the present invention, various conformational epitopes of the pentamer complex were known. For example, Macagno et al. (2010 J. Virol. 84: 1005-1013) isolated a panel of human monoclonal antibodies that neutralized HCMV infection of endothelial, epithelial, and myeloid cells. With only one exception, an antibody that bound to a conserved epitope in the UL128 gene product, all other antibodies bound to conformational epitopes that required expression of two or more proteins of the gH / gL / UL128-131A complex.Preferably, the pentameric complexes of the invention possess one or more conformational epitopes identified by Macagno et al. (2010 J. Virol. 84: 1005-1013) and / or further described by the Examples herein.
[0163] The present invention provides an antibody that recognizes a modified HCMV gH, gL, pUL128, pUL130, or pUL131A polypeptide or complex of the present invention. The antibody of the present invention may be produced using an isolated polypeptide of the present invention or an isolated complex containing the same as an antigen. Preferably, the antibody of the present invention is a neutralizing antibody. The antibody of the present invention may be a monoclonal antibody, a polyclonal antibody, a multispecific antibody (e.g., a bispecific antibody), a labeled antibody, or an antibody fragment, so long as it exhibits the desired antigen-binding activity. An "antibody fragment" or an "antigen-binding fragment" refers to a molecule other than a complete antibody that contains a portion of a complete antibody that binds to the antigen that the complete antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, a name denoting the ability to crystallize readily. Pepsin treatment produces an F(ab')2 fragment that has two antigen-binding sites and is still capable of cross-linking antigen.
[0164] Alternatively, the HCMV polypeptides or HCMV complexes of the invention may be used to identify antibodies using in vitro selection methods, such as phage display using diverse antibody libraries. The invention also provides methods for producing antibodies using isolated HCMV polypeptides or HCMV complexes of the invention. The antibodies of the invention may be human or humanized. The antibodies of the invention may be used in diagnostic assays and may be directly or indirectly labeled. In some embodiments, the antibodies of the invention may be used in therapy, such as in the treatment of HCMV infection, and may be in the form of neutralizing antibodies that can inhibit or neutralize the biological activity of the antigen.
[0165] Isolation and purification of the complex The complexes of the present invention are preferably prepared and used in isolated form. The term "isolated" as used herein means removed from its natural environment. Thus, "isolated HCMV membrane protein complex" does not include HCMV membrane protein complexes on the surface of HCMV-infected cells, HCMV membrane protein complexes within infectious HCMV virions, or HCMV membrane protein complexes bound to antibodies (or antibody fragments). Using the expression methods described in the Examples and, for example, in WO2014 / 005959 (also published as U.S. Patent Publication No. 2016 / 0159864, and WO2016 / 116904), the complexes of the present invention can be produced in high yields. For example, in a method comprising growing a cell of the invention in a growth medium, a protein complex of the invention may accumulate to a level of greater than 0.4 mg per liter of growth medium (e.g., 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4, 4.5, or 5 mg per liter of growth medium or more).
[0166] The present invention provides methods for purifying the HCMV membrane complexes of the present invention. Such methods of the present invention allow for the production of HCMV membrane protein complexes with a purity of more than 85%, more than 86%, more than 87%, more than 88%, more than 89%, more than 90%, more than 91%, more than 92%, more than 93%, more than 94%, or more than 95% of the total protein by mass as determined by gel electrophoresis. These high levels of purity make the complexes suitable for use as immunogens in diagnostic applications or antigens in vaccine formulations. The HCMV membrane protein complexes of the present invention can be prepared with various levels of purity, for example at least 80%, 85%, 90%, 95%, or 99% of the total protein by mass, i.e., the complexes constitute at least 80% of the total protein amount in the composition. The composition may be free of polyacrylamide.
[0167] The invention provides methods of purifying HCMV complexes of the invention (e.g., HCMV pentamer complexes). In some embodiments of the invention, the purification comprises one or more chromatography steps. The one or more chromatography steps comprise affinity chromatography, e.g., Ni2+ affinity chromatography and / or size exclusion chromatography. In some embodiments of the invention, the one or more chromatography steps comprise ion exchange chromatography. See, e.g., WO2014 / 005959 (also published as U.S. Patent Publication No. 2016 / 0159864), WO2016 / 116904, and WO2015 / 181142. Thus, a polypeptide of the invention may include, for example, a tag for isolation of the polypeptide (e.g., an affinity tag, such as a strep tag, a myc tag, a polyhistidine tag, or a combination thereof) (see Kimple et al., Overview of Affinity Tags for Protein Purification, 2015 Curr. Protoc. Protein. Sci. 73: Unit-9.9. doi:10.1002 / 0471140864.ps0909s73, which summarizes known tags and their use for biotechnology applications).
[0168] Adjuvants The vaccines and immunogenic compositions of the present invention may include an adjuvant in addition to the antigen. Adjuvants are "non-antigenic components" used in vaccines to enhance and modulate the immune response to the antigen. However, adjuvants may result in increased reactogenicity. Adjuvants include (but are not limited to) AS01, oil-in-water emulsions (e.g., MF59 and AS03), liposomes, saponins, TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR5 agonists, TLR6 agonists, TLR7 agonists, TLR8 agonists, TLR9 agonists, aluminum salts, nanoparticles, microparticles, ISCOMS, complexes of calcium fluoride with organic compounds, or combinations thereof. See, e.g., U.S. Patent Publication No. 2015 / 0093431 and WO2011 / 027222 (also published as U.S. Patent Publication No. 2012 / 0237546). In a particular embodiment, the vaccine or immunogenic composition of the invention comprises an antigen and an adjuvant, where the adjuvant is AS01, an oil in water emulsion (e.g., MF59 and AS03, and their respective subtypes, including subtypes B and E), an aluminum salt (e.g., aluminum phosphate and aluminum hydroxide), a saponin (e.g., QS21), an agonist of a Toll-like receptor (TLRa) (e.g., TLR4a and TLR7a), or a combination thereof (e.g., Alum-TLR7a (Buonsanti et al., Novel adjuvant Alum-Tlr7a significantly potentiates immune response to glycoconjugate vaccines, 2016 Sci. Rep. 6:29063 (DOI: 10.1038 / srep29063)). By "TLR agonist" is meant a component that is capable of triggering a signaling response via the TLR signaling pathway, either as a direct ligand or indirectly by the production of an endogenous or exogenous ligand (Sabroe et al., Toll-like Receptors in Health and Disease: Complex Questions Remain, 2003 J. Immunol. 171(4): 1630~1635).For example, a TLR4 agonist can trigger a signaling response via the TLR-4 signaling pathway. A suitable example of a TLR-4 agonist is lipopolysaccharide, preferably a non-toxic derivative of lipid A, particularly monophosphoryl lipid A, or more particularly 3-deacylated monophosphoryl lipid A (3D-MPL). The adjuvants described herein may be combined with any of the antigen(s) described herein.
[0169] The following embodiments are contemplated in the present invention: Mutations at positions determined relative to the sequence of SEQ ID NO:1, namely: A102W, A102F, A102Y, A102V, A102I, A102L, A372W, A372F, A372Y, A372V, A372I, A372 L, A352W, A352F, A352Y, A352V, A352I, A352L, L257W, L257F, L257Y, L257V, L257I, L25 7L, H252W, H252F, H252M, H252C, H252A, H252L, H252I, H252V, H252P, H252Y, K404W, K 404F, K404M, K404C, K404A, K404L, K404I, K404V, K404P, K404Y, R255W, R255F, R255M, R255C, R255A, R255L, R255I, R255V, R255P, R255Y, E355W, E355F, E355M, E355C, E355 A, E355L, E355I, E355V, E355P, E355Y, H480W, H480F, H480M, H480C, H480A, H480L, H48 0I, H480V, H480P, H480Y, S601W, S601F, S601M, S601C, S601A, S601L, S601I, S601V, S 601P, S601Y, R405W, R405F, R405M, R405C, R405A, R405L, R405I, R405V, R405P, R405Y, G358S, G358T, G358C, G358Y, G358N, G358Q, G358R, G358E, G358K, G358H, G358D, H275S, H275T, H275C, H275Y, H275N, H275Q, H275R, H275E, H275K, H275H, H275D, V109C, L111C, N55Q, N55S, N55T, N55A, N55E, N55D, N62Q, N62S, N62T, N62A, N62E, N62D, N67Q, N67S, N67T, N67A, N67E, N67D, N192Q, N192S, N192T, N192A, N192E, N192D, N641Q, N641S, N641T, N641A, N641E, N641D, N700Q, N700S, N700T, N700A, N700E, or combinations thereof HCMV gH polypeptide or a complex-forming fragment thereof comprising:
[0170] Mutations at positions determined relative to the sequence of SEQ ID NO: 7, namely: H177W, H177F, H177Y, H177V, H177I, H177L, G224W, G224F, G224Y, G224V, G224I, G224L, G140 W, G140F, G140Y, G140V, G140I, G140L, G145W, G145F, G145Y, G145V, G145I, G145L, D146W, D14 6F, D146Y, D146V, D146I, D146L, G218W, G218F, G218Y, G218V, G218I, G218L, L119W, L119F, L 119Y, L119V, L119I, L119L, C233W, C233F, C233Y, C233L, P272W, P272F, P272Y, P272V, P272I, P272L, H267W, H267F, H267M, H267C, H267A, H267L, H267I, H267V, H267P, H267Y, H236W, H236 F, H236M, H236C, H236A, H236L, H236I, H236V, H236P, H236Y, H245W, H245F, H245M, H245C, H24 5A, H245L, H245I, H245V, H245P, H245Y, G161W, G161F, G161M, G161C, G161A, G161L, G161I, G 161V, G161P, G161Y, C233W, C233F, C233M, C233C, C233A, C233L, C233I, C233V, C233P, C233Y, G161C, D163C, G224C, G218C, R166C, G140C, R160C, A150C, N74Q, N74S, N74T, N74A, N74E, and N74D, or combinations thereof HCMV gL polypeptide or a complex-forming fragment thereof comprising the polypeptide.
[0171] Mutations at positions determined relative to the sequence of SEQ ID NO: 13, namely: G123W, G123F, G123Y, G123V, G123I, G123L, V77W, V77F, V77Y, V77I, V77L, L103W, L103F, L1 03Y, L103V, L103I, L103L, Q119W, Q119F, Q119Y, Q119V, Q119I, Q119L, G145W, G145F, G145M, G145C, G145A, G145L, G145I, G145V, G145P, G145Y, H90W, H90F, H90M, H90C, H90A, H90L, H90I , H90V, H90P, H90Y, G112W, G112F, G112M, G112C, G112A, G112L, G112I, G112V, G112P, G112Y, R142C, N99C, Y98C, A124C, G126C, L159C, D45C, V88C, M48C, G107C, R51C, D106C, S83C, or combinations thereof HCMV pUL128 polypeptide or a complex-forming fragment thereof comprising the polypeptide
[0172] Mutations at positions determined relative to the sequence of SEQ ID NO: 17, namely: D165W, D165F, D165Y, D165L, H209W, H209F, H209Y, H209L, G116W, G116F, G116M, G116C, G116A, G116L, G116I, G116V, G116P, G116Y, G135W, G135F, G135M, G135C, G135A, G135L, G135I, G135V, G135P, G135Y, H150W, H150F, H150M, H150C, H150A, H150L, H150I, H150V, H150P, H150Y, H209W, H209F, H209M, H209C, H209A, H209L, H209I, H209V, H209P, H209Y, G116C, H150C, P64C, S178C, P62C, E95C, Y204C, N211C, I213C, Y56C, T167C, N85Q, N85S, N85T, N85A, N85E, N85D, N118Q, N118S, N118T, N118A, N118E, N118D, N201Q, N201S, N201T, N201A, N201E, and N201D, or combinations thereof HCMV pUL130 polypeptide or a complex-forming fragment thereof comprising the polypeptide
[0173] Mutations at positions determined relative to the sequence of SEQ ID NO: 21, namely: G99W, G99F, G99Y, G99V, G99I, G99L, S86W, S86F, S86Y, S86V, S86I, S86L, S90W, S90F, S90Y, S90V, S90I, S90L, H69W, H69F, H69M, H69C, H69A, H69L, H69I, H69V, H69P, H69Y, H35W, H35F, H35M, H35C, H35A, H35L, H35I, H35V, H35P, H35Y, H64W, H64F, H64M, H64C, H64A, H64L, H64I, H64V, H64P, H64Y, D38W, D38F, D38M, D38C, D38A, D38L, D38I, D38V, D38P, D38Y, V85W, V85F, V85M, V85C, V85A, V85L, V85I, V85V, V85P, V85Y, Y52W, Y52F, Y52M, Y52C, Y52A, Y52L, Y52I, Y52V, Y52P, Y52Y, A67W, A67F, A67M, A67C, A67A, A67L, A67I, A67V, A67P, A67Y, R118S, R118T, R118C, R118Y, R118N, R118Q, R118R, R118E, R118K, R118H, R118D, H64C, W37C, N81Q, N81A, N81T, N81A, N81E, and N81D, or combinations thereof HCMV pUL131A polypeptide or a complex-forming fragment thereof comprising the polypeptide.
[0174] [Example] Numerous modifications and variations of the present invention are possible in light of the above teachings. It should be understood, therefore, that within the scope of the appended claims, those skilled in the art will recognize that the invention may be practiced other than as specifically described. The exemplary embodiments and examples should not be construed as limiting the invention.
[0175] [Example 1] Expression of pentamer complexes in mammalian cells Expression of wild-type or selenomethionine-tagged (SeMet) pentamers was achieved through transient or stable transfection of two vectors using a two-vector strategy as outlined in Hofmann et al. (Expression of the Human Cytomegalovirus Pentamer Complex for Vaccine use in a CHO System, 2015 Biotech. & Bioeng. 112(12): 2505-2515), where one vector encodes gH and gL (having the sequences of SEQ ID NOs: 3 and 7, respectively) and the other encodes pUL128, pUL130, and pUL131A (having the sequences of SEQ ID NOs: 13, 17, and 21, respectively). - This was carried out in cells.
[0176] For anti-pentamer Fab expression, the heavy chain Fab fragment and the full-length light chain were cloned into the mammalian pRS5a expression vector (Novartis AG), respectively. The heavy chain Fab had a cleavable double Strep tag at its C-terminus. Anti-pentamer Fab was transiently expressed in 293Expi cells (Invitrogen Inc.) by transfecting the two vectors encoding the antibody heavy chain Fab fragment and the full-length light chain in a 1:1 ratio using the Expifectamine 293 transfection kit (ThermoFisher) according to the manufacturer's recommendations.
[0177] [Example 2] Purification of the pentameric complex For pentamer purification, the expression medium was loaded directly onto a StrepTrap HP column (GE Lifesciences) and the protein was eluted using 0.1 M Tris pH 8.0, 150 mM NaCl and 2.5 mM desthiobiotin in elution buffer (IBA Lifesciences) according to the manufacturer's recommendations. The eluate was incubated with TEV protease (ThermoFisher) overnight at 4°C. The sample was diluted 3-fold with 20 mM Hepes pH 7 to reduce the total salt concentration to 50 mM before loading onto a MonoS10 / 30 column (GE Lifesciences) for ion exchange chromatography. The protein was eluted from the column with a linear gradient from 0 to 1 M NaCl over 10 column volumes. The protein was concentrated and loaded onto a Superose 6 10 / 300 column and the elution peak was concentrated to >1 mg / mL.
[0178] For Fab purification, the expression medium was concentrated 10-fold and buffer exchanged into 25 mM Tris pH 8.0, 150 mM NaCl and 1 mM EDTA using a tangential flow filtration system (Millipore) with a 10 kDa cutoff. The sample was then loaded onto a StrepTrap HP column and eluted similarly to the pentamer purification described above. The Strep tag was cleaved using PreScission protease (GE Lifesciences) according to the manufacturer's recommendations. The cleaved Fab was then purified by size exclusion chromatography on an S200 column (GE Lifesciences) equilibrated with a buffer containing 25 mM Tris pH 8.0 and 150 mM NaCl.
[0179] To purify the pentamer-Fab complex for crystallization, the pentamer eluted from the MonoS column was incubated with a 2-fold molar excess of purified Fab and incubated at room temperature for at least 15 min. The sample was then loaded onto a Superose 6 10 / 300 column to separate the pentamer-Fab complex from the excess Fab. Peak fractions were pooled and concentrated to >5 mg / mL.
[0180] [Example 3] Crystallization of the pentamer complex For crystallization experiments, purified wild-type or selenomethionine-labeled (SeMet) pentamers were deglycosylated using Endo Hf (New England Biolabs) according to the manufacturer's guidelines prior to complexation with Fab. Initial crystal hits were obtained for complexes between the pentamer and the fragment antigen binding (Fab) of monoclonal antibodies (mAbs) 8I21 and 9I6 (Macagno et al., (2010 J. Virol. 84:1005-1013) which appeared as small microcrystals in droplets containing 0.1 μl protein and 0.1 μl of 20% ethanol, 0.1 M Tris pH 8.5 at 20 °C. Ethanol was replaced with the less volatile isopropanol in subsequent experiments, and benzamidine was used as an additive (from a Hampton Research additive screen) to optimize the crystallization conditions. The best crystals of WT or SeMet-pentamer-8I21 Fab crystals were obtained using a reservoir containing 10% (wt / vol) PEG400, 10% isopropanol, 2% (wt / vol) benzamidine and 0.1 M Tris pH 8.2. 9I6 Crystal hits of the pentamer in complex with Fab were initially obtained in 0.1 M MES pH 6.5 and 15% (wt / vol) PEG methyl ether 500. These crystals were optimized for growth using various additives. The best diffracting crystals were obtained using a reservoir containing 10% (wt / vol) PEG methyl ether 500, 0.1 M MES pH 6.2 and 10 μM phenol.
[0181] 3.1 Results – Crystal Structure The pentamer structure adopts a helical shape with a length of 180 Å and crossovers of 30–80 Å (Fig. 1). The gH / gL portion of the complex has a domain organization and structure similar to other herpesvirus gH / gL, with the four gH domains (DI–D-IV) stacking on top of each other and the most N-terminal one (DI) cofolding with gL. The polypeptide chains of UL are highly interconnected, forming a gently curved subcomplex that binds to the N-terminal gL extension. Analysis of the pentamer surface reveals 11 N-linked glycosylation sites, six in gH, one in gL, and the remaining four in UL.
[0182] Structural comparison reveals close similarity between HCMV gH and the gH of the γ-herpesvirus Epstein-Barr virus (EBV), although HCMV gH adopts a boot-shaped structure reminiscent of the α-herpesviruses Varicella-Zoster virus (VZV) and Herpes Simplex Virus-2 (HSV-2) gH / gL rather than the rod-shaped conformation of EBV gH / gL. A major difference between EBV gH and HCMV gH is the presence of three additional N-terminal β-strands in the latter that interact with residues from gH.
[0183] UL forms a central core domain flanked by two smaller globular domains at the opposite ends (Figs. 1 and 2A-2F). The core domain is formed by the pUL130 C-terminus and pUL131A, both of which consist of an N-terminal α-helix followed by three β-strands of similar length (Figs. 2A-2F). The strands assemble into a large, rather flat, antiparallel β-sheet covered on one face by a helix. The N-terminus of UL128 forms a globular domain located at the tip of the pentamer, with the first 80 residues adopting a CC-type chemokine fold, whereas the C-terminal UL128 is anchored to gH / gL by a 50 Å long linker, with the terminal helix docking in a hydrophobic groove formed by the three α-helices and two β-strands of gL.
[0184] 10P3 (site 4) and 15D8 (site 1) bind to the concave face of the UL, and 10F7 (site 2) binds to the other face of the pentamer along the UL130 / UL131 Aβ sheet.
[0185] The 9I6 CDRs are in contact with both UL128 (residues 47-52 of the chemokine domain, and residues 92-93 and 106-109 of α2β4β5β6) and UL131A (residues 23-24 and 27-31). The epitope is consistent with published NS-EM data and mapping studies. This suggests that site 5 antibodies require all three ULs for binding, possibly due to cofolding of UL130 and UL131A.
[0186] A key feature of the pentamer-8I21 Fab complex is the interaction between the long HCDR3 of the Fab and the UL130 chemokine domain. At the tip of HCDR3, Arg104 and Trp105 protrude into a cleft composed of hydrophobic and polar residues from the N-terminal UL130-α1 helix and UL130 / gL β-sheet, and establish H-bonds with UL130 Ser47 and gL Asp156, respectively. Mutation of HCDR3 Trp105 to alanine resulted in a >150-fold decrease in binding affinity, consistent with its critical role in the interaction. Several other interactions that stabilize the complex include a hydrogen bond between the guanidinium group of HCDR3 Arg107 and the hydroxyl group of UL130 Tyr46, and H-bonds between the main-chain carbonyl oxygen of HCDR3 and the side chains of LCDR3 Trp94 and Trp97.
[0187] summary The pentamer structure shows the presence of small interfaces between some of the domains and of some cavities at the domain interfaces (Figure 2). Data from negative staining electron microscopy (NS-EM) of the pentamer-nAb complexes (see previously published Ciferri et al., Antigenic Characterization of the HCMV gH / gL / gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies, 2015 PLOS Path DOI:10.1371 / journal.ppat.1005230), data from hydrogen-deuterium exchange coupled to mass spectrometry (HDX-MS), and analysis of superpositions of the solved pentamer crystal structures in complex with two different neutralizing antibodies were analyzed. Taken together, this information revealed the presence of an inherent flexibility of the pentamer protein complex. Specifically, the UL undergoes rigid-body rotation around the gH DI / D-II linker helix, which serves as a hinge or "shoulder." As a result, the UL can move as a rigid arm, displacing up to 30 Å (Figure 3). The HDX-MS data also showed how antibody binding to the pentamer can affect peptides far from the epitope (or the region directly involved in antibody binding), suggesting that the pentamer complex may be stabilized when bound by the antibody.
[0188] The pentamer structure revealed herein indicates that the gH and gL components of the complex bear close structural similarity to EBV gH / gL, while UL features an α / β core domain flanked at opposite ends by UL128 and UL130 chemokine domains. Notably, HCMV gL has a unique N-terminal extension that is lacking in EBV and HSV gL, forming a docking site for the UL128 C-terminal α3 helix and the UL130 chemokine domain.
[0189] The pentamer structural characteristics include relatively small interfaces and some interdomain cavities, suggesting an inherent flexibility of the complex. Structural comparison revealed a large rigid rotation of the gH / gL DI domains and the UL arm around the gH DI / D-II linker helix, resulting in a large displacement of the UL. Although the 8I21 epitope remains the same in the pentamer-9I6 Fab complex, antibody binding appears to stabilize the pentamer in a separate, yet distinct, conformational state. Indeed, single particle reconstructions reveal a large rigid rotation of the UL in the pentamer bound to 10F7 Fab compared to the 8I21 and 9I6 Fab complexes. Consistent with this idea, HDX-MS analysis of the pentamer-Fab complex indicates that the antibody stabilizes a region of the pentamer away from its corresponding epitope. Thus, the combination of HDX-MS and crystallographic data reveals regions of the pentamer where mutations can be introduced to generate more stable complexes (see, e.g., McLellan et al., 2013 Science 342: 592-598, which showed that greater stability of the prefusion conformation of the respiratory syncytial virus fusion protein is associated with improved immunogenicity).
[0190] Analysis of this structure of the pentamer-Fab complex combined with cell-binding assays provides new insights into the mechanism of antibody-mediated HCMV neutralization. We show that the pentamer binds to adult retinal pigment epithelial (ARPE-19) and human umbilical vein endothelial (HUVEC) cells, but not to MRC-5 cells.
[0191] Preincubation of the pentamer with mAbs 15D8 (site 1), 10P3 (site 4), 2C12 and 9I6 (site 5) or 7I13 (site 6) inhibited pentamer binding to endothelial cells (Figures 6A-6C). In contrast, mAbs 4N10 and 8I21 (sites 3 and 7, respectively) and 10F7 (site 2) did not affect pentamer binding to cells. Thus, our data suggest that pentamer-specific antibodies may neutralize HCMV through interference with multiple pentamer functions during viral infection. We show that antibodies that bind to UL128 and UL131A residues located at the tip of the pentamer (9I6, site 5), the UL128-α3 helix (15D8, site 1), and close to the linker connecting UL128-α2β4β5β6 to UL128-α3 (10P3, sites 4 and 6) prevent pentamer binding to cells. Thus, these antibodies likely inhibit the interaction of the pentamer with cell surface receptors by either direct competition or steric hindrance, and the antibody binding sites likely correspond to sites on the surface of the pentamer for cell surface receptor binding.
[0192] In contrast, antibody binding to the elbow of the UL arm (4N10 and 8I21, sites 3 and 7, respectively) and the solvent-exposed side of the UL130 / UL131 Aβ sheet (10F7, site 2) did not affect pentamer binding to cells, suggesting a different neutralization mechanism. 8I21 binds to the positively charged surface of UL130 with the long heavy chain CDR3 (HCDR3), which simultaneously protrudes into the groove of the UL130 chemokine domain and contacts the UL130 N-terminal residues. Both of these are involved in receptor binding in chemokines. This site of UL130 is thought to bind to co-receptors at the cell surface or at a post-entry stage. Thus, site 2 and site 3 / 7 antibodies may interfere with these interactions and processes without affecting pentamer binding to cells.
[0193] Without wishing to be bound by theory, based on the structural and functional characteristics of the neutralizing mAbs, we propose a potential mechanism for pentamer-mediated activation of HCMV entry. We suggest that a cellular receptor binds to the surface proximal to UL128 and the epitopes for site 1 and 4 / 6 neutralizing antibodies. Receptor binding may in turn result in rotation of gH / gL DI mediated by the UL128 linker and UL128-α3 interaction with the gL 3-helix bundle. Rearrangement of the DI may affect the width of the DI / D-II groove involved in gB binding in EBV gH / gL, ultimately triggering membrane fusion.
[0194] In conclusion, the structure described herein of the pentamer reveals the binding site of a potent, broadly neutralizing mAb and suggests the location of important functional sites and targets for antibody therapeutics. The structure also reveals dynamic rearrangements of the UL upon antibody binding, suggesting a mechanism for ligand-induced conformational changes during cell entry. Finally, the structural, biochemical and cell-based functional analysis of the HCMV pentamer reported herein provides at least an atomic-level framework for the mechanism of pentamer activity and antigen design.
[0195] Analysis of glycans and deglycosylation mutations that mask the 3.2 pentamer epitope Seven neutralizing epitopes on the pentamer (sites 1-7) have been previously identified and extensively mapped (see, e.g., Macagno et al., 2010 J. Virol. 84: 1005-1013 and U.S. Patent No. 9,527,902). Five of the sites are non-overlapping (sites 1, 2, 3, 4, and 5), but site 3 overlaps with site 7 and site 4 overlaps with site 6. Antibodies that bind to these seven sites are also known, including, for example, the 15D8 antibody, which is known to bind to site 1, the 10F7 antibody, which is known to bind to site 2, the 4N10 antibody, which is known to bind to site 3, the 10P3 antibody, which is known to bind to site 4, the 9I6 and 2C12 antibodies, which are known to bind to site 5, the 7I13 antibody, which is known to bind to site 6, and the 8I21 antibody, which is known to bind to site 7 (see, e.g., Macagno et al., 2010 J. Virol. 84: 1005-1013 and U.S. Pat. No. 9,527,902). Using the pentamer structures obtained as described above, we first mapped the pentamer epitope sequences (amino acid residues of neutralizing epitopes on the pentamer) by differential HDX incorporation upon Fab binding and characterized site 1, 4, 5, and 2 epitopes with greater specificity (15D8, 10P3, 2C12, and 10F7 Fabs were used as representative neutralizing antibodies that bind to sites 1, 4, 5, and 2, respectively). Second, we manually inspected and analyzed the X-ray structure, HDX-MS data, and EM fitting results to propose that the site 1 epitope sequence corresponds to pUL128 residues 149-171, numbered relative to the sequence of SEQ ID NO: 13, the site 4 epitope sequence corresponds to pUL128 residues 56-72 and 131-148, numbered relative to the sequence of SEQ ID NO: 13, the site 5 epitope sequence corresponds to pUL131A residues 31-40 and 42-56, numbered relative to the sequence of SEQ ID NO: 21, and the site 2 epitope sequence corresponds to pUL131A residues 92-122, numbered relative to the sequence of SEQ ID NO: 21. The location of each of these epitope sequences on the surface of the pentamer structure is shown in FIG. 7 (general locations shown in ovals).
[0196] The general locations of the eleven glycans on the surface of the pentamer are also shown in FIG. 7 (locations shown as rectangles, with spheres within them representing carbon atoms, nitrogen atoms, oxygen atoms, and hydrogen atoms). There are ten on one face of the pentamer (six on gH, one on gL, and four on UL) (see pentamer face shown on the left side of FIG. 7). The other face of the pentamer features one glycan on UL130 (shown on the right side of FIG. 7, adjacent to site 2) and a positively charged region containing a cluster of exposed arginine and lysine residues. The pentamer-8I21 Fab structure reveals that two glycans (attached to pUL130-Asn85 and pUL130-Asn118 for the sequence of SEQ ID NO: 17) are adjacent to the 8I21 epitope. Based on the structural information obtained and our analysis thereof, we believe that the UL130-Asn85 and pUL130-Asn118 glycans limit the accessibility of the epitope (i.e., the glycans "mask" or "shield" the epitope). We therefore predict that removing one or both of these glycans will make the epitope more accessible. In particular, removing the glycans "unmasks" the epitope.
[0197] The inventors selected additional glycans that are in close proximity to neutralizing epitopes and are also expected to limit the accessibility of the respective epitopes, namely gH-Asn55, gH-Asn62, gH-Asn67, gH-Asn192, gH-Asn641, and gH-Asn700 numbered relative to SEQ ID NO: 1; gL-Asn74 numbered relative to SEQ ID NO: 7; pUL130-Asn201 numbered relative to SEQ ID NO: 17 (in addition to pUL130-Asn85 and pUL130-118); and pUL131A-Asn81 numbered relative to SEQ ID NO: 21. The inventors therefore expect that by removing one or more of the glycans listed above, the corresponding epitope(s) will become more accessible. In particular, removal of the glycans will "unmask" the epitope. We specifically propose substituting the asparagine residues listed above with any non-asparagine amino acid (e.g., glutamine) using known techniques to prevent N-linked glycosylation at that position, thereby unmasking the pentameric epitope. Whether a deglycosylation mutation unmasks an epitope and / or makes an epitope more accessible can be assayed by comparing the antigenicity of the mutant polypeptide or mutant complex to the antigenicity of the non-mutant polypeptide or complex using known techniques (see, e.g., Zhou et al., Quantification of the Impact of the HIV-1- Glycan Shield on Antibody Elicitation, 2017 Cell Reports 19:719-732; and Ma et al., Envelope Deglycosylation Enhances Antigenicity of HIV-I gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies, 2011 PLoS Path. 7(9), e1002200).Enhanced binding of neutralizing antibodies to the epitope (i.e., increased antigenicity) indicates that the deglycosylation mutations have the effect of unmasking the epitope and / or making the epitope more accessible. (Id.)
[0198] Based on the known positive effects that deglycosylation and the resulting epitope unmasking has on the immunogenicity of various antigens, and without wishing to be bound by theory, it is believed that unmasking of HCMV pentamer epitopes by the deglycosylation mutations described herein will result in mutant HCMV polypeptides (or fragments thereof) or mutant HCMV complexes being increased in immunogenicity compared to non-mutant (e.g., wild-type) polypeptides or complexes, respectively (see Liu et al., Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design, 2016 J. of Virol. 90(19): 8496-8508; Zhou et al., 2017 Cell Reports 19:719-732; and Ma et al., 2011 PLoS Path. 7(9), e1002200). The increase in antigenicity following deglycosylation provides acceptable proof of concept for increased immunogenicity through deglycosylation (see, e.g., Ma et al., 2011 PLoS Path. 7(9), e1002200).
[0199] Computational analysis of amino acids involved in the stability of the 3.3 pentamer complex In addition to manual inspection, analysis of the structures from section 3.1 above was performed using the molecular graphics program Pymol (PyMOL Molecular Graphics System, version 1.8 Schrodinger, LLC, available at WorldWideWeb(www).pymol.org) and the Crystallographic Object-Oriented Toolkit ("Coot") (Emsley et al., 2010, available at WorldWideWeb(www)2.mrc-lmb.cam.ac.uk / Personal / pemsley / coot / ). Molecular Operating Environment (MOE) software (see Molecular Operating Environment (MOE) software; Chemical Computing Group Inc., available at WorldWideWeb(www).chemcomp.com) was then used. In particular, the "residue scanning" and "sample sequence" variants of the "protein design" module within MOE were applied to the pentamer complex crystal structures obtained as described in the above section. The "residue scanning" simulations sequentially mutate all or a subset of the residues of the input protein. The "sample sequence" is randomly mutated at all of the specified residues. Both single and multiple point mutations were generated using MOE.
[0200] Additionally, the in silico “disulfide scan” variant of the “protein design” module within MOE was applied to the crystal structure of the pentamer complex obtained as described in the section above. This tool was used to analyze the surrounding environment of the residues to assess the presence of other residue(s) close enough to form a disulfide bond. Roughly speaking, two residues were characterized as being close enough to form a disulfide bond if the β-carbons of the two amino acids were within 5 Å of each other. Once such a pair of residues was selected, MOE was utilized to mutate both residues to cysteines and characterize the resulting effect on the stability of the protein complex.
[0201] Results from each MOE protocol were compiled and manually inspected. For all MOE protocols above, the impact of each proposed mutation was scored on stability using a delta stability scoring method (denoted as dS and measured as kcal / mol). In MOE, dS is defined as the relative thermal stability of a given mutation with respect to the wild-type or non-mutant protein, with more negative values of dS indicating a more stable mutation. This scoring method takes into account both the conformational changes upon mutation and the changes with respect to the wild-type or non-mutant. Furthermore, dS is predicted from the difference in stability between the mutant protein and its wild-type (or non-mutant) counterpart in both folded and unfolded states.
[0202] [Table 6]
[0203] [Table 7]
[0204] [Table 8]
[0205] [Table 9]
[0206] [Table 10]
[0207] [Table 11]
[0208] [Table 12]
[0209] [Table 13]
[0210] [Table 14]
[0211] [Example 4] Stabilization assay of mutant pentamer complexes 4.1 Characterization of complex stability at least with respect to gH Structural analysis of gH revealed the presence of several buried cavities mainly localized in the gH N-terminal region (near the interface with gL) and in the C-terminus of the gH ectodomain. Residue A102 of wild-type (WT) gH, relative to the sequence of gH in SEQ ID NO: 3, is located in a short α-helix (made up of gH residues 100-108) that runs parallel to the gL α-helix (made up of gL residues 216-234, relative to the sequence of gL in SEQ ID NO: 7). The methyl (CH3) side group of gH A102 points towards the interface with the gL α-helix where an apparent cavity exists. We therefore suggest that the cavity-filling mutations of gH A102 may contribute to better packing within this buried interface environment. Furthermore, gH residue H480 is observed to be partially exposed at the surface and is therefore identified by the inventors as a target site for repacking mutations to introduce more favorable packing of the residue with its surrounding environment. Also, considering the introduction of two additional disulfide bridges at the gH-gL interface (see mutations V109C(gH)-G224C(gL) and L111C(gH)-G218C(gL) in Table 11), the inventors also suggest that the introduction of disulfide bridge mutations stabilizes this region by fixing gH with the gL α-helix at gL residues 216-234 in a more rigid manner.
[0212] 4.2 Characterization of complex stability at least with respect to gL The location of the buried cavity in gL spans the entire buried region from the N-terminus to the C-terminus. In particular, gL residue H177 (numbered relative to the sequence of gL in SEQ ID NO: 7) is centrally located in gL and sandwiched between three structures: one loop on its side, one loop on its bottom, and an α-helix on the top. The side chain of gL H177 points toward a cavity that covers most of the region within these two loops. Therefore, we propose to mutate H177 to a hydrophobic cavity-filling residue (i.e., introduce a cavity-filling mutation at gL H177) to stabilize this region. Similarly, since at gL residue G224 and its surroundings a large cavity can be observed buried between the gH helix-loop-helix motif (gH residues corresponding to 108-122 in SEQ ID NO:3) and the gL α-helix (gL residues corresponding to 216-234 in SEQ ID NO:7), we propose to introduce a cavity-filling mutation there (gL residue G224) to stabilize the region. There is also a cavity in front of the side chain of gL C233 at the interface between the gH helix-loop-helix region at gH residues 92-101 (numbered relative to SEQ ID NO:3) and the gL helix-loop-helix region around gL residues 228-242 (numbered relative to SEQ ID NO:7). We therefore propose to introduce a cavity-filling or hydrophobic mutation at gL residue C233. Finally, the gL-UL130 interface is made up of main chain and side chain hydrogen bonds and large side chain hydrophobic contacts. Based in part on the structural analysis of this region, we suggest the insertion of a disulfide bond into the gL-UL130 interface by disulfide bridge mutations to lock these two subunits together (e.g., by a P64C mutation at the UL130 residue corresponding to P64 in SEQ ID NO: 17 and a G161C mutation at the gL residue corresponding to G161 in SEQ ID NO: 7).
[0213] 4.3 Characterization of complex stability at least with respect to UL128 The UL128 residue corresponding to G123 in SEQ ID NO: 13 is located under a large buried cavity and is buried in a small domain of 30 residues at the interface between pUL128, pUL130 and pUL131A. Since at least residue G123 is located under a large buried cavity, we propose to make a cavity-filling mutation at UL128 G123 to increase the complex stability. Furthermore, the small UL128 G145 residue (numbered relative to SEQ ID NO: 13) is located in the last UL128 C-terminal α-helix that docks into the gL 3-helix bundle, and is therefore a target identified by the inventors for introducing a repacking mutation to increase the interaction at the gL-UL128 interface, thereby increasing the complex stability. Finally, due to the context and three-dimensional location of residues UL128 R142 and UL130 E95 (numbered relative to the UL128 sequence of SEQ ID NO: 13 and the UL130 sequence of SEQ ID NO: 17, respectively) along the 50 Å long linker connecting the N-terminal domain of UL128 to gL, we propose to introduce UL128 R142C and UL130 E95C disulfide bridge mutations into the complex to anchor UL128 to UL130, thus contributing to increased stability of the UL region and overall increased stability of the complex.
[0214] 4.4 Characterization of complex stability at least with respect to UL130 At the pUL130-pUL131A interface, pUL130 residue H209 (numbered relative to the sequence of pUL130 in SEQ ID NO: 17) points towards pUL131A H35 (numbered relative to the sequence of pUL131A in SEQ ID NO: 21). Based on this, we suggest that these histidines repel each other when protonated, thereby causing a conformational change or providing flexibility to this region. Therefore, we propose to introduce repacking mutations at the residues corresponding to UL130 H209 to reduce the flexibility of this region of UL and increase the complex stability. Furthermore, a large buried cavity was detected near pUL130 H209, and we propose to introduce either or both of cavity-filling and repacking mutations therein to increase the complex stability. Also, at the pUL130-pUL131A interface, the pUL130 residue corresponding to H150 in the sequence of SEQ ID NO:17 points towards pUL131A H69 (numbered relative to SEQ ID NO:21), and therefore we similarly propose introducing a repacking mutation into pUL130 H150 to reduce the flexibility of this UL region and increase the complex stability.
[0215] 4.5 Characterization of complex stability at least for pUL131A At the pUL130-pUL131A interface (αβ-core), pUL131A G99 (numbered relative to the sequence of pUL131A in SEQ ID NO:21) is located in the peripheral strand of the flat, 130-131 mixed large β-sheet, with its Cb backbone atom (i.e., the first carbon atom of the G99 side chain) pointing toward the buried region where the pUL130 and pUL131A helices and the large buried cavity are located. We target pUL131A G99 for the introduction of cavity-filling mutations that enhance complex stability. Similarly, pUL131A residue S86 (numbered relative to the sequence of pUL131A in SEQ ID NO:21) is located in the pUL131A helix and points toward the flat, large pUL130-pUL131A mixed β-sheet. Therefore, we propose to introduce a cavity-filling mutation at pUL131A S86 to increase the complex stability. Similarly, pUL131A residue H64 (numbered relative to the sequence of pUL131A in SEQ ID NO:21) faces toward a buried environment between the pUL130-pUL131A mixed αβ-core, and therefore we propose to introduce a repacking mutation (specifically, a hydrophobic mutation) at pUL131A H64, for example, with a bulkier, more hydrophobic residue (e.g., tryptophan (W)), to introduce interactions that increase the thermal stability of the complex.
[0216] 4.6 Design of stabilizing mutants As shown in the sections above, we performed computational analysis (summarized in Example 3.3 above) and processed the data by manual inspection and manipulation (summarized in Examples 4.1-4.5 above) to design mutations in gH, gL, pUL128, pUL130, and pUL131A that, when used alone or in combination, improve the stability of complexes containing those mutations. Without wishing to be bound by theory, we believe that conformational flexibility is reduced and the overall thermal stability of the complex is increased by (A) filling the buried cavities between the domain interfaces with atoms from amino acids made of longer side chains than those found in the wild-type protein, (B) increasing adjacent residue contacts or replacing unfavorable clusters of charged residues, and / or (C) introducing intra- or inter-disulfide bridges throughout the structure. Exemplary mutants we designed that result in one or more of A-C are listed below in Tables 15-21.
[0217] The following tables have been compiled to illustrate specific mutations within specific pentamer complex subunits, however, designed mutants include combinations of these mutations ("stacking mutations", i.e., combinations of mutations within one polypeptide (e.g., several mutations within gH), as well as combinations of mutations within different polypeptides (e.g., mutant gH and mutant gL, both of which may contain more than one mutation). By way of example, mutant HCMV pentamer complexes designed by the inventors include any one or more of the mutations listed in Tables 20 and 21 below.
[0218] [Table 15]
[0219] [Table 16]
[0220] [Table 17]
[0221] [Table 18]
[0222] [Table 19]
[0223] [Table 20]
[0224] While Tables 15-20 above exemplify disulfide bridge mutations introduced into a complex subunit (e.g., into one of the pentameric complex subunit proteins gH, gL, pUL128, pUL130, and pUL131A), because a disulfide bridge is formed between two residues (two cysteine residues in the same polypeptide (intra-disulfide bridge), or between two cysteine residues, one cysteine in each of a first and a second polypeptide (inter-disulfide bridge)), we provide in Table 21 below an overview of combinations of disulfide bridge mutations that we have designed that increase the stability of complexes that contain them (numbered in the left-most column as groups of disulfide bridge mutations). The combinations of disulfide bridge mutations provided in Table 21 may be stacked (e.g., a mutation listed in Group No. 1 may be combined with a mutation listed in Group No. 2) or may be combined with at least one cavity-filling and / or repacking mutation listed in Tables 15-20 above.
[0225] [Table 21]
[0226] 4.7 Express and purify complexes containing at least one designed mutant The HCMV pentamer complex exhibits bimodal unfolding reflected by having two thermal transition midpoint (Tm) values (two peaks) in a differential scanning fluorimetry (DSF) assay (the first lower temperature value is called "Tm1" and the second higher temperature value is called "Tm2"). The cavity-filling, repacking, disulfide-bridge, or deglycosylation mutations of the present invention may shift (i.e., raise or lower) one or several Tm peaks of the complex. An increase in the Tm value (i.e., a shift of the Tm peak to the right in the resulting sigmoid graph of the DSF assay) means a temperature change greater than zero (positive Tm shift). A decrease in the Tm value (i.e., a shift of the Tm peak to the left) means a temperature change less than zero (negative Tm shift). With respect to the HCMV pentamer complex, the mutations of the present invention may shift only one or both of Tm1 and Tm2. For these experiments, whether a mutation or combination of mutations is stabilizing, neutral, or destabilizing depends on the size of the Tm1 shift, the Tm2 shift, or both. An increase of at least one of Tm1 and Tm2 by at least 2°C compared to the control is considered an increase in the thermostability of the HCMV complex (i.e., if a mutation or combination of mutations results in a Tm1 shift or Tm2 shift of at least 2°C compared to the control, they are said to be "stabilizing"). An increase of at least one of Tm1 and Tm2 by at least 5°C compared to the control is considered a significant increase in the thermostability of the complex (i.e., if a mutation or combination of mutations results in a Tm1 shift or Tm2 shift of at least 5°C compared to the control, they are said to be "significantly stabilizing"). A mutation or combination of mutations is said to be "neutral" when both the Tm1 shift and the Tm2 shift values are between 2°C and -2°C compared to the control (not including the endpoints). A mutation or combination of mutations is said to be "destabilizing" when at least one of the Tm1 shift and the Tm2 shift values is below -2°C compared to the control. Here, a variant or combination of variants is classified as "indeterminate" if it is not possible to assess any effect on Tm1 shift, Tm2 shift or both, and / or stability, e.g., due to insufficient expression or amount of protein in the assay.
[0227] Modified HCMV pentamer complexes were expressed and purified as described in Examples 1 and 2 above. Each HCMV pentamer complex contained at least one modified subunit polypeptide, gH, gL, UL128, UL130, and pUL131A, where the modified subunit polypeptides contained the mutations listed in Tables 22-23. The purified mutant HCMV pentamer complexes were evaluated in a differential scanning fluorimetry (DSF) assay using a Nanotemper Prometheus NT.48 instrument. The intrinsic fluorescence of aromatic residues, such as Tyr and Trp, was obtained by exciting at 280 nm wavelength and measuring the emission spectrum at 330 nm (representing the folded state) and 350 nm (representing the unfolded state) over a temperature ramp (25-85°C). The difference in the fluorescence ratio (350 nm / 330 nm) was plotted using the instrument's software, and the temperature corresponding to the inflection point of the curve was considered as the melting temperature (Tm) of the mutant HCMV pentamer complex. The Tm1 and Tm2 of each mutant HCMV pentamer complex were compared to the corresponding Tm1 or Tm2 of a control (non-mutant) HCMV pentamer complex. The control complex utilized was an HCMV pentamer complex comprising a gH complex-forming fragment and a gL polypeptide with a mutation in the protease recognition site (specifically, the gH polypeptide comprised the sequence of SEQ ID NO:4, the gL polypeptide comprised the sequence of SEQ ID NO:10, the pUL128 polypeptide comprised the sequence of SEQ ID NO:14, the pUL130 polypeptide comprised the sequence of SEQ ID NO:18, and the pUL131A polypeptide comprised the sequence of SEQ ID NO:22). Where possible, any changes (shifts) in Tm1 and / or Tm2 compared to the control were calculated and are summarized in Tables 22 and 23. The residue numbers in Tables 22 and 23 are relative to the sequences of gH in SEQ ID NO: 3, gL in SEQ ID NO: 7, pUL128 in SEQ ID NO: 13, pUL130 in SEQ ID NO: 17, and pUL131A in SEQ ID NO: 21, respectively. An increase in the calculated Tm of at least 5°C is considered a significant increase in the thermal stability of the complex. The stabilized mutant HCMV pentamer complexes listed in Tables 22 and 23 were assayed for the presence of wild-type conformational epitopes using Bio-layer Interferometry (BLI) technology and the 10P3 antibody.All of the complexes listed in Tables 22 and 23 maintain the wild-type HCMV pentamer complex conformational epitope recognized by the 10P3 antibody.
[0228] Effect of designed mutations on the stability of the 4.8 pentamer complex Some mutant HCMV pentamer complexes produced by these methods were more heat stable than the control, while others had a neutral or destabilizing effect. Mutant HCMV pentamer complexes containing disulfide mutations within the gL and pUL130 polypeptides, within the pUL128 and pUL130 polypeptides, or within the pUL128 polypeptide alone had increased heat stability compared to the control (Table 22). Similarly, mutant HCMV pentamer complexes containing cavity-filling mutations in the gL, pUL128, or pUL131 polypeptides had increased heat stability compared to the control (Table 22).
[0229] Stacking (combining) one type of mutation (see column A, Table 23) with a second type of mutation (see column B, Table 23) was also stabilizing (Table 23). In particular, combining a cavity-filling mutation in gL with a disulfide bridge mutation in pUL128 and pUL130, combining a disulfide bridge mutation in pUL128 and pUL130 with a deglycosylation mutation in gL, combining a repacking (hydrophilic) mutation in gH with a disulfide bridge mutation in pUL128 and pUL130, combining a repacking (hydrophobic) mutation in gL with a disulfide bridge mutation in pUL128 and pUL130, and combining two repacking (hydrophobic) mutations in pUL131 with a cavity-filling mutation in gL were all stabilizing (Table 23).
[0230] Without wishing to be bound by theory, it is believed that these cavity-filling, repacking, and disulfide bridging mutations enhance the thermostability of the HCMV pentamer complex by optimizing local interactions or reducing conformational flexibility, and similarly, it is believed that these deglycosylation mutations make HCMV pentamer complex epitopes more accessible.
[0231] [Table 22] TIFF0007584405000029.tif252165TIFF0007584405000030.tif253164TIFF0007584405000031.tif253164TIFF00075844050 00032.tif253164TIFF0007584405000033.tif253162TIFF0007584405000034.tif253162TIFF0007584405000035.tif253130
[0232] [Table 23] TIFF0007584405000037.tif253166TIFF0007584405000038.tif253159TIFF0007584405000039.tif253106
[0233] [Example 5] Further stabilization assays of mutant pentamer complexes 5.1 Express and purify a complex containing at least one designed mutant Modified HCMV pentamer complexes were expressed and purified as described in the examples above. Each HCMV pentamer complex contained at least one modified subunit polypeptide, gH, gL, UL128, UL130, and pUL131A, where the modified subunit polypeptide contained the mutations listed in Table 24. The purified mutant HCMV pentamer complexes were evaluated in a differential scanning fluorimetry (DSF) assay using a Nanotemper Prometheus NT.48 instrument. The intrinsic fluorescence of aromatic residues, such as Tyr and Trp, was obtained by exciting at 280 nm wavelength and measuring the emission spectrum at 330 nm (representing the folded state) and 350 nm (representing the unfolded state) over a temperature ramp (25-85°C). The difference in the fluorescence ratio (350 nm / 330 nm) was plotted using the instrument's software, and the temperature corresponding to the inflection point of the curve was considered as the melting temperature (Tm) of the mutant HCMV pentamer complex. The Tm1 and Tm2 of each mutant HCMV pentamer complex were compared to the corresponding Tm1 or Tm2 of a control (non-mutant) HCMV pentamer complex under the same experimental conditions. The control complex utilized was an HCMV pentamer complex comprising a gH complex-forming fragment and a gL polypeptide having a mutation in the protease recognition site (specifically, the gH polypeptide comprised the sequence of SEQ ID NO:4, the gL polypeptide comprised the sequence of SEQ ID NO:10, the pUL128 polypeptide comprised the sequence of SEQ ID NO:14, the pUL130 polypeptide comprised the sequence of SEQ ID NO:18, and the pUL131A polypeptide comprised the sequence of SEQ ID NO:22).
[0234] Any changes (shifts) in Tm1 and / or Tm2 compared to the control were calculated and summarized in Table 24. The residue numbers in Table 24 relate to the sequences gH in SEQ ID NO: 3, gL in SEQ ID NO: 7, pUL128 in SEQ ID NO: 13, pUL130 in SEQ ID NO: 17, and pUL131A in SEQ ID NO: 21, respectively. As in Example 4, and taking into account a standard deviation of + / - 0.3°C, a "stabilized" result is when the Tm1, Tm2, or both shifts are at least 2°C; an increase of at least 5°C in either Tm1 or Tm2 is considered a significant stabilization increase in the thermal stability of the complex; a "neutral" result is when both Tm1 and Tm2 shifts are between -2°C and 2°C; and a "destabilized" result is when either Tm1 or Tm2 shifts are below -2°C. The stabilized mutant HCMV pentamer complexes listed in Table 24 were assayed for the presence of wild-type conformational epitopes using Bio-layer Interferometry (BLI) technology and the 10P3, 8I21, 916, 10F7, 13H11 or MSL-109, and 15D8 antibodies. All complexes listed in Table 24 maintain the wild-type HCMV pentamer complex conformational epitopes recognized by the 10P3, 8I21, 9I6, 10F7, 13H11 or MSL-109, and 15D8 antibodies.
[0235] For identification no. 176, stacking the disulfide mutation in row C with the previously evaluated mutations in rows A and B results in significant stabilization. For identification no. 177, stacking the disulfide mutation in row B with the previously evaluated disulfide mutation in row A results in significant stabilization. For identification no. 178, stacking the disulfide mutation in row C with the previously stacked and evaluated mutations in row A (cavity filling) and row B (disulfide) results in significant stabilization. For identification no. 179 and 180, the cavity filling mutation gL_G22V has not been previously stacked with another mutation and its effect on thermostability was not evaluated. Stacking the cavity filling mutation gL_G22V with the previously evaluated disulfide mutations in rows B and C (in identification no. 179) or row B (in identification no. 180) results in significant stabilization. For identification numbers 181 and 182, the cavity filling mutant UL128_V77I has not been previously stacked with another mutation and the effect on thermostability was not evaluated. Similarly, for identification numbers 181, 182, and 184, the cavity filling mutations gL_G140F and gL_G145L have not been previously combined and the effect on thermostability was not evaluated. For identification number 181, stacking the cavity filling mutations in row A with the cavity filling mutations in row B is stabilizing. For identification number 182, stacking the three cavity filling mutations in row A with the cavity filling mutations in row B is stabilizing. For identification number 183, stacking the previously evaluated repacking hydrophobic mutations in row A with the previously evaluated cavity filling mutations in row B is stabilizing. For identification number 184, stacking the three cavity filling mutations in row A is destabilizing. It was surprising to find that stacking the three cavity-filling mutations in ID #184 results in destabilization, whereas combining the mutant in ID #184 with the cavity-filling mutation in row B in ID #182 results in stabilization. All but one of the mutant HCMV pentamer complexes in Table 24 are more thermostable than the control, with some resulting in significant stabilization.
[0236] [Table 24]
[0237] 5.2 Express, purify, and verify antigenicity and immunogenicity of additional complexes containing at least one designed variant Modified HCMV pentamer complexes were expressed and purified as described in the Examples above. Each HCMV pentamer complex contained at least one modified subunit polypeptide (gH, gL, UL128, UL130, and / or pUL131A), where the modified subunit polypeptide contained the mutations listed in Table 25. The purified mutant HCMV pentamer complexes were evaluated for thermal stability in a Differential Scanning Fluorometry (DSF) assay using a Nanotemper Prometheus NT.48 instrument (NanoDSF). The intrinsic fluorescence of aromatic residues, e.g., Tyr and Trp, was excited at 280 nm wavelength and emission spectra were measured at 330 nm (representing the folded state) and 350 nm (representing the unfolded state) over a temperature ramp (25-85°C). The difference in the fluorescence ratio (350 nm / 330 nm) was plotted using the instrument software, and the temperature corresponding to the inflection point of the curve was considered as the melting temperature (Tm) of the mutant HCMV pentamer complex. The Tm1 and Tm2 of each mutant HCMV pentamer complex were compared with the corresponding Tm1 or Tm2 of a control (non-mutant) HCMV pentamer complex under the same experimental conditions. The control complex utilized was a known HCMV pentamer complex ("LSG mutant penta" in WO 2016 / 116904) that comprises a gH complex-forming fragment and a gL polypeptide with a mutation in the protease recognition site (specifically, the gH polypeptide comprises the sequence of SEQ ID NO:4, the gL polypeptide comprises the sequence of SEQ ID NO:10, the pUL128 polypeptide comprises the sequence of SEQ ID NO:14, the pUL130 polypeptide comprises the sequence of SEQ ID NO:18, and the pUL131A polypeptide comprises the sequence of SEQ ID NO:22).
[0238] Any changes (shifts) in Tm1 and / or Tm2 compared to the control were calculated and summarized in Table 25. The residue numbers in Table 25 relate to the sequences gH of SEQ ID NO: 3, gL of SEQ ID NO: 7, pUL128 of SEQ ID NO: 13, pUL130 of SEQ ID NO: 17, and pUL131A of SEQ ID NO: 21, respectively. As in Example 4, and taking into account a standard deviation of + / - 0.3°C, a "stabilized" result is when the Tm1, Tm2, or both shifts are at least 2°C; an increase of at least 5°C in either Tm1 or Tm2 is considered a significant stabilization increase in the thermal stability of the complex; a "neutral" result is when both the Tm1 and Tm2 shifts are between -2°C and 2°C; and a "destabilized" result is when either the Tm1 or Tm2 shift is below -2°C. The results show that all mutants have increased melting temperatures (Tm) due to disulfide bond mutations, which have a greater effect on thermal stability than cavity-filling mutations. - A mutant HCMV pentamer complex (set 1_154) containing a pUL131 polypeptide with the S86F mutation numbered according to SEQ ID NO: 21 exhibits increased thermostability compared to the control, but only a neutral total Tm shift. - A mutant HCMV pentamer complex (set 2_36) comprising a gL polypeptide having the G140F and G145L mutations numbered according to SEQ ID NO: 7 and a pUL128 polypeptide having the V77I and L103I mutations numbered according to SEQ ID NO: 13 has increased thermostability compared to the control by an amount that results in significant stabilization. - A mutant HCMV pentamer complex (set 2_20) comprising a gL polypeptide having an A150C mutation numbered according to SEQ ID NO: 7, a pUL128 polypeptide having an R142C mutation numbered according to SEQ ID NO: 13, and a pUL130 polypeptide having P64C and E95C mutations numbered according to SEQ ID NO: 17, has increased thermostability compared to the control by an amount that results in significant stabilization. - A mutant HCMV pentamer complex (set 2_21) comprising a gL polypeptide having the A150C and G140F mutations numbered according to SEQ ID NO: 7, a pUL128 polypeptide having the R142C mutation numbered according to SEQ ID NO: 13, and a pUL130 polypeptide having the P64C and E95C mutations numbered according to SEQ ID NO: 17, has increased thermostability compared to the control by an amount that results in significant stabilization. - A mutant HCMV pentamer complex (set 2_22) comprising a gL polypeptide having the A150C and G145L mutations numbered according to SEQ ID NO: 7, a pUL128 polypeptide having the R142C mutation numbered according to SEQ ID NO: 13, and a pUL130 polypeptide having the P64C and E95C mutations numbered according to SEQ ID NO: 17, has increased thermostability compared to the control by an amount that results in significant stabilization. - A mutant HCMV pentamer complex (set 1_72) comprising a pUL128 polypeptide having an S83C mutation numbered according to SEQ ID NO: 13 and a pUL130 polypeptide having a T167C mutation numbered according to SEQ ID NO: 17 has increased thermostability compared to the control by an amount that results in significant stabilization.
[0239] [Table 25]
[0240] The antigenicity of the stabilized mutant HCMV pentamer complexes in Table 25 was confirmed by Octet-Bio-layer Interferometry (Octet-BLI) using known site-specific monoclonal antibodies (MAbs) 15D8 (site 1), 2F4 (site 2), 8I21 (sites 3 and 7), 10P3 (sites 4 and 6), 9I6 (site 5), and 3G16 (specific for gH). All MAbs bound to each mutant HCMV pentamer complex in Table 25, thereby confirming the conformational epitope integrity and antigenicity of the mutant complexes.
[0241] 0.03 μg of each of the mutant HCMV pentamer conjugates in Table 25 and the control HCMV pentamer conjugates (total of 7 groups) was added to AS01 E The compositions were formulated with adjuvant (a liposome-based adjuvant containing 2.5 μg each of monophosphoryl lipid A (MPL) and QS21). Three separate doses of 50 μL of the composition were administered intramuscularly into the hind leg of C57BL / 6 mice (12 per group) on days 1, 22, and 43, with non-terminal bleeds on all mice on days 21 and 42, and exsanguination and terminal bleeds on day 64. See regimen in table below.
[0242] TIFF0007584405000042.tif100169
[0243] Serum samples taken 3 weeks after administration of the second dose (3wp2) were complement tested in a neutralization assay performed according to known methods utilizing ARPE-19 epithelial cells, TB40 virus strain, and Cederlane guinea pig complement. Using geometric mean antibody titers (GMT) as the endpoint, the neutralization assay confirmed the immunogenicity of all seven HCMV pentamer complexes (Figure 8). Notably, the results showed that all samples from mice immunized with one of the six mutant HCMV pentamer complexes had neutralizing antibody (nAb) titers that exceeded those from mice immunized with the control pentamer (Figure 8).
[0244] Samples taken 3 weeks after administration of the third dose are expected to show similar trend in results under the same neutralization assay protocol.
[0245] Array Description Amino acid sequences are written in N-terminal to C-terminal orientation; nucleic acid sequences are written in 5'-to-3' orientation. SEQ ID NO:1 - Amino acid sequence of full-length gH polypeptide from HCMV Merlin strain (predicted signal sequence residues 1-23) (NCBI GI No.: 52139248; NCBI accession no. YP_081523.1). SEQ ID NO:2 - Amino acid sequence of the gH polypeptide from HCMV strain Merlin lacking the signal sequence (hence the mature gH polypeptide). SEQ ID NO:2 represents amino acids 24 to 742 of SEQ ID NO:1. SEQ ID NO:3 - Amino acid sequence of the gH polypeptide from HCMV strain Merlin, lacking the transmembrane (TM) domain and the C-terminal cytoplasmic domain, and ectodomain residues 716 and 717. SEQ ID NO:3 consists of amino acids 1-715 of SEQ ID NO:1 (predicted signal sequence residues 1-23). See WO 2014 / 005959 (published in U.S. Patent Publication No. 2016 / 0159864). SEQ ID NO:4 - the amino acid sequence of the mature gH polypeptide from HCMV strain Merlin, and lacking the TM domain and the C-terminal cytoplasmic domain. SEQ ID NO:4 consists of amino acids 24 to 715 of SEQ ID NO:1. SEQ ID NO:5 - Amino acid sequence of full length gH polypeptide from HCMV Towne strain (NCBI GI No.: 138314; NCBI accession number P17176.1). SEQ ID NO:6 - Amino acid sequence of full length gH polypeptide from HCMV strain AD169 (NCBI GI No.: 138313; NCBI accession number P12824.1). SEQ ID NO:7 - Amino acid sequence of full-length gL polypeptide from HCMV Merlin strain (predicted signal sequence residues 1-30) (NCBI GI No.: 39842115; NCBI GenBank accession number AAR31659.1). SEQ ID NO:8 - The amino acid sequence of the mature gL polypeptide from HCMV strain Merlin, lacking the signal sequence. SEQ ID NO:8 consists of amino acids 31 to 278 of SEQ ID NO:7. SEQ ID NO:9 - Amino acid sequence of full length gL polypeptide from HCMV strain Merlin including mutations of the putative protease recognition site (predicted signal sequence residues 1-30). SEQ ID NO:9 consists of SEQ ID NO:7 and clipping mutations A96L, N97S, and S98G. See WO2016 / 116904. SEQ ID NO:10 - the amino acid sequence of the mature gL polypeptide from HCMV strain Merlin, including a mutation at the putative protease recognition site. SEQ ID NO:10 consists of residues 31 to 278 of SEQ ID NO:9. See WO2016 / 116904. SEQ ID NO:11 - Amino acid sequence of the full-length gL polypeptide from HCMV Towne strain (NCBI GI No.: 239909463; NCBI GenBank accession number ACS32410.1). SEQ ID NO:12 - Amino acid sequence of the full-length gL polypeptide from HCMV strain AD169 (NCBI GI No.:2506510; NCBI accession number P16832.2). SEQ ID NO:13 - Amino acid sequence of full-length pUL128 polypeptide from HCMV Merlin strain (predicted signal sequence residues 1-27) (NCBI GI No.:39842124; NCBI GenBank accession no. AAR31668.1). SEQ ID NO: 14 - The amino acid sequence of the mature pUL128 polypeptide from HCMV strain Merlin, lacking the signal sequence. SEQ ID NO: 14 consists of amino acids 28 to 171 of SEQ ID NO: 13. SEQ ID NO:15 - Amino acid sequence of full-length pUL128 polypeptide from HCMV Towne strain (NCBI GI No.:39841882; NCBI GenBank accession number AAR31451.1). SEQ ID NO:16 - Amino acid sequence of full-length pUL128 polypeptide from HCMV strain AD169 (NCBI GI No.: 59803078; NCBI accession number P16837.2). SEQ ID NO:17 - Amino acid sequence of full-length pUL130 polypeptide from HCMV Merlin strain (predicted signal sequence residues 1-25) (NCBI GI No.:39842125; NCBI accession no. AAR31669.1). SEQ ID NO:18 - The amino acid sequence of the mature pUL130 polypeptide from HCMV strain Merlin, lacking the signal sequence. SEQ ID NO:18 consists of amino acids 26 to 214 of SEQ ID NO:17. SEQ ID NO:19 - Amino acid sequence of full-length pUL130 polypeptide from HCMV Towne strain (predicted signal sequence residues 1-25) (NCBI GI No.: 239909473; NCBI accession number ACS32420.1). SEQ ID NO:20 - Amino acid sequence of full-length pUL130 polypeptide from HCMV strain AD169 (predicted signal sequence residues 1-25). (NCBI UniProtKB Accession No. P16772.1). SEQ ID NO:21 - Amino acid sequence of full length pUL131A polypeptide from HCMV Merlin strain (predicted signal sequence residues 1-18) (NCBI GI No.:39842126; NCBI accession number AAR31670.1). SEQ ID NO:22 - The amino acid sequence of the mature pUL131A polypeptide from HCMV strain Merlin. SEQ ID NO:22 consists of amino acids 19 to 129 of SEQ ID NO:21. SEQ ID NO:23 - Amino acid sequence of full length pUL131A polypeptide from HCMV Towne strain (predicted signal sequence residues 1-18) (NCBI GI No.:239909474; NCBI accession number ACS32421.1). SEQ ID NO:24 - Amino acid sequence of full length pUL131A polypeptide from HCMV strain AD169 (predicted signal sequence residues 1-18). (NCBI GI No.:219879712; NCBI GenBank Accession No. DAA06452.1). SEQ ID NO:25 - Amino acid sequence of full length gO polypeptide from HCMV Merlin strain (predicted signal sequence residues 1-30). (NCBI GI No.:39842082; NCBI GenBank Accession No. AAR31626.1). SEQ ID NO:26 - The amino acid sequence of the mature gO polypeptide from HCMV strain Merlin. SEQ ID NO:26 consists of amino acids 31 to 472 of SEQ ID NO:25. SEQ ID NO:27 - Amino acid sequence of full length gO polypeptide from HCMV Towne strain (predicted signal sequence residues 1-30). (NCBI GI No.:239909431; NCBI Accession No. ACS32378.1). SEQ ID NO:28 - Amino acid sequence of full-length gO polypeptide from HCMV strain AD169 (predicted signal sequence residues 1-30). (NCBI GI No.: 136968; NCBI UniProtKB Accession No. P16750.1). SEQ ID NO:29 - Amino acid sequence of full length gL polypeptide from HCMV strain Merlin including mutations of the putative protease recognition site (predicted signal sequence residues 1-30). SEQ ID NO:29 consists of SEQ ID NO:7 and clipping mutations A96I, N97D, and S98G (also underlined). See WO2016 / 116904. SEQ ID NO:30 - Amino acid sequence of the mature gL polypeptide from HCMV strain Merlin, including a mutation at the putative protease recognition site. SEQ ID NO:30 consists of residues 31 to 278 of SEQ ID NO:29 (including the IDG mutant clipping residues). See WO2016 / 116904. SEQ ID NO:31 - A nucleic acid sequence encoding the amino acid sequence of the full-length gH of SEQ ID NO:1 (sequence corresponding to base pairs 109224 to 111452 (encoded in the 3' to 5' direction) of NCBI GenBank Accession No. AY446894.2). SEQ ID NO:32 - Nucleic acid sequence encoding the amino acid sequence of gH of SEQ ID NO:3 (codon-optimized for mammalian generation). SEQ ID NO:33 - A nucleic acid sequence encoding the amino acid sequence of full-length gL of SEQ ID NO:7. SEQ ID NO:34 - A nucleic acid sequence encoding the amino acid sequence of full-length LSG gL of SEQ ID NO:9. SEQ ID NO:35 - A nucleic acid sequence encoding the amino acid sequence of full-length IDG gL of SEQ ID NO:29. SEQ ID NO:36 - A nucleic acid sequence encoding the full-length pUL128 amino acid sequence of SEQ ID NO:13. SEQ ID NO:37 - A nucleic acid sequence encoding the amino acid sequence of full-length pUL130 of SEQ ID NO:17. SEQ ID NO:38 - A nucleic acid sequence encoding the amino acid sequence of full-length pUL131A of SEQ ID NO:21. SEQ ID NO:39 - A nucleic acid sequence encoding the amino acid sequence of full-length gO of SEQ ID NO:25 (corresponding to base pairs 108848 to 107454 of GenBank Accession No. AY446894.2). SEQ ID NO:40 - corresponds to the amino acid sequence of gH of HCMV Merlin strain SEQ ID NO:3 and further contains the G358R mutation (underlined). Predicted signal sequence residues 1-23. SEQ ID NO:41 - corresponds to the amino acid sequence of gH of HCMV Merlin strain SEQ ID NO:4 and further contains the G358R mutation. SEQ ID NO:42 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:9 and further contains the N74Q mutation. Predicted signal sequence: residues 1-30. SEQ ID NO:43 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:10 and further contains the N74Q mutation. SEQ ID NO: 44 - corresponds to the amino acid sequence of gL of HCMV Merlin strain of SEQ ID NO: 9, and further contains the G140F mutation. Predicted signal sequence: residues 1-30. SEQ ID NO:45 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:10 and further contains the G140F mutation. This corresponds to the amino acid sequence of gL of HCMV Merlin strain in SEQ ID NO:46-SEQ ID NO:9, and further includes the G145L mutation, with residues 1-30 of the predicted signal sequence underlined. SEQ ID NO:47 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:10 and additionally contains the G145L mutation. This corresponds to the amino acid sequence of HCMV Merlin strain gL in SEQ ID NO:48-SEQ ID NO:9, and further includes the A150C mutation, with residues 1-30 of the predicted signal sequence underlined. SEQ ID NO:49 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:10 and further contains the A150C mutation. SEQ ID NO:50 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:9, and further includes the R160C mutation, with predicted signal sequence residues 1-30 underlined. SEQ ID NO:51 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:10 and further contains the R160C mutation. SEQ ID NO:52-9 corresponds to the amino acid sequence of gL of HCMV Merlin strain, and further includes the R166C mutation, with residues 1-30 of the predicted signal sequence underlined. SEQ ID NO:53 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:10 and further contains the R166C mutation. SEQ ID NO:54 - corresponds to the amino acid sequence of gL of HCMV Merlin strain of SEQ ID NO:9 and further contains the C233V mutation. Predicted signal sequence: residues 1-30. SEQ ID NO:55 - corresponds to the amino acid sequence of gL of HCMV Merlin strain SEQ ID NO:10 and further contains the C233V mutation. SEQ ID NO:56 - corresponds to the amino acid sequence of pUL128 of HCMV Merlin strain SEQ ID NO:13, and further contains the mutations M48C and G107C. Predicted signal sequence residues 1 to 27. This signal sequence differs from the signal sequence of SEQ ID NO:13 at residue 12. SEQ ID NO:57 - corresponds to the amino acid sequence of pUL128 of HCMV Merlin strain SEQ ID NO:14 and further contains the mutations M48C and G107C. SEQ ID NO:58 - corresponds to the amino acid sequence of pUL128 of HCMV Merlin strain SEQ ID NO:13 and further contains the mutation V77I. Predicted signal sequence residues 1 to 27. This signal sequence differs from the signal sequence of SEQ ID NO:13 at residue 12. SEQ ID NO:59 - corresponds to the amino acid sequence of pUL128 of HCMV Merlin strain SEQ ID NO:14 and further contains the mutation V77I. SEQ ID NO:60 - corresponds to the amino acid sequence of pUL128 of HCMV strain Merlin of SEQ ID NO:13 and further contains the mutation S83C. Predicted signal sequence residues 1 to 27. This signal sequence differs from the signal sequence of SEQ ID NO:13 at residue 12. SEQ ID NO:61 - corresponds to the amino acid sequence of pUL128 of the HCMV Merlin strain of SEQ ID NO:14 and further contains the mutation S83C. SEQ ID NO:62 - corresponds to the amino acid sequence of pUL128 of HCMV strain Merlin of SEQ ID NO:13 and further contains the mutation Y98C. Predicted signal sequence residues 1 to 27. This signal sequence differs from the signal sequence of SEQ ID NO:13 at residue 12. SEQ ID NO:63 - corresponds to the amino acid sequence of pUL128 of HCMV strain Merlin of SEQ ID NO:14 and further contains the mutation Y98C. SEQ ID NO:64 - corresponds to the amino acid sequence of pUL128 of HCMV Merlin strain SEQ ID NO:13 and further contains the mutation L103I. Predicted signal sequence residues 1 to 27. This signal sequence differs from the signal sequence of SEQ ID NO:13 at residue 12. SEQ ID NO:65 - corresponds to the amino acid sequence of pUL128 of the HCMV Merlin strain of SEQ ID NO:14 and further contains the mutation L103I. SEQ ID NO:66 - corresponds to the amino acid sequence of pUL128 of HCMV Merlin strain SEQ ID NO:13 and further contains the mutation R142C. Predicted signal sequence residues 1 to 27. This signal sequence differs from the signal sequence of SEQ ID NO:13 at residue 12. SEQ ID NO:67 - corresponds to the amino acid sequence of pUL128 of HCMV strain Merlin of SEQ ID NO:14 and further contains the mutation R142C. SEQ ID NO:68 - corresponds to the amino acid sequence of pUL130 of HCMV Merlin strain SEQ ID NO:17 and further contains the mutation Y56C. Predicted signal sequence residues 1-25. SEQ ID NO:69 - corresponds to the amino acid sequence of pUL130 of the HCMV Merlin strain of SEQ ID NO:18 and further contains the mutation Y56C. SEQ ID NO:70 - corresponds to the amino acid sequence of pUL130 of HCMV strain Merlin of SEQ ID NO:17, and further contains the mutation P62C. Predicted signal sequence: residues 1-25. SEQ ID NO:71 - corresponds to the amino acid sequence of pUL130 of the HCMV Merlin strain of SEQ ID NO:18 and further contains the mutation P62C. SEQ ID NO:72 - corresponds to the amino acid sequence of pUL130 of HCMV strain Merlin of SEQ ID NO:17, and further contains the mutation P64C. Predicted signal sequence: residues 1-25. SEQ ID NO:73 - corresponds to the amino acid sequence of pUL130 of the HCMV Merlin strain of SEQ ID NO:18 and further contains the mutation P64C. SEQ ID NO:74 - corresponds to the amino acid sequence of pUL130 of HCMV strain Merlin of SEQ ID NO:17 and further contains the mutation E95C. Predicted signal sequence residues 1-25. SEQ ID NO:75 - corresponds to the amino acid sequence of pUL130 of the HCMV Merlin strain of SEQ ID NO:18 and further contains the mutation E95C. SEQ ID NO:76 - corresponds to the amino acid sequence of pUL130 of HCMV Merlin strain SEQ ID NO:17 and further contains the mutation T167C. Predicted signal sequence residues 1-25. SEQ ID NO:77-SEQ ID NO:18 correspond to the amino acid sequence of pUL130 of the HCMV Merlin strain and further contain the mutation T167C. SEQ ID NO:78 - corresponds to the amino acid sequence of pUL130 of HCMV Merlin strain SEQ ID NO:17 and further contains the mutation Y204C. Predicted signal sequence residues 1-25. SEQ ID NO:79 - corresponds to the amino acid sequence of pUL130 of HCMV Merlin strain SEQ ID NO:18 and further contains the mutation Y204C. SEQ ID NO:80 - corresponds to the amino acid sequence of pUL131A of HCMV Merlin strain SEQ ID NO:21 and further contains the mutations Y52F and A67V. Predicted signal sequence residues 1-18. SEQ ID NO:81 - corresponds to the amino acid sequence of pUL131A of HCMV Merlin strain SEQ ID NO:22 and further contains the mutations Y52F and A67V. SEQ ID NO:82 - corresponds to the amino acid sequence of pUL131A of HCMV strain Merlin of SEQ ID NO:21 and further contains the mutation S86F. Predicted signal sequence residues 1-18. SEQ ID NO:83 - corresponds to the amino acid sequence of pUL131A of HCMV strain Merlin according to SEQ ID NO:22 and further contains the mutation S86F.
[0246] All patents and publications referred to herein are expressly incorporated herein by reference in their entirety. The present invention includes, for example, the following embodiments:
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0029]
[0031]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028] [ (a) a pUL128 polypeptide having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, or a complex-forming fragment thereof; a gL polypeptide or a complex-forming fragment thereof having a cavity-filling mutation at residue 140 and a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7; and a pUL130 polypeptide having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, or a complexing fragment ...
Claims
1. A complex comprising one or more mutant human cytomegalovirus (HCMV) polypeptides, said one or more mutant HCMV polypeptides comprising (a) a pUL128 polypeptide or a fragment thereof having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, or (ii) a complexing fragment comprising at least amino acid residues 28-171 of SEQ ID NO:13; A gL polypeptide or fragment thereof having a phenylalanine (F) at residue 140 and a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:7, or (ii) a complexing fragment comprising at least amino acid residues 31-278 of SEQ ID NO:7; and A pUL130 polypeptide or fragment thereof having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:17, or (ii) a complexing fragment comprising at least amino acid residues 26-214 of SEQ ID NO:
17. (b) a pUL128 polypeptide or fragment thereof having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, or (ii) a complexing fragment comprising at least amino acid residues 28-171 of SEQ ID NO:
13. A gL polypeptide or fragment thereof having a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7, wherein the fragment is (i) a complex-forming fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:7, or (ii) a complex-forming fragment comprising at least amino acid residues 31-278 of SEQ ID NO:7; and A pUL130 polypeptide or fragment thereof having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:17, or (ii) a complexing fragment comprising at least amino acid residues 26-214 of SEQ ID NO:
17. (c) a pUL128 polypeptide or fragment thereof having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, or (ii) a complexing fragment comprising at least amino acid residues 28-171 of SEQ ID NO:
13. a gL polypeptide or fragment thereof having a leucine (L) at residue 145 and a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7, wherein the fragment is (i) a complex-forming fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:7, or (ii) a complex-forming fragment comprising at least amino acid residues 31-278 of SEQ ID NO:7; and A pUL130 polypeptide or fragment thereof having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:17, or (ii) a complexing fragment comprising at least amino acid residues 26-214 of SEQ ID NO:
17. (d) a pUL128 polypeptide or fragment thereof having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, or (ii) a complexing fragment comprising at least amino acid residues 28-171 of SEQ ID NO:
13. a gL polypeptide or fragment thereof having a valine (V) at residue 224 and a cysteine (C) at residue 150, numbered relative to SEQ ID NO:7, wherein the fragment is (i) a complex-forming fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:7, or (ii) a complex-forming fragment comprising at least amino acid residues 31-278 of SEQ ID NO:7; and A pUL130 polypeptide or fragment thereof having a cysteine (C) at residue 64 and a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:17, or (ii) a complexing fragment comprising at least amino acid residues 26-214 of SEQ ID NO:
17. (e) a pUL128 polypeptide or fragment thereof having a cysteine (C) at residue 142, numbered relative to SEQ ID NO:13, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, or (ii) a complexing fragment comprising at least amino acid residues 28-171 of SEQ ID NO:
13. A gL polypeptide or fragment thereof having a valine (V) at residue 224, numbered relative to SEQ ID NO:7, wherein the fragment is (i) a complex-forming fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:7, or (ii) a complex-forming fragment comprising at least amino acid residues 31-278 of SEQ ID NO:7; and A pUL130 polypeptide or fragment thereof having a cysteine (C) at residue 95, numbered relative to SEQ ID NO:17, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:17, or (ii) a complexing fragment comprising at least amino acid residues 26-214 of SEQ ID NO:
17. (f) a pUL128 polypeptide or fragment thereof having an isoleucine (I) at residue 77 and an isoleucine (I) at residue 103, numbered relative to SEQ ID NO:13, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, or (ii) a complexing fragment comprising at least amino acid residues 28-171 of SEQ ID NO:13; and A gL polypeptide or a fragment thereof having a phenylalanine (F) at residue 140 and a leucine (L) at residue 145, numbered relative to SEQ ID NO:7, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:7, or (ii) a complexing fragment comprising at least amino acid residues 31-278 of SEQ ID NO:
7. (g) a pUL128 polypeptide or fragment thereof having an isoleucine (I) at residue 77 and an isoleucine (I) at residue 103, numbered relative to SEQ ID NO:13, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, or (ii) a complexing fragment comprising at least amino acid residues 28-171 of SEQ ID NO:13; and a gL polypeptide or a fragment thereof having a phenylalanine (F) at residue 140, a leucine (L) at residue 145, and a valine (V) at residue 224, numbered relative to SEQ ID NO:7, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:7, or (ii) a complexing fragment comprising at least amino acid residues 31-278 of SEQ ID NO:7; or (h) a gL polypeptide or a fragment thereof having a phenylalanine (F) at residue 140, numbered relative to SEQ ID NO:7, wherein the fragment is (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:7, or (ii) a complexing fragment comprising at least amino acid residues 31-278 of SEQ ID NO:7; and A pUL131 polypeptide or fragment thereof having a phenylalanine (F) at residue 52 and a valine (V) at residue 67, numbered relative to SEQ ID NO:21, said fragment being (i) a complexing fragment comprising an amino acid sequence having at least 90% identity to SEQ ID NO:21, or (ii) a complexing fragment comprising at least amino acid residues 19-129 of SEQ ID NO:
21. A complex.
2. 2. The complex of claim 1, having increased thermal stability compared to a control complex under the same conditions.
3. 3. An immunogenic composition comprising a complex according to any one of claims 1 to 2 and optionally non-antigenic components.
4. 3. An isolated nucleic acid molecule comprising one or more operably linked polynucleotide sequences encoding the complex of any one of claims 1 to 2.
5. 5. An expression vector comprising the isolated nucleic acid molecule of claim 4.
6. 6. A host cell comprising the isolated nucleic acid molecule of claim 4 or the expression vector of claim 5.
7. A method for producing a complex comprising culturing the host cell of claim 6.
8. The immunogenic composition of claim 3 for use in a method for inducing an immune response against human cytomegalovirus (HCMV), the method comprising administering an immunologically effective amount of the immunogenic composition to a subject.
9. 13. A composition comprising the complex of claim 1 for use in a method for inhibiting entry of human cytomegalovirus (HCMV) into a cell.
Citation Information
Patent Citations
Stabilized viral envelope proteins and their uses
JP2003509013A
Cytomegalovirus complexes and uses thereof
WO2015181142A1
Norovirus s particle based vaccines and methods of making and using same
WO2018182983A1
